<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006894" GROUP_ID="RENAL" ID="475406032723493105" MERGED_FROM="" MODIFIED="2009-11-09 01:40:21 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="151" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2009-11-09 01:40:21 +0100" MODIFIED_BY="Narelle Willis">
<TITLE MODIFIED="2009-11-05 13:47:16 +1100" MODIFIED_BY="Narelle S Willis">Interventions for preventing infectious complications in haemodialysis patients with central venous catheters</TITLE>
<CONTACT MODIFIED="2009-11-09 01:40:21 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="3DA877B282E26AA20112E9E69ECC82B1" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Margaret</FIRST_NAME><LAST_NAME>McCann</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>mccannm1@tcd.ie</EMAIL_1><ADDRESS><DEPARTMENT>School of Nursing &amp; Midwifery</DEPARTMENT><ORGANISATION>Trinity College Dublin</ORGANISATION><ADDRESS_1>24 D'Olier St</ADDRESS_1><CITY>Dublin</CITY><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 1 8968542</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-11-09 01:40:21 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="3DA877B282E26AA20112E9E69ECC82B1" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Margaret</FIRST_NAME><LAST_NAME>McCann</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>mccannm1@tcd.ie</EMAIL_1><ADDRESS><DEPARTMENT>School of Nursing &amp; Midwifery</DEPARTMENT><ORGANISATION>Trinity College Dublin</ORGANISATION><ADDRESS_1>24 D'Olier St</ADDRESS_1><CITY>Dublin</CITY><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 1 8968542</PHONE_1></ADDRESS></PERSON><PERSON ID="19863" ROLE="AUTHOR"><FIRST_NAME>Zena</FIRST_NAME><MIDDLE_INITIALS>EH</MIDDLE_INITIALS><LAST_NAME>Moore</LAST_NAME><POSITION>HRB Clinical Nursing and Midwifery Research Fellow</POSITION><EMAIL_1>zmoore@rcsi.ie</EMAIL_1><MOBILE_PHONE>+ 353 87 6597509</MOBILE_PHONE><ADDRESS><DEPARTMENT>Faculty of Nursing and Midwifery</DEPARTMENT><ORGANISATION>Royal College of Surgeons in Ireland</ORGANISATION><ADDRESS_1>123 St Stephens Green</ADDRESS_1><CITY>Dublin</CITY><ZIP>Dublin 15</ZIP><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 8 765 97509</PHONE_1><FAX_1>+353 1 402 2465</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-11-04 15:06:41 +1100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="11" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="11" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="6" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2009-11-04 15:06:50 +1100" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2009-11-04 15:06:59 +1100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>School of Nursing and Midwifery, Trinity College Dublin</NAME>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Health Research Board Cochrane Fellowship</NAME>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-05 16:06:39 +1100" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2009-11-05 13:57:50 +1100" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2009-11-05 13:05:09 +1100" MODIFIED_BY="Narelle S Willis">Interventions for preventing infectious complications in haemodialysis patients with central venous lines</TITLE>
<SUMMARY_BODY MODIFIED="2009-11-05 13:57:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>Patients whose kidneys no longer work need to have water, toxins and other chemicals removed from their blood using an artificial kidney. One method of achieving this is to use a central venous catheter (CVC) which is a small tube inserted via the skin into a blood vessel in the neck of the patient. This tube allows blood to go from the patient, pass through an artificial kidney and return back to the patient. This process is referred to as a dialysis session which takes four hours and is usually performed three times a week. As CVC have direct access to the blood system they can cause serious infections which can be life threatening to the patient. Several strategies can be used to prevent these infections occurring including the application of different types of ointments (mupirocin, povidone-iodine and polysporin) or medicinal honey to the catheter site, and the use of different dressings which cover the catheter site (transparent or gauze and tape). The review of 10 studies (786 patients) found that mupirocin ointment reduced the risk of patients developing catheter-related bacteraemia (bacteria in the blood). However, monitoring of mupirocin resistance needs to be considered in future studies. There was not enough evidence to determine which ointment (povidone-iodine and polysporin) or dressing was the best in preventing infection. There was also insufficient evidence to support the use of medicinal honey for the prevention of infection.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-11-05 14:18:39 +1100" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND MODIFIED="2009-11-05 13:03:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>Central venous catheters (CVC) continue to play a prominent role in haemodialysis vascular access with 46% to 70% of patients commencing haemodialysis via a CVC. CVC access is associated with catheter-related infections, increased patient hospitalisations and death due to infection. A variety of interventions are used to prevent CVC infection.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-05 13:04:19 +1100" MODIFIED_BY="Narelle S Willis">
<P>To evaluate the benefits and harms of prophylactic topical antimicrobials, topical antiseptics, medicated and non-medicated dressings on infectious complications among haemodialysis patients with CVC.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-11-05 13:50:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and reference lists of articles without language restriction.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-11-05 12:58:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>We included randomised controlled trials (RCTs) and quasi-RCTs investigating any intervention that prevented infectious complications among haemodialysis patients with CVC. We excluded antimicrobial impregnated CVC or CVC using locking solutions with antimicrobial properties.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-11-05 13:51:45 +1100" MODIFIED_BY="Narelle S Willis">
<P>Two authors assessed study quality and extracted data. Dichotomous outcomes were expressed as risk ratios (RR) with 95% confidence intervals (CI) and continuous outcomes as mean differences (MD).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-11-05 14:18:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Ten studies (786 patients) were included. Mupirocin ointment reduced the risk of catheter-related bacteraemia (RR 0.17, 95%CI 0.07 to 0.43) and had a significant effect on catheter-related infections caused by <I>S. aureus</I>. The risk of catheter-related bacteraemia was reduced by polysporin (RR 0.40, 95%CI 0.19 to 0.86) and povidone-iodine ointment (RR 0.10, 95%CI 0.01 to 0.72). Subgroup analysis suggested mupirocin (RR 0.12, 95%CI 0.01 to 2.13) and povidone-iodine ointment (RR 0.84, 95%CI 0.24 to 2.98) had no effect on all-cause mortality while polysporin ointment showed a significant reduction (RR 0.22, 95%CI 0.07 to 0.74). Mortality related to infection was not reduced by mupirocin, polysporin or povidone-iodine ointment. Topical honey did not reduce the risk of exit site infection (RR 0.45, 95%CI 0.10 to 2.11) or catheter-related bacteraemia (RR 0.80, 95%CI 0.37 to 1.73). Transparent polyurethane dressing compared to dry gauze dressing did not reduce the risk of CVC or exit site infection, or catheter-related bacteraemia. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-11-05 13:55:29 +1100" MODIFIED_BY="Narelle S Willis">
<P>Mupirocin ointment appears effective in reducing the risk of catheter-related bacteraemia. Insufficient reporting on mupirocin resistance was noted and needs to be considered in future studies. A lack of high quality data on the routine use of povidone-iodine ointment, polysporin ointment and topical honey warrant larger RCTs. Insufficient data were available to determine which dressing type (transparent polyurethane or dry gauze dressing) has the lowest risk of catheter-related infections.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-11-05 16:06:39 +1100" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2009-11-05 15:59:41 +1100" MODIFIED_BY="Narelle S Willis">
<P>Chronic kidney disease (CKD) is a gradual and permanent loss of kidney function. The progression of this disease has been classified into 5 stages with stage 5 described as kidney failure or end-stage kidney disease (ESKD). This stage usually requires the patient to start renal replacement therapy (RRT) be it haemodialysis, peritoneal dialysis or transplantation (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>). World wide the number of prevalent patients with ESKD reported to the United States renal data system (USRDS) in 2004 was 1,172,658, a 21% increase from 1999 (<LINK REF="REF-USRDS-2006" TYPE="REFERENCE">USRDS 2006</LINK>). Adjusted incident rates per million of the population (pmp) for ESKD RRT patients range from 103 pmp (UK) to 339 pmp (USA). This represents a 7% and 1.5% increase for the UK and USA respectively (<LINK REF="REF-UKRR-2005" TYPE="REFERENCE">UKRR 2005</LINK>; <LINK REF="REF-USRDS-2006" TYPE="REFERENCE">USRDS 2006</LINK>). This global increase in the number of people requiring RRT is predicted to continue over the next 10 years (<LINK REF="REF-DoH-2004" TYPE="REFERENCE">DoH 2004</LINK>; <LINK REF="REF-Frankel-2006" TYPE="REFERENCE">Frankel 2006</LINK>).</P>
<P>Maintenance haemodialysis is the modality of RRT for 70% to 91% of new patients (<LINK REF="REF-CIHI-2006" TYPE="REFERENCE">CIHI 2006</LINK>; <LINK REF="REF-UKRR-2005" TYPE="REFERENCE">UKRR 2005</LINK>; <LINK REF="REF-USRDS-2006" TYPE="REFERENCE">USRDS 2006</LINK>). The vascular access of choice for maintenance haemodialysis is the native arterio-venous fistula (AVF). The National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (KDOQI) guidelines recommend an AVF prevalence rate of greater than 65% (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>). CVC (CVC) as vascular access are considered inferior to other means of vascular access with 2006 K/DOQI guidelines recommending less than 10% prevalence rate. However, despite these recommendations the Dialysis Outcomes and Practice Patterns Study (DOPPS II), reports that 46% to 70% of European and Canadian ESKD patients commencing maintenance haemodialysis do so via a CVC. This dependence on CVC is also reflected in the prevalence rates which range from 18% (Europe) to 34% (Canada) (<LINK REF="REF-Mendelssohn-2006" TYPE="REFERENCE">Mendelssohn 2006</LINK>). This over reliance on catheters may be attributed to late referrals to nephrologists, delay in access formation, lack of sufficient time for an AVF to mature or an ever increasing older ESKD population who experience higher rates of vascular disease and diabetes resulting in an inadequate vasculature for AVF formation (<LINK REF="REF-Butterly-2001" TYPE="REFERENCE">Butterly 2001</LINK>; <LINK REF="REF-Letourneau-2003" TYPE="REFERENCE">Letourneau 2003</LINK>; <LINK REF="REF-Mendelssohn-2006" TYPE="REFERENCE">Mendelssohn 2006</LINK>).</P>
<P>A CVC can be non-tunnelled or tunnelled. A non-tunnelled catheter - sometimes referred to in the literature as non-cuffed, temporary, short-term or acute - is intended for short-term haemodialysis use. On the other hand tunnelled catheters - also known as cuffed, chronic, long-term or permanent catheters - are generally used when patients require more than two to three weeks haemodialysis (<LINK REF="REF-Frankel-2006" TYPE="REFERENCE">Frankel 2006</LINK>). However, the reported use of these different catheters suggest that tunnelled catheters have been used for periods of short duration and, although not recommended, non-tunnelled catheters have been used for periods of long duration (months or years) (<LINK REF="REF-Ash-2001" TYPE="REFERENCE">Ash 2001</LINK>; <LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>; <LINK REF="REF-Oliver-2001" TYPE="REFERENCE">Oliver 2001</LINK>; <LINK REF="REF-Ponikvar-2005" TYPE="REFERENCE">Ponikvar 2005</LINK>).</P>
<P>The type of haemodialysis vascular access may contribute independently to patient mortality. This is evident in a reported one- to three-fold increase in the risk of death with a CVC when compared to an AVF (<LINK REF="REF-Dhingra-2001" TYPE="REFERENCE">Dhingra 2001</LINK>; <LINK REF="REF-Pastan-2002" TYPE="REFERENCE">Pastan 2002</LINK>; <LINK REF="REF-Polkinghorne-2004" TYPE="REFERENCE">Polkinghorne 2004</LINK>). The Choices for Healthy Outcomes in Caring for ESKD (CHOICE) study revealed a 41% higher risk for infection-related death in patients dialysed using a CVC when compared with those using an AVF (<LINK REF="REF-Astor-2005" TYPE="REFERENCE">Astor 2005</LINK>). Although there are no specific statistics provided, KDOQI guidelines argue that infectious complications associated with catheter use in haemodialysis patients contributes to making infection the second leading cause of death in patients with ESKD (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>).</P>
<P>Infectious complications include bacteraemia and exit site infections. The incidence of catheter-related episodes of bacteraemia range from 1.4 to 8.3/1000 catheter days for a non-tunnelled CVC and 1.6 to 6.18/1000 catheter days for a tunnelled CVC (<LINK REF="REF-Saeed-2002" TYPE="REFERENCE">Saeed 2002</LINK>; <LINK REF="REF-Stevenson-2000" TYPE="REFERENCE">Stevenson 2000</LINK>; <LINK REF="REF-Weijmere-2004" TYPE="REFERENCE">Weijmere 2004</LINK>). In addition, it has been reported that the rate of catheter-related bacteraemia corresponds closely with duration of time and the insertion site (<LINK REF="REF-Oliver-2000" TYPE="REFERENCE">Oliver 2000</LINK>). Metastatic complications can occur following episodes of CVC bacteraemia with 7% to 44% of CVC related bacteraemia developing complications such as endocarditis, osteomyelitis and septic arthritis (<LINK REF="REF-Marr-1998" TYPE="REFERENCE">Marr 1998</LINK>; <LINK REF="REF-Mokrzycki-2006" TYPE="REFERENCE">Mokrzycki 2006</LINK>). Episodes of exit site CVC infections vary from 8.2 to 16.75/1000 catheter days and 0.35 to 8.3/1000 catheter days for non-tunnelled and tunnelled catheters respectively (<LINK REF="REF-Develter-2005" TYPE="REFERENCE">Develter 2005</LINK>; <LINK REF="REF-Stevenson-2000" TYPE="REFERENCE">Stevenson 2000</LINK>; <LINK REF="REF-Weijmere-2004" TYPE="REFERENCE">Weijmere 2004</LINK>). Overall, these infectious complications impact negatively on CVC survival, hospitalisation and overall cost of care.</P>
<P>Premature removal of a CVC due to clinical evidence of CVC infection varied from 31.8% to 55% for tunnelled catheters and 49% to 59% for non-tunnelled catheters (<LINK REF="REF-Alomari-2007" TYPE="REFERENCE">Alomari 2007</LINK>; <LINK REF="REF-Kairaitis-1999" TYPE="REFERENCE">Kairaitis 1999</LINK>; <LINK REF="REF-Weijmere-2004" TYPE="REFERENCE">Weijmere 2004</LINK>). Indeed, the frequency of hospitalisation for vascular access-related infection in haemodialysis patients was highest for patients with a CVC and lowest for patients with an AVF (<LINK REF="REF-Allon-2003" TYPE="REFERENCE">Allon 2003</LINK>; <LINK REF="REF-Klevens-2005" TYPE="REFERENCE">Klevens 2005</LINK>). <LINK REF="REF-Lee-2002" TYPE="REFERENCE">Lee 2002</LINK> reported that the cost for vascular access related care for prevalent maintenance haemodialysis patients was more than five times higher for patients who began the study with a long-term CVC or graft compared to those with a functioning AVF.</P>
<P>A variety of interventions are currently used to prevent CVC-related infections suggesting confusion regarding best practice in this area. Examples of these interventions include prophylactic antibiotics prior to catheter insertion, antimicrobial catheter locking solutions, antimicrobial impregnated catheters, various antiseptics solutions to clean the exit site, use of antimicrobial ointments and various dressings to cover the exit site (<LINK REF="REF-Chatzinikolaou-2003" TYPE="REFERENCE">Chatzinikolaou 2003</LINK>; <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="REF-Le-Corre-2003" TYPE="REFERENCE">Le Corre 2003</LINK>; <LINK REF="REF-McIntyre-2004" TYPE="REFERENCE">McIntyre 2004</LINK>; <LINK REF="REF-Percival-2005" TYPE="REFERENCE">Percival 2005</LINK>; <LINK REF="REF-Saxena-2005" TYPE="REFERENCE">Saxena 2005</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>). However, international guidelines offer conflicting advice on interventions preventing CVC related infections in haemodialysis patients, thereby, compounding the confusion for clinicians (<LINK REF="REF-CARI-2000" TYPE="REFERENCE">CARI 2000</LINK>; <LINK REF="REF-CDC-2002" TYPE="REFERENCE">CDC 2002</LINK>; <LINK REF="REF-ERA_x002d_EDTA-2002" TYPE="REFERENCE">ERA-EDTA 2002</LINK>; <LINK REF="REF-Jindal-2006" TYPE="REFERENCE">Jindal 2006</LINK>; <LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>).</P>
<P>Haemodialysis via a CVC is associated with a significantly higher risk of catheter-related bacteraemia, increased patient hospitalisation and an increased incidence of death due to infection. Lower catheter survival rates are also reported (<LINK REF="REF-Allon-2003" TYPE="REFERENCE">Allon 2003</LINK>; <LINK REF="REF-Astor-2005" TYPE="REFERENCE">Astor 2005</LINK>; <LINK REF="REF-Pisoni-2002" TYPE="REFERENCE">Pisoni 2002</LINK>; <LINK REF="REF-Polkinghorne-2004" TYPE="REFERENCE">Polkinghorne 2004</LINK>). In light of the continued growth in the number of haemodialysis patients using a CVC as a form of vascular access there is a need to conduct a systematic review in order to summarise the evidence available on the interventions preventing CVC related infections. This systematic review will offer a basis for the development of best practice guidelines and will identify areas for further research into this particular aspect of patient care. This review did not examine interventions relating to CVC locking solutions as they are the focus of the following Cochrane review '<I>Antibiotic lock therapy for preventing dialysis </I>catheter-related<I> infections in haemodialysis patients</I>' or intranasal application of antimicrobial agents.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-11-03 03:59:32 +1100" MODIFIED_BY="Margaret McCann">
<P>To evaluate the benefits and harms of prophylactic topical antimicrobials, topical antiseptics, medicated dressings and non-medicated dressings have on the incidence of infectious complications among haemodialysis patients with CVC.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-05 15:59:54 +1100" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2009-11-05 15:59:54 +1100" MODIFIED_BY="Narelle S Willis">
<CRIT_STUDIES MODIFIED="2009-01-29 04:59:41 +1100" MODIFIED_BY="Margaret McCann">
<P>All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at the effect of prophylactic antimicrobials, topical antiseptics, medicated dressings and non-medicated dressings have on the incidence of infectious complications among haemodialysis patients with CVC. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-11-05 15:59:50 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<UL>
<LI>Adults and children with ESKD who had or were about to commence either short-term or maintenance haemodialysis using tunnelled or non-tunnelled CVC as vascular access.</LI>
<LI>Children were defined as up to the age of 18 years of age or as defined by the paper.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<UL>
<LI>Adults and children whose vascular access for haemodialysis included antimicrobial impregnated CVC or CVC using locking solutions which have antimicrobial properties. These interventions were excluded as they are the focus of the following Cochrane review <I>Antibiotic lock therapy for preventing dialysis </I>catheter-related<I> infections in haemodialysis patients'.</I>
</LI>
<LI>Adults and children with ESKD whose CVC was used for purposes other than haemodialysis.</LI>
</UL>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-11-05 15:59:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Studies describing the following comparisons were eligible for the review:<BR/>
</P>
<UL>
<LI>Skin cleansers versus no skin cleansers.</LI>
<LI>Skin cleansing using different cleaning solutions.</LI>
<LI>Comparison between different cleaning techniques.</LI>
<LI>Antibiotics versus no antibiotics.</LI>
<LI>Antibiotics using different modes of administration oral /Intravenous /topical.</LI>
<LI>Antibiotics using different dosages.</LI>
<LI>Antibiotics using different durations.</LI>
<LI>Antibiotics using different starting points.</LI>
<LI>Topical antimicrobial versus no topical antimicrobial.</LI>
<LI>Topical antimicrobial using different durations.</LI>
<LI>Different topical antimicrobial agents.</LI>
<LI>Different non-medicated topical dressings.</LI>
<LI>Different medicated dressings.</LI>
<LI>Non-medicated and medicated dressings.</LI>
<LI>Frequency of dressing changes.</LI>
<LI>Different health care staff who inserted CVC.</LI>
<LI>Different insertion techniques.</LI>
<LI>Different health care staff accessing CVC.</LI>
<LI>Different techniques used to access CVC.</LI>
</UL>
<P>Studies describing intranasal application of mupirocin in haemodialysis patients were not considered and are included in a Cochrane review on mupirocin ointment for preventing <I>S. aureus</I> infections in nasal carriers (<LINK REF="REF-Van-Rijen-2008" TYPE="REFERENCE">Van Rijen 2008</LINK>).</P>
<P>For the purposes of clarity the following definitions were used:<BR/>
</P>
<UL>
<LI>Antimicrobials are any agents capable of destroying or inhibiting the growth of micro-organisms (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>).</LI>
<LI>Skin cleansers such as antiseptic agents aid in the physical removal of foreign materials such as dirt, micro-organisms, and dead cells.</LI>
<LI>Antiseptic is any agent capable of preventing infection by inhibiting the growth of micro-organisms. These agents are routinely thought of as topical agents for application to the skin (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>).</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-11-04 15:14:50 +1100" MODIFIED_BY="[Empty name]">
<P>The following outcomes were to be assessed.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-03-30 10:45:00 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Incidence and type of infectious complication.</LI>
<LI>Patient mortality.</LI>
<LI>Survival rate of CVC.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-03-30 10:45:06 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Time to development of infection.</LI>
<LI>Episodes of hospitalisation.</LI>
<LI>Patient morbidity.</LI>
<LI>Quality of life issues.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-11-04 15:53:56 +1100" MODIFIED_BY="[Empty name]">
<P>The following sources were used to identify relevant studies.</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-11-04 15:53:56 +1100" MODIFIED_BY="[Empty name]">
<OL>
<LI>The Cochrane Renal Groups Specialised Register and the Cochrane Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I>. CENTRAL and the Renal Groups Specialised Register contain the handsearched results of conference proceedings from general and speciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both retrospective and prospective (<LINK REF="REF-Master-List-2009" TYPE="REFERENCE">Master List 2009</LINK>). Therefore we did not specifically search conference proceedings. Please refer to The Cochrane Renal Group's Module in <I>The Cochrane Library </I>for the most up-to-date list of conference proceedings (<LINK REF="REF-Renal-Group-2009" TYPE="REFERENCE">Renal Group 2009</LINK>)</LI>
<LI>MEDLINE using the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) with a specific search strategy developed with input from the Cochrane Renal Group's Trial Search Co-ordinator.</LI>
<LI>EMBASE using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) together with a specific search strategy developed with input from the Cochrane Renal Group's Trial Search Co-ordinator.</LI>
</OL>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for electronic search strategies.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-11-04 15:39:40 +1100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reference lists of nephrology textbooks, review articles and relevant studies.</LI>
<LI>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-05 14:12:12 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_SELECTION MODIFIED="2009-11-04 15:39:44 +1100" MODIFIED_BY="[Empty name]">
<P>The search strategy described above was used to obtain titles and abstracts of studies that might be relevant to the review. The titles and abstracts were screened independently by MMcC and ZM, who discarded studies that were not applicable based on the inclusion criteria for this review, however studies and reviews that might include relevant data or information on studies were retained initially. The authors (MMcC and ZM) independently assessed retrieved abstracts and, if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-11-04 15:39:52 +1100" MODIFIED_BY="[Empty name]">
<P>Data extraction was carried out independently by the same authors using standard data extraction forms. It was planned that studies reported in non-English language journals would be translated before assessment. Where more than one publication of one study existed, reports were grouped together and the most recent or most complete dataset was used. Any discrepancy between published versions are highlighted. Any further information required from the original author was requested through written or electronic correspondence and any relevant information obtained in this manner was included in the review. Disagreements were resolved in consultation with the Cochrane Renal Group.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-11-04 15:23:16 +1100" MODIFIED_BY="[Empty name]">
<P>The quality of studies to be included were assessed independently by MMcC and ZM without blinding to authorship or journal, using the checklist developed for the Cochrane Renal Group. Discrepancies were resolved by discussion with the Cochrane Renal Group. The quality items assessed were allocation concealment, blinding (participants, investigators, outcome assessors and data analysis), intention-to-treat analysis and completeness of follow-up.</P>
<SUBSECTION>
<HEADING LEVEL="4">Quality checklist</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment</HEADING>
<UL>
<LI>Adequate (A) - Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study</LI>
<LI>Unclear (B) - Randomisation stated but no information on method used is available</LI>
<LI>Inadequate (C) - Method of randomisation used such as alternate medical record numbers or unsealed envelopes; any information in the study that indicated that investigators or participants could influence intervention group</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blinding</HEADING>
<UL>
<LI>Blinding of investigators: Yes/no/not stated</LI>
<LI>Blinding of participants: Yes/no/not stated</LI>
<LI>Blinding of outcome assessor: Yes/no/not stated</LI>
<LI>Blinding of data analysis: Yes/no/not stated</LI>
</UL>
<P>The above are considered not blinded if the treatment group can be identified in &gt; 20% of participants because of the side effects of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Intention-to-treat</HEADING>
<UL>
<LI>Yes: Specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.</LI>
<LI>Yes: Not stated but confirmed on study assessment</LI>
<LI>No: Not reported and lack of intention-to-treat analysis confirmed on study assessment. (Patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation)</LI>
<LI>No: Stated but not confirmed upon study assessment</LI>
<LI>Not stated</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Completeness of follow-up</HEADING>
<UL>
<LI>Per cent of participants excluded or lost to follow-up.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-11-04 15:20:58 +1100" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes (mortality, presence of infection) results are expressed as risk ratios (RR) with 95% confidence intervals (CI). It was planned that if continuous scales of measurement were used to assess the effects of treatment (e.g. catheter survival), the mean difference (MD) would be used, or the standardised mean difference (SMD) if different scales have been used.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-11-05 14:12:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-11-05 14:06:01 +1100" MODIFIED_BY="Narelle S Willis">
<P>Data was pooled using the random-effects model but the fixed-effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-11-04 15:19:10 +1100" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was used to explore possible sources of heterogeneity (e.g. participants, interventions and study quality). Heterogeneity among participants could be related to age and renal pathology. Heterogeneity in treatments could be related to prior agent(s) used and the agent, dose and duration of therapy. It was planned that adverse effects would be tabulated and assessed with descriptive techniques, as they are likely to be different for the various agents used.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-11-05 16:06:39 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2009-11-05 16:06:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>A search of CENTRAL, MEDLINE, EMBASE and the Cochrane Renal Group's specialised register yielded 81 titles and abstracts (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Letters and emails seeking information on published and unpublished RCTs were sent to medical and nursing nephrology experts. Following this process one additional study was identified (<LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>). After an initial review, 64 were excluded because they were RCTs evaluating other interventions (e.g. catheter locking solutions), involved another patient population (e.g. peritoneal dialysis population) or were not RCTs. Full text versions of the remaining 18 were reviewed. Two papers were excluded, one was not an RCT and the second study was excluded as it involved the use of CVC for purposes other than haemodialysis (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). In total 10 studies (786 participants), reported in 16 publications were included in this review (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) (<LINK REF="STD-Atapour-2006" TYPE="STUDY">Atapour 2006</LINK>; <LINK REF="STD-Huraib-1994" TYPE="STUDY">Huraib 1994</LINK>; <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK>; <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>; <LINK REF="STD-Levin-1991" TYPE="STUDY">Levin 1991</LINK>; <LINK REF="STD-le-Corre-2003" TYPE="STUDY">le Corre 2003</LINK>; <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>; <LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>). Attempts were made to seek further information on study methods, one author could not be contacted (<LINK REF="STD-Huraib-1994" TYPE="STUDY">Huraib 1994</LINK>). The authors of four studies were contacted for further information (<LINK REF="STD-Atapour-2006" TYPE="STUDY">Atapour 2006</LINK>; <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>; <LINK REF="STD-le-Corre-2003" TYPE="STUDY">le Corre 2003</LINK>; <LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>), one author (<LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>) responded and information given was included. All studies were published in English between 1986 and 2006 and were conducted in seven countries (Australia, Brazil, Canada, Iran, Malaysia, Saudi Arabia and USA).</P>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Topical antimicrobials</HEADING>
<P>Five studies (379 patients) randomised patients to a topical antimicrobial ointment which was compared to either no ointment or placebo (<LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>; <LINK REF="STD-Levin-1991" TYPE="STUDY">Levin 1991</LINK>; <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical mupirocin ointment</HEADING>
<P>Three studies (217 patients) evaluated the effect of topical mupirocin ointment versus no ointment (<LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>). <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK> only focused on catheter-related infections caused by <I>Staphylococcus aureus</I>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical povidone-iodine ointment</HEADING>
<P>
<LINK REF="STD-Levin-1991" TYPE="STUDY">Levin 1991</LINK> (129 patients) compared povidone-iodine ointment with no ointment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical polysporin ointment</HEADING>
<P>The <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK> (162 patients) investigated the effect of polysporin triple ointment versus a placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Topical honey</HEADING>
<P>Two studies (150 patients) compared topical honey ointment with an antimicrobial ointment (<LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK>; <LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>). <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK> (50 patients) compared Medihoney and mupirocin ointment and <LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK> (49 patients) compared Manuka honey with povidone-iodine ointment.  </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Non medicated dressings</HEADING>
<P>One study (58 patients) compared a transparent dressing with a dry dressing (<LINK REF="REF-Le-Corre-2003" TYPE="REFERENCE">Le Corre 2003</LINK>). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tunnelled versus non-tunnelled CVC</HEADING>
<P>
<LINK REF="STD-Atapour-2006" TYPE="STUDY">Atapour 2006</LINK> (30 patients) compared tunnelled CVC versus non-tunnelled CVC.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Post-insertion catheter care protocol</HEADING>
<P>
<LINK REF="STD-Huraib-1994" TYPE="STUDY">Huraib 1994</LINK> (40 patients) compared two different post-insertion catheter care protocols.</P>
<P>No RCTs investigating the effect of the following interventions could be found: skin cleaners versus no skin cleaners, different cleansing solutions, different cleaning techniques; use of antibiotics and different modes of administration, dosage, duration and starting points; medicated dressings; frequency of dressing change; different health care staff who inserted CVC and different techniques used to access CVC.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-11-05 11:59:27 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Randomisation</HEADING>
<P>Method of randomisation was not stated in 3/10 studies (<LINK REF="STD-Huraib-1994" TYPE="STUDY">Huraib 1994</LINK>; <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>; <LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>). The randomisation methods used in the remaining seven studies were as follows:</P>
<UL>
<LI>Computer generated random number list (<LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK>; <LINK REF="STD-le-Corre-2003" TYPE="STUDY">le Corre 2003</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>)</LI>
<LI>Independent central randomisation facility using a computer generated random number list (<LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>)</LI>
<LI>Sequenced allocation using designation box (<LINK REF="STD-Levin-1991" TYPE="STUDY">Levin 1991</LINK>)</LI>
<LI>Every other case randomly assigned to one of two groups tunnelled or non-tunnelled CVC (<LINK REF="STD-Atapour-2006" TYPE="STUDY">Atapour 2006</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Allocation concealment was adequate in four studies (<LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK>; <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>; ), unclear in five (<LINK REF="STD-Huraib-1994" TYPE="STUDY">Huraib 1994</LINK>; <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>; <LINK REF="STD-Levin-1991" TYPE="STUDY">Levin 1991</LINK>; <LINK REF="STD-le-Corre-2003" TYPE="STUDY">le Corre 2003</LINK>; <LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>) and inadequate in one (<LINK REF="STD-Atapour-2006" TYPE="STUDY">Atapour 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<UL>
<LI>
<I>Blinding of participants: </I>Two studies stated the participants were blinded (<LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>; <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>). For the remaining studies this was either not possible or not stated.</LI>
<LI>
<I>Blinding of investigators: </I>Two studies stated the investigators were blinded (<LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>; <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>). For the remaining studies this was either not possible or not stated.</LI>
<LI>
<I>Blinding of outcome assessors: </I>Four studies stated the outcome assessors were blinded (<LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>; <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>; <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK>). For the remaining studies this was not stated.</LI>
<LI>
<I>Blinding of data assessors: </I>Only one study stated the data assessors were blinded (<LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>). For the remaining studies blinding was not stated.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to treat</HEADING>
<P>Analysis was based on intention-to-treat in five studies (<LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>; <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>; <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness of follow-up</HEADING>
<P>The completeness of follow-up ranged from 55% to 100%.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-11-05 14:29:34 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Topical antimicrobial ointment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incidence and type of infections</HEADING>
<P>The risk of CVC infection (exit site and catheter-related bacteraemia) was significantly reduced by topical antimicrobial ointments when compared to no ointments or placebo (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1 (2 studies, 193 patients): RR 0.33, 95% CI 0.18 to 0.61). The outcome of this analysis can be explained by the <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK> which had a weighting of 90.5%. There was no significant heterogeneity between studies used in this analysis (Chi² = 0.49, P = 0.48; I² = 0%). Subgroup analysis indicates that polysporin ointment (<LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>) significantly reduced the risk of CVC infection (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.3 (1 study, 162 patients): RR 0.35, 95% CI 0.18 to 0.68) while mupirocin ointment had no significant effect on CVC infection (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2 (1 study, 31 patients): RR 0.16, 95% CI 0.02 to 1.25).</P>
<P>Topical antimicrobial ointments compared to no ointments or placebo significantly reduced the risk of exit site infection (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.1 (4 studies, 346 patients): RR 0.20, 95% CI 0.09 to 0.45) and catheter-related bacteraemia (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.1 (5 studies, 508 patients): RR 0.26, 95% CI 0.15 to 0.46), which were caused by all types of organisms. There was no significant heterogeneity across the relevant studies investigating either exit site infection (Chi² = 0.69, P = 0.88; I² = 0%) or catheter-related bacteraemia (Chi² = 3.37, P = 0.50; I² = 0%). <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK> only investigated infections caused by <I>S. aureus</I>. A subgroup analysis which excluded<I> </I>
<LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>
<I> </I>indicated similar significant reduced risk for exit site infection (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.2 (3 studies, 210 patients): RR 0.22, 95% CI 0.08 to 0.64) and catheter-related bacteraemia (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.2 (4 studies, 372 patients): RR 0.30, 95% CI 0.16 to 0.55).</P>
<P>Analysis of individual topical antimicrobial ointments suggest mupirocin when compared to no ointment or placebo significantly reduced the risk of exit site infections caused by all types of organisms (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.4 (3 studies, 217 patients): RR 0.17, 95% CI 0.06 to 0.48). Heterogeneity was not evident between studies (Chi² = 0.40, P = 0.82; I² = 0%). However, a subgroup analysis which excluded <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK> indicated that mupirocin ointment did not significantly reduce the risk of exit site infection (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.5 (2 studies, 81 patients): RR 0.14, 95% CI 0.02 to 1.14). Analysis of exit site infections caused only by <I>S. aureus</I> indicate that mupirocin significantly reduced the risk of this type of infection (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.6 (I study, 136 patients): RR 0.18, 95% CI 0.06 to 0.60).</P>
<P>Mupirocin ointment compared to no ointment or placebo significantly reduced the risk of catheter-related bacteraemia caused by all types of organisms (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.4 (3 studies, 217 patients): RR 0.17, 95% CI 0.07 to 0.43). There was no evidence of heterogeneity between studies (Chi² = 0.27, P = 0.87; I² = 0%). Analysis which excluded <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK> indicated a similar significant reduced risk (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.5 (2 studies, 81 patients): RR 0.21, 95% CI 0.06 to 0.69). The risk of catheter-related bacteraemia caused by <I>S. aureus</I> was significantly reduced in those patients using mupirocin ointment (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.6 (1 study, 136 patients): RR 0.13, 95% CI 0.03 to 0.54).</P>
<P>When compared to no ointment or placebo povidone-iodine ointment significantly reduced the risk of exit site infection (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.7 (1 study, 129 patients): RR 0.26, 95% CI 0.08 to 0.88). The risk of catheter-related bacteraemia was significantly reduced by polysporin ointment (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.7 (1 study, 162 patients): RR 0.40, 95% CI 0.19 to 0.86) and povidone-iodine ointment (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.8 (1 study, 129 patients): RR 0.10, 95% CI 0.01 to 0.72).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patient mortality</HEADING>
<P>Topical antimicrobials compared to no ointment or placebo had no significant effect on all-cause mortality (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.1 (3 studies, 322 patients): RR 0.36, 95% CI 0.12 to 1.07). There was some degree of heterogeneity across studies (Chi² = 2.95, P = 0.23; I² = 32%). Subgroup analyses suggest that mupirocin (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.2 (1 study, 31 patients): RR 0.12, 95% CI 0.01 to 2.13) and povidone-iodine ointment (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.4 (1 study, 129 patients): RR 0.84, 95% CI 0.24 to 2.98) had no effect on all-cause mortality while polysporin ointment showed a significant reduction (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.3 (1 study, 162 patients): RR 0.22, 95% CI 0.07 to 0.74).</P>
<P>Topical antimicrobials significant reduced mortality related to infection (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>.1 (3 studies, 322 patients): RR 0.15, 95% CI 0.03 to 0.81). There was no significant heterogeneity between these studies (Chi² = 0.66, P = 0.72; I² = 0%). However, in a subgroup analysis mupirocin, polysporin or povidone-iodine ointments did not have a significant effect on mortality related to infection (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>.2; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>.3; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Survival rate of CVC</HEADING>
<P>Topical antimicrobial ointments compared to no ointment or placebo had a significant favourable effect on catheter removal due to infection caused by all types of organisms (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.1 (4 studies, 379 patients): RR 0.35, 95% CI 0.25 to 0.50). No significant heterogeneity was evident (Chi² = 1.43, P = 0.70; I² = 0%). Subgroup analysis excluding <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK> indicated similar significant effects (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.2 (3 studies, 243 patients): RR 0.30, 95% CI 0.16 to 0.56). Heterogeneity was not evident (Chi² = 0.98, P = 0.61; I² = 0%). Catheter removal due to <I>S. aureus</I> was significantly reduced by topical antimicrobial ointment (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.3 (1 study, 136 patients): RR 0.38, 95% CI 0.25 to 0.58).</P>
<P>Analysis of individual topical antimicrobial ointments compared to no ointment or placebo indicated that polysporin ointment had a significant effect on catheter removal due to infection (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.7 (1 study, 162 patients): RR 0.36, 95% CI 0.17 to 0.77). Mupirocin also had a significant effect on catheter removal due to infections caused by all types of organisms (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.4 (3 studies, 217 patients): RR 0.35, 95% CI 0.23 to 0.52). This significant effect persisted when <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK> was excluded (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.5 (2 studies, 81 patients): RR 0.18, 95% CI 0.06 to 0.58). Heterogeneity was not evident. Mupirocin had a significant positive effect on catheter removal due to <I>S. aureus</I> infection (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.6 (1 study, 136 patients): RR 0.38, 95% CI 0.25 to 0.58).</P>
<P>It was not possible to analyse the effect of topical antimicrobial ointments, when compared to no ointments or placebo, on survival time of CVC due to the inconsistency in the manner in which survival time of catheters was reported (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK> used median duration of catheter placement, range and number of cumulative days catheter was in place. <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK> reported median catheter survival censored for end of treatment. <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK> used mean duration and range of catheter placement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Episodes of hospitalisation</HEADING>
<P>When compared to no ointment or placebo, mupirocin ointment had no significant effect on frequency of hospitalisation (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>.1 (1 study, 136 patients): RR 0.85, 95% CI 0.72 to 1.01) but had a significant effect on episodes of hospitalisation due to <I>S. aureus</I> infection (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>.1 (1 study, 136 patients): RR 0.35, 95% CI 0.13 to 0.91). Polysporin had a significant effect on episodes of hospitalisation (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>.1 (1 study, 162 patients): RR 0.30, 95% CI 0.13 to 0.71).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time to development of infection</HEADING>
<P>Only <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK> and <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK> reported time to development of infection. However, it was not possible to analyse the effect of topical antimicrobial ointments due to the inconsistency in the manner in which they were reported (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK> noted median interval between catheter insertion and onset of catheter-associated bacteraemia and reported time to first exit site infection in patients receiving mupirocin ointment. <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK> also reported the effect of nasal colonisation with <I>S. aureus</I> at baseline on time to first infection. <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK> noted time to first infection and first bacteraemia using log rank test.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse reactions</HEADING>
<P>Three studies reported no adverse reactions to mupirocin ointment (<LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>). Of these three studies only <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK> addressed mupirocin resistance, indicating that no mupirocin-resistant staphylococcal isolates were observed. Adverse reactions to povidone-iodine ointment were not detected in <LINK REF="STD-Levin-1991" TYPE="STUDY">Levin 1991</LINK>, while the <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK> did not comment on adverse reactions to polysporin ointment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical honey</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incidence and type of infections</HEADING>
<P>The use of topical honey (Medihoney/Manuka) when compared to topical antimicrobial ointments did not significantly reduce the risk of exit site infection (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.1 (2 studies, 150 patients): RR 0.45, 95% CI 0.10 to 2.11) or catheter-related bacteraemia (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.1 (2 studies, 150 patients): RR 0.80, 95% CI 0.37 to 1.73). There was no evidence of heterogeneity. Subgroup analyses suggest that honey did not significantly reduce the risk of exit site infection or catheter-related bacteraemia when compared to topical mupirocin or povidone-iodine ointment (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.2; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.3; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.2; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.3). <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK> reported the bacteraemia-free survival periods for Medihoney (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse reactions</HEADING>
<P>No adverse reactions to topical honey were noted by <LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>. One case of transient, mild local skin discomfort was reported by <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK> which resolved after a number of days despite continued administration of the agent. A similar reaction was noted in one patient who received mupirocin ointment. No systemic reaction to either honey or mupirocin was observed. Mupirocin resistant strains were not detected in any staphylococcal isolates from study patients with catheter-associated bacteraemia.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Non-medicated dressings</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incidence and type of infections</HEADING>
<P>The use of transparent polyurethane dressing compared to dry gauze dressing did not significantly reduce the risk of CVC infection (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> (1 study, 58 patients): RR 0.33, 95% CI 0.04 to 3.02), exit site infection (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> (1 study, 58 patients): RR 0.33, 95% CI 0.01 to 7.86) or catheter-related bacteraemia (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK> (1 study, 58 patients): RR 0.50, 95% CI 0.05 to 5.21).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse reactions</HEADING>
<P>Erythema (two patients) and pruritus (six patients) was observed in patients whose CVC site was dressed with dry gauze while nine patients who received a transparent dressing also experienced both erythema and pruritus (<LINK REF="STD-le-Corre-2003" TYPE="STUDY">le Corre 2003</LINK>). The majority of the transparent dressing local reactions were linked to insufficient time been given to drying of chlorhexidine cleansing solution before application of dressing.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tunnelled CVC versus non-tunnelled CVC</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incidence and type of infections</HEADING>
<P>Tunnelled CVC did not significantly reduce the risk of exit site infection (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> (1 study, 29 patients): RR 1.07, 95% CI 0.17 to 6.61) or catheter-related bacteraemia (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK> (1 study, 29 patients): RR 0.98, 95% CI 0.68 to 1.43) when compared to non-tunnelled CVC.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Post insertion catheter care protocols - haemodialysis nurses using heparin 3 times/week versus intravenous team using heparin 3 times/day</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incidence and type of infections</HEADING>
<P>There was no significance difference in the risk of CVC infection (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> (1 study, 40 patients): RR 0.50, 95% CI 0.14 to 1.73), exit site infection (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK> (1 study, 40 patients): RR 0.67, 95% CI 0.12 to 3.57) or catheter-related bacteraemia (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK> (1 study, 40 patients): RR 0.33, 95% CI 0.04 to 2.94) between haemodialysis nurses using heparin three times/week and an intravenous team using heparin 3 times/day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patient mortality</HEADING>
<P>When compared to the intravenous team, haemodialysis nurses did not significantly effect all-cause mortality (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK> (1 study, 40 patients): RR 5.00, 95% CI 0.26 to 98.00).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other outcomes</HEADING>
<P>Catheter removal due to infection, survival time of CVC, time to development of infection, all-cause mortality, mortality related to infection, frequent and episodes of hospitalisation and episodes of hospitalisations due to infection were seldom reported.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-11-05 16:00:29 +1100" MODIFIED_BY="Narelle S Willis">
<SUMMARY_OF_RESULTS MODIFIED="2009-11-05 14:30:28 +1100" MODIFIED_BY="Narelle S Willis">
<P>Results from this systematic review suggest:</P>
<SUBSECTION>
<HEADING LEVEL="3">Topical antimicrobial ointments</HEADING>
<UL>
<LI>Topical antimicrobial ointments which include mupirocin, polysporin and povidone-iodine ointment significantly reduced the risk of catheter-related infections, exit site infections and catheter-related bacteraemia while having a significant effect on mortality-related infection and catheter removal due to infection.</LI>
<LI>Topical mupirocin ointment significantly reduced the risk of catheter-related bacteraemia and catheter removal due to infection. It did not significantly reduce the risk of exit site infection and had no significant effect on all-cause mortality, mortality related to infection or frequency of hospitalisation.</LI>
<LI>Topical mupirocin ointment significantly reduced the risk of <I>S. aureus</I> exit site infection and catheter-related bacteraemia. The risk of catheter removal and episodes of hospitalisation due to <I>S. aureus</I> were also significantly reduced in those patients who used topical mupirocin ointment.</LI>
<LI>Topical polysporin ointment significantly reduced the risk of catheter-related infection and catheter-related bacteraemia. It also significantly reduced the risk of catheter removal due to infection and episodes of hospitalisation. Polysporin ointment had a significant effect on all-cause mortality but did not significantly reduce mortality related to infection.</LI>
<LI>Topical povidone-iodine significantly reduced the risk of exit site infection and catheter-related bacteraemia but had no significant effect on all-cause mortality or mortality related to infection.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical honey</HEADING>
<UL>
<LI>The use of topical honey (Medihoney/Manuka honey) did not significantly reduce the risk of exit site infection or catheter-related bacteraemia when compared to mupirocin or povidone-iodine ointment.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dressings</HEADING>
<UL>
<LI>There was no significant difference in the incidence of CVC infection, exit site infection or catheter-related bacteraemia when transparent dressing was compared to dry gauze dressing.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other interventions</HEADING>
<P>Our review also identified weak evidence from small poor quality studies which suggested that tunnelled CVC did not significantly reduce the risk of exit site infection or catheter-related infection when compared to non-tunnelled CVC. In addition, haemodialysis nurses using heparin three times/ week did not significantly reduce the risk of CVC infection, exit site infection, or catheter-related bacteraemia when compared to intravenous team using heparin three times/day.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-11-05 15:58:58 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Topical antimicrobial ointments</HEADING>
<P>Topical antimicrobial ointments are used as prophylactic agents against CVC infection and include mupirocin and povidone-iodine ointment. A third agent is polysporin triple ointment which is an antibiotic ointment composed of three agents, bacitracin, gramicidin and polymyxin B. In our review topical antimicrobial ointments, which included mupirocin, polysporin and povidone-iodine ointment, significantly reduced the risk of catheter-related infections, exit site infection and catheter-related bacteraemia while having a significant effect on mortality related to infection and catheter removal due to infection.</P>
<P>Mupirocin ointment, like povidone-iodine and polysporin ointment, is normally applied topically to the exit site of the CVC every time it's dressing is changed. It causes few side effects and high concentrations are achieved at the application site. Mupirocin is not used systemically or to treat serious infections (<LINK REF="REF-Herwaldt-1998" TYPE="REFERENCE">Herwaldt 1998</LINK>). Within the dialysis patient population mupirocin ointment can be applied to the skin (CVC exit site or peritoneal dialysis catheter exit site) or intranasally. It has a reported beneficial effect in peritoneal dialysis and haemodialysis patients by eradicating colonisation with <I>S. aureus</I> and significantly reducing the risk of <I>S. aureus</I> infections, including exit site infection and CVC-related bacteraemia (<LINK REF="REF-Laupland-2003" TYPE="REFERENCE">Laupland 2003</LINK>; <LINK REF="REF-Strippoli-2004" TYPE="REFERENCE">Strippoli 2004</LINK>; <LINK REF="REF-Tacconelli-2003" TYPE="REFERENCE">Tacconelli 2003</LINK>; <LINK REF="REF-Van-Rijen-2008" TYPE="REFERENCE">Van Rijen 2008</LINK>). This review focused on topical catheter exit site application of mupirocin ointment. Studies describing intranasal application of mupirocin in haemodialysis patients were not considered and are included in a Cochrane review on mupirocin ointment for preventing <I>S. aureus</I> infections in nasal carriers (<LINK REF="REF-Van-Rijen-2008" TYPE="REFERENCE">Van Rijen 2008</LINK>).</P>
<P>Our review included three studies that investigated the effect of mupirocin ointment on CVC-related infections. One study, which included a small sample size, did not report the method of randomisation or allocation concealment and the type of dressing used in both study groups differed (<LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>). Another study focused exclusively on <I>S. aureus</I> CVC-related infections (<LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>). A meta-analysis which excluded the <I>S. aureus</I> study suggests that mupirocin ointment while significantly reducing the risk of catheter-related bacteraemia did not significantly reduce the risk of exit site infections. This analysis also indicates that mupirocin ointment had a significant effect on catheter removal due to infection. Analysis of the study that focused on <I>S. aureus</I> infections (<LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>) indicates that mupirocin ointment had a significant effect on catheter-related infections caused by <I>S. aureus</I> whereby the risk of <I>S. aureus</I> exit site infection and catheter-related bacteraemia was significantly reduced. In addition, mupirocin has a significant effect on catheter removal due to <I>S. aureus</I> infection. The Trialist involved in this study reported that patients using mupirocin ointment had a 96.6% (95% CI, 92.1 to 100) cumulative probability of not having a <I>S. aureus</I> catheter-related bacteraemia after 15 days versus 82% (95% CI, 72.4 to 91.6; P &lt; 0.001) cumulative probability for those patient with no treatment. This probability remained at 96.6% after 30 days (95% CI, 92.1 to 100) for the mupirocin group but decreased to 75.7% (95% CI, 64.5 to 86.9; P &lt; 0.001) for those not using mupirocin. The hazard ratio of developing <I>S. aureus</I> bacteraemia was 7.2 (95% CI -1.6 to 31.6) times greater in patients not receiving mupirocin. All three studies (<LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>) reported no adverse reactions to the use of mupirocin ointment.</P>
<P>As <I>S. aureus</I> is one of the leading causes of CVC infections in haemodialysis patients (<LINK REF="REF-Herwaldt-1998" TYPE="REFERENCE">Herwaldt 1998</LINK>) our review indicates a beneficial effect against <I>S. aureus</I> CVC infections, however, this is based on the findings of one high quality study (<LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>). Mupirocin resistance among <I>S. aureus</I> isolates is a concern that has been raised within the dialysis and broader medical community (<LINK REF="REF-Cookson-1990" TYPE="REFERENCE">Cookson 1990</LINK>; <LINK REF="REF-Tacconelli-2003" TYPE="REFERENCE">Tacconelli 2003</LINK>; <LINK REF="REF-Van-Rijen-2008" TYPE="REFERENCE">Van Rijen 2008</LINK>). However, our review found no case of mupirocin resistance in the one study that monitored this outcome. Mupirocin resistance has been reported in other patient populations (<LINK REF="REF-Van-Rijen-2008" TYPE="REFERENCE">Van Rijen 2008</LINK>) so there is a need for future studies to monitor mupirocin resistant in staphylococcal isolates. Concerns about mupirocin resistance is also reflected in the manner in which International guidelines differ in their recommendations (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>) and as a result there is no evidence of an optimal strategy for its use. Dialysis facilities that routinely use mupirocin ointment should develop a strategy to monitor the impact of its use on antimicrobial resistance.</P>
<P>Povidone-iodine ointment like mupirocin is not used systemically or to treat serious infections. It has residual antibacterial effect at the site of application but can cause allergic reactions and some local side effects (<LINK REF="REF-Herwaldt-1998" TYPE="REFERENCE">Herwaldt 1998</LINK>). Our review noted no adverse reactions to the use of povidone-iodine ointment. A Cochrane review that investigated antimicrobial agents for preventing peritonitis in peritoneal dialysis patients noted that povidone-iodine ointment or povidone-iodine powder when applied to the peritoneal dialysis catheter exit site did not significantly reduce the risk of peritonitis, exit site or tunnel infection when compared to no treatment or soap and water (<LINK REF="REF-Strippoli-2004" TYPE="REFERENCE">Strippoli 2004</LINK>). In contrast, our review indicated that povidone-iodine ointment significantly reduced the risk of CVC exit site infection and catheter-related bacteraemia. However, these findings are based on one study (<LINK REF="STD-Levin-1991" TYPE="STUDY">Levin 1991</LINK>) which lacked detailed information on allocation concealment. Our review also indicated that the routine application of polysporin triple ointment to the CVC exit site significantly reduced the risk of catheter-related bacteraemia, catheter removal due to infection and episodes of hospitalisation. Again these findings are based on one study. Adverse reaction to polysporin ointment was not reported.</P>
<P>Despite the lack of high level evidence supporting the routine use of povidone-iodine ointment and polysporin ointment and the reported concerns of mupirocin resistance, international guidelines continue to recommend the routine use of mupirocin, povidone-iodine and polysporin ointment in the prevention of CVC infection in haemodialysis patients. The Canadian Society of Nephrology recommends either povidone, mupirocin or polysporin ointments. These recommendations were informed by the findings of three studies which are included in this review (<LINK REF="STD-Levin-1991" TYPE="STUDY">Levin 1991</LINK>; <LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>; <LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>). Similarly the <LINK REF="REF-UK-Renal--Association-2007" TYPE="REFERENCE">UK Renal Association 2007</LINK> recommends that local protocols may incorporate infection control measures that previous RCT have shown can lead to a reduction in catheter-related infection and suggest the use of topical mupirocin, Medihoney or an antiseptic at the catheter exit site. In contrast to these recommendations the UK Epic 2 guidelines recommends that topical antimicrobial ointments should not be used in the prevention of CVC (<LINK REF="REF-Pratt-2007" TYPE="REFERENCE">Pratt 2007</LINK>). While the CDC, using one study to inform their opinion, recommends the use of povidone-iodine ointment (<LINK REF="REF-CDC-2002" TYPE="REFERENCE">CDC 2002</LINK>). Finally, two International Nephrology Guideline groups make no recommendations on the use of topically antimicrobials ointments (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>; <LINK REF="REF-Tordoir-2007" TYPE="REFERENCE">Tordoir 2007</LINK>). While there is high level evidence supporting the routine use of mupirocin concerns remain regarding the emergence of mupirocin resistance. However, our review reports no case of mupirocin resistance and therefore can not confirm if this concern is a real or proven threat.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Honey </HEADING>
<P>Historically honey has been used in the treatment of wounds, however only in the last decade have RCTs been conducted to evaluate the efficacy of this agent (<LINK REF="REF-Jull-2008b" TYPE="REFERENCE">Jull 2008b</LINK>). Honey is also reported to have antimicrobial properties that lends itself to its possible use as a prophylactic agent at temporary and permanent invasive device exit sites, such as CVC and peritoneal dialysis catheters. In vitro investigations have confirmed the susceptibility of pathogens to the antimicrobial actions of honey (<LINK REF="REF-French-2005" TYPE="REFERENCE">French 2005</LINK>). A RCT comparing the use of Manuka honey versus hydrogel dressing in chronic leg ulcers suggests that Manuka honey was effective in eradicating MRSA from 70% of chronic venous ulcers (<LINK REF="REF-Gethin-2008" TYPE="REFERENCE">Gethin 2008</LINK>). A Cochrane review on honey as a topical treatment for wounds noted that while honey dressings increased the likelihood a burn wound would remain sterile when compared to other treatments it did not significantly decrease the infection rate in other types of wounds (<LINK REF="REF-Jull-2008a" TYPE="REFERENCE">Jull 2008a</LINK>). In our review Medihoney and Manuka honey when compared to mupirocin or povidone-iodine did not significant reduce the risk of exit site infection or catheter-related bacteraemia. No adverse reactions to honey were noted by <LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK> while <LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK> reported a local skin reaction in one patient. This meta-analysis consisted of two studies whose samples size ranged from 49 to 101, with one study not reporting the method of randomisation or allocation concealment (<LINK REF="STD-Quadri-1999" TYPE="STUDY">Quadri 1999</LINK>). As there is no significant difference between the topical use of honey and mupirocin ointment in the prevention of CVC infection the use of honey as a possible alternative prophylactic agent can not be ruled out and needs to be explored further.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dressings </HEADING>
<P>The purpose of a CVC dressing is to protect the catheter insertion site from external contamination; anchor the catheter so preventing trauma or CVC accidental dislodgement and provide a barrier permeable to water and bacteria, which deters bacterial proliferation at the insertion site (<LINK REF="REF-Treston_x002d_Aurand-1997" TYPE="REFERENCE">Treston-Aurand 1997</LINK>). Historically two types of dressings are used to protect the CVC site, a transparent semipermeable polyurethane dressing or dry gauze type dressing. Transparent dressings are occlusive dressings which allow continuous inspection of the insertion site, are comfortable for patients who can bath and shower without saturating the dressing and require less frequent changes when compared to dry gauze dressing (<LINK REF="REF-CDC-2002" TYPE="REFERENCE">CDC 2002</LINK>). Transparent dressings are considered more cost effective as they require less nursing time due to the reduced number of dressings changes that occur in a week and the reduced time it takes to change the dressing (<LINK REF="REF-Brandt-1996" TYPE="REFERENCE">Brandt 1996</LINK>; <LINK REF="REF-Shivnan-1991" TYPE="REFERENCE">Shivnan 1991</LINK>).</P>
<P>The moisture vapour permeability of transparent dressings is sufficiently low to enable skin evaporative water loss through. If however blood or serous fluid leakage occurs at the insertion site, its accumulation under a film type dressing may create an environment that is conducive to microbial growth (<LINK REF="REF-Wille-1993" TYPE="REFERENCE">Wille 1993</LINK>). Indeed, concerns have been raised in a number of studies that the type of dressing applied to the CVC may influence the risk of catheter-related infection with some authors suggesting that transparent dressings are conducive to micro-organism growth (<LINK REF="REF-Conly-1989" TYPE="REFERENCE">Conly 1989</LINK>; <LINK REF="REF-Richet-1990" TYPE="REFERENCE">Richet 1990</LINK>). Conversely, a number of RCTs on bone marrow transplant patients report no significant difference existed between transparent and dry dressing in the incidence of catheter-related infection (<LINK REF="REF-Brandt-1996" TYPE="REFERENCE">Brandt 1996</LINK>; <LINK REF="REF-Shivnan-1991" TYPE="REFERENCE">Shivnan 1991</LINK>).</P>
<P>In our systematic review only one study was found that compared the use of transparent and dry gauze dressing in a haemodialysis patient population. Local skin reactions were reported in six patients using dry dressings and nine patients using transparent dressings. Local skin reactions that occurred with transparent dressings developed as a result of not letting the chlorhexidine cleansing solution dry before applying the dressing. Results suggests that there was no significant difference in the incidence of CVC infection, exit site infection or catheter-related bacteraemia when transparent dressing was compared to dry gauze dressing. As these findings were based on one study (<LINK REF="STD-le-Corre-2003" TYPE="STUDY">le Corre 2003</LINK>), which had a small sample population (58 patients) it is not feasible to draw any conclusions regarding the risk of CVC infection with each dressing type. This lack of clarity on what is the best dressing to use is reinforced by a Cochrane review (<LINK REF="REF-Gilles-2003" TYPE="REFERENCE">Gilles 2003</LINK>) on the use of gauze and tape and transparent polyurethane dressings for CVC in a variety of clinical settings. This 2003 review noted that there was no evidence of any difference in the incidence of infectious complications between any dressing types and suggested that this lack of difference could be explained by the lack of adequate data as each comparison in the review was based on no more than two studies and all studies reported data from a small patient sample. The authors concluded that choice of dressing for CVC can be based on patient preference and or cost. Recommendations by international guidelines (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>) differ on the type of dressings that should be used. Those guidelines that recommended the use of a dry dressing did so on the evidence of one RCT (<LINK REF="REF-UK-Renal--Association-2007" TYPE="REFERENCE">UK Renal Association 2007</LINK>) or a RCT that also included the additional intervention of topical antimicrobial ointment (<LINK REF="REF-Jindal-2006" TYPE="REFERENCE">Jindal 2006</LINK>). The <LINK REF="REF-CDC-2002" TYPE="REFERENCE">CDC 2002</LINK> and <LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK> have no preference and recommend either transparent or dry gauze dressing but suggest if the exit site is oozing a dry gauze dressing should be used. In conclusion, there is an insufficient number of quality studies to evaluate the effects of different non medicated dressing types on the incidence of CVC infection, exit site infection or catheter-related bacteraemia in haemodialysis patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other interventions </HEADING>
<P>Other interventions included in our review were a comparison between tunnelled and non-tunnelled CVC and different post insertion catheter care protocols. Our review suggests that there was no difference between tunnelled and non-tunnelled CVC in the prevention of CVC infection in haemodialysis patients (<LINK REF="STD-Atapour-2006" TYPE="STUDY">Atapour 2006</LINK>). Similarly, there was also no differences between different post insertion catheter care protocols. This protocols investigated the effect haemodialysis nurses using heparin three times/week had on CVC infections when compared to an intravenous team using heparin three times/day (<LINK REF="STD-Huraib-1994" TYPE="STUDY">Huraib 1994</LINK>). The findings from both of these studies should be treated with caution as they are based on poor quality data from small sample sets. In particular the studies that compared the two different post insertion catheter care protocols consisted of two different sets of health professional personnel using different dosages of heparin solution so it is unclear as to what intervention was been investigated; the different heparin locking dosages, the frequency of its delivery or the personnel who delivered the dosage.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<AGREEMENT MODIFIED="2009-11-05 16:00:29 +1100" MODIFIED_BY="Narelle S Willis">
<P>Most catheter-related infections are caused by micro-organism that colonise the skin surrounding the catheter exit site with increased density of micro-organism increasing the risk of catheter-related infection. Therefore, an integral component of CVC care and the prevention of catheter-related infection is cleaning the catheter exit site and surrounding skin with an antiseptic solution (<LINK REF="REF-UK-Renal--Association-2007" TYPE="REFERENCE">UK Renal Association 2007</LINK>).<B> </B>A meta-analysis of RCTs compared different strengths of chlorhexidine gluconate with povidone-iodine solution, within intensive care units. This analysis suggests that the incidence of catheter-related infections was significantly reduced in those patients whose catheter exit site and surrounding skin was cleaned by a chlorhexidine gluconate solution. Thereby justifying the use of chlorhexidine gluconate as an cutaneous antiseptic agent (<LINK REF="REF-Chalyakunapruk-2002" TYPE="REFERENCE">Chalyakunapruk 2002</LINK>). However, we found no RCTs on the use of skin cleansers and different cleansing solutions. In particular there was no RCTs on the use of chlorhexidine gluconate and the different strengths of this solution in haemodialysis patients with CVC. The use of chlorhexidine gluconate, specifically 2% chlorhexidine gluconate in 70% alcohol, as a cleansing agent for CVC is recommended in many international guidelines (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). However, to the best of our knowledge no direct comparison has been performed between 2% chlorhexidine gluconate in 70% alcohol and other alcoholic or aqueous concentrations of chlorhexidine gluconate.</P>
<P>An optimal strategy for the prevention of catheter-related infections in haemodialysis patients is not confined to those interventions included in this review. Other interventions include catheter locking solutions, which are the focus of a separate Cochrane review. Catheter locking solutions such as cefazolin, cefotaxime, gentamicin, minocycline, EDTA, vancomycin and citrate have been the subject of a number of meta-analyses (<LINK REF="REF-Jaffer-2008" TYPE="REFERENCE">Jaffer 2008</LINK>; <LINK REF="REF-James-2008" TYPE="REFERENCE">James 2008</LINK>; <LINK REF="REF-Labriola-2008" TYPE="REFERENCE">Labriola 2008</LINK>; <LINK REF="REF-Yahav-2008" TYPE="REFERENCE">Yahav 2008</LINK>). These meta-analyses confirm that antibiotic catheter locking solutions have a significant effect in the reduction of catheter-related blood stream infection and catheter removal. Only one study reported a single case of gentamicin resistant <I>S. aureus</I>, however, the development of resistance was not recorded in all studies. Analysis of those studies that compared non antibiotic locking solutions such as citrate showed no significantly effect. However, when these agents were used in conjunction with additional preventive measures such as topical povidone-iodine and nasal mupirocin they were highly effective. International guidelines caution against the routine use of catheter antibiotic locking solutions due to the possible development of resistance (<LINK REF="REF-CDC-2002" TYPE="REFERENCE">CDC 2002</LINK>; <LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-05 16:04:51 +1100" MODIFIED_BY="Narelle S Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2009-11-05 16:02:42 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Topical antimicrobial ointments and honey</HEADING>
<P>Our review indicates that mupirocin ointment is effective in reducing the risk of catheter-related bacteraemia and CVC infections caused by <I>S. aureus</I>. No case of mupirocin resistance was reported and our review can therefore not conclude that mupirocin resistance is a real or proven threat. The clinical decision to use mupirocin ointment as a prophylactic agent in the prevention of CVC infections requires local knowledge of the prevalence of antibiotic sensitivity within that community. A lack of studies on the routine use of povidone-iodine ointment, polysporin ointment and topical honey in haemodialysis patient population means that there is insufficient evidence to guide clinical practice. Clinical decisions on the use of these topical agents as part of a prophylactic strategy in the prevention of CVC infection needs to be informed by larger high quality studies demonstrating evidence of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dressings</HEADING>
<P>Based on our review it was not feasible to determine which dressing was the most effective as there is insufficient quality data available to determine which dressing type has the lowest risk of catheter-related infections. In addition, no conclusion can be made on the frequency of dressing changes. However, CVC sites need to dressed and for the interim period those caring for haemodialysis patients with CVC may consider using either a dry gauze or transparent dressing. This choice may be informed by the presence of an oozing exit site, patients preference or cost.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other Interventions</HEADING>
<P>Due to the poor quality of data there is insufficient evidence available in our review to guide clinical practice in relation to the use of either tunnelled or non-tunnelled CVC or the components of an effective post catheter insertion protocol.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-05 16:04:51 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">For all interventions </HEADING>
<P>Our review indicated inconsistency between studies in the manner in which they were reported. There is a need to:</P>
<UL>
<LI>State the methods used in randomisation, allocation sequence and concealment.</LI>
<LI>Use a double blind approach where possible and if not blind assessors.</LI>
<LI>Report completeness of follow-up and withdrawals.</LI>
<LI>Indicate intention-to-treat analysis and outline how data from those lost to follow-up were treated</LI>
<LI>Use standard valid outcome measures that will allow comparisons between RCTs in a meta-analysis (particularly in the area of incidence of catheter-related infection, time to development of infection and survival time).</LI>
<LI>Include outcome measure such as mortality, quality of life measure and cost evaluation.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical antimicrobial ointments and Honey</HEADING>
<P>Objective evidence should be used to support and monitor for mupirocin resistance in any future studies. Topical honey, povidone-iodine ointment and polysporin ointment are possible alternative prophylactic strategies and should be explored further. High quality RCTs should investigate their effectiveness in the prevention of catheter-related infections including catheter-related blood stream infections and the development of resistance. RCTs could explore the effectiveness of:</P>
<UL>
<LI>Povidone-iodine ointment versus no treatment</LI>
<LI>Polysporin ointment versus no treatment</LI>
<LI>Povidone-iodine ointment versus polysporin ointment</LI>
<LI>Honey versus no treatment</LI>
<LI>Honey versus polysporin</LI>
<LI>Honey versus povidone-iodine</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dressings</HEADING>
<P>Only one study, which had a small sample, investigated different types of dressings in a haemodialysis patient population. In order to increase the body of evidence in this area it is important that larger more robust RCTs, investigating dry gauze and transparent dressing, be undertaken. Future studies need to consider the influence frequency of dressing changes may have on the incidence of catheter-related infections.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other Interventions </HEADING>
<P>No RCTs were found on antiseptic cleansing agents used for catheter hub and exit site care. To ensure that clinical decisions in the management of CVC in haemodialysis patients are informed by high quality evidence it is important that this area is the focus of future clinical studies. International guidelines currently recommend the use of 2% chlorhexidine gluconate in 70% alcohol, however, we did not find any RCTs that directly compared aqueous and alcohol preparations of chlorhexidine gluconate. Future RCTs could compare 2% chlorhexidine gluconate in 70% alcohol and other alcoholic or aqueous concentrations of chlorhexidine gluconate.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-11-05 12:07:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>We would like to thank Narelle Willis and Dr Mike Clarke for their assistance during the process of completing this review and Ruth Mitchell in developing the search strategy and providing relevant studies. We would also like to thank the following authors for providing additional information on their studies:</P>
<UL>
<LI>Dr Serge Cournoyer</LI>
<LI>Dr Dulce Barbosa</LI>
<LI>Dr William Fong</LI>
<LI>Dr David Johnson</LI>
<LI>Dr Mohd Daud Kamaliah</LI>
<LI>Dr Charmaine Lok</LI>
<LI>Dr Mujtaba Quadri</LI>
<LI>Dr Tarun Kumer Bansal</LI>
</UL>
<P>We would also like to thank the following people for their support, comments and advice during the preparation of this review,<BR/>
</P>
<UL>
<LI>Dr Ashley Irish</LI>
<LI>Dr Krishan Madhan</LI>
<LI>Dr Paul Snelling</LI>
<LI>Ms Sonia Crampton</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-11-04 15:18:36 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Writing of protocol and review - MMcC, ZM</LI>
<LI>Screening of titles and abstracts - MMcC, ZM</LI>
<LI>Assessment for inclusion - MMcC, ZM</LI>
<LI>Quality assessment - MMcC, ZM</LI>
<LI>Data extraction - MMcC, ZM</LI>
<LI>Data entry into RevMan - MMcC</LI>
<LI>Data analysis - MMcC, ZM</LI>
<LI>Disagreement resolution - The Cochrane Renal Group</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-11-06 10:37:57 +1100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-11-04 15:57:51 +1100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-11-04 15:57:51 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Atapour-2006" MODIFIED="2009-11-03 12:10:20 +1100" MODIFIED_BY="[Empty name]" NAME="Atapour 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-03 12:10:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atapour A, Shahidi S</AU>
<TI>Does tunneling the temporary vascular access extend its lifetime?</TI>
<SO>Journal of Research in Medical Sciences</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:10:20 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:10:20 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2006430766"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-25 13:09:33 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HIPPO-Study" MODIFIED="2009-11-04 15:57:17 +1100" MODIFIED_BY="[Empty name]" NAME="HIPPO Study" YEAR="2003">
<REFERENCE MODIFIED="2009-11-04 15:57:17 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lok CE, Hux JE, Tobe S, Richardson R, Stanley K, Conly J</AU>
<TI>The hemodialysis infection prevention with polysporin ointment (HIPPO) study: a multicentre double blind randomized trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program and Abstracts</NO>
<PG>295A</PG>
<IDENTIFIERS MODIFIED="2009-10-27 13:39:52 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 13:39:52 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00446466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-25 13:37:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J</AU>
<TI>Hemodialysis infection prevention with polysporin ointment</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>1</NO>
<PG>169-79</PG>
<IDENTIFIERS MODIFIED="2009-05-25 13:37:52 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 13:37:52 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12506149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huraib-1994" MODIFIED="2009-05-25 13:16:11 +1000" MODIFIED_BY="[Empty name]" NAME="Huraib 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-05-25 13:16:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huraib S, Askar A, Abu-Aisha H, al-Wakeel J</AU>
<TI>Prevalence of infection from subclavian dialysis catheters with two different postinsertion catheter cares: a randomized comparative study</TI>
<SO>Angiology</SO>
<YR>1994</YR>
<VL>45</VL>
<NO>12</NO>
<PG>1047-51</PG>
<IDENTIFIERS MODIFIED="2009-05-25 13:16:11 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 13:16:11 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7985832"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2002" MODIFIED="2009-11-03 12:11:51 +1100" MODIFIED_BY="[Empty name]" NAME="Johnson 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-03 12:11:51 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, MacGinley R, Kay TD, Hawley CM, Campbell SB, Isbel NM, et al</AU>
<TI>A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>10</NO>
<PG>1802-7</PG>
<IDENTIFIERS MODIFIED="2009-05-25 13:17:48 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 13:17:48 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12270988"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2005" MODIFIED="2009-11-04 15:57:33 +1100" MODIFIED_BY="[Empty name]" NAME="Johnson 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-03 12:12:11 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, van Eps C, Mudge DW, Wiggins KJ, Armstrong K, Hawley CM, et al</AU>
<TI>Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>5</NO>
<PG>1456-62</PG>
<IDENTIFIERS MODIFIED="2009-05-25 13:19:33 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 13:19:33 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15788475"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-04 15:57:33 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Eps C, Mudge D, Wiggins K, Armstrong K, Hawley C, Campbell S, et al</AU>
<TI>Randomised controlled trial of topical exit-site application of medihoney versus mupirocin for prevention of haemodialysis catheter-associated infections. [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>(Suppl 3)</NO>
<PG>A407</PG>
<IDENTIFIERS MODIFIED="2009-10-27 13:41:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 13:41:50 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00583767"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamaliah-2004" MODIFIED="2009-11-03 12:13:08 +1100" MODIFIED_BY="[Empty name]" NAME="Kamaliah 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-10-27 13:43:07 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kamaliah MD, Azril HY, Zaki MS</AU>
<TO>Role of topical mupirocin ointment as a prophylaxis in catheter related infection in haemodialysis patients [abstract]</TO>
<SO>13th Asian Colloquium in Nephrology; 2000 Nov 23-25; Bali, Indonesia</SO>
<YR>2000</YR>
<PG>179</PG>
<IDENTIFIERS MODIFIED="2009-10-27 13:42:46 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 13:42:46 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00461034"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-03 12:13:08 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kamaliah MD, Haris YA, Zaki SM</AU>
<TI>Role of topical mupirocin as a prophylaxis in catheter related infection in haemodialysis patients</TI>
<SO>International Medical Journal</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>1</NO>
<PG>41-6</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:13:08 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:13:08 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2004200244"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-le-Corre-2003" MODIFIED="2009-05-25 13:33:21 +1000" MODIFIED_BY="[Empty name]" NAME="le Corre 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-25 13:32:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Corre I, Delorme M, Cournoyer S</AU>
<TI>A prospective, randomized trial comparing a transparent dressing and a dry gauze on the exit site of long term central venous catheters of hemodialysis patients</TI>
<SO>Journal of Vascular Access</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>2</NO>
<PG>56-61</PG>
<IDENTIFIERS MODIFIED="2009-05-25 13:32:37 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 13:32:37 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2003309224"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-1991" MODIFIED="2009-05-25 13:34:54 +1000" MODIFIED_BY="[Empty name]" NAME="Levin 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-05-25 13:34:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB</AU>
<TI>Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine</TI>
<SO>Kidney International</SO>
<YR>1991</YR>
<VL>40</VL>
<NO>5</NO>
<PG>934-8</PG>
<IDENTIFIERS MODIFIED="2009-05-25 13:34:51 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 13:34:51 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1762298"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quadri-1999" MODIFIED="2009-10-27 14:26:05 +1100" MODIFIED_BY="[Empty name]" NAME="Quadri 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-10-27 14:26:05 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quadri K, Huraib S</AU>
<TI>Manuka honey for central venous catheter exit site care</TI>
<SO>Seminars in Dialysis</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>5</NO>
<PG>397-8</PG>
<IDENTIFIERS MODIFIED="2009-10-27 14:26:05 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 14:26:05 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1046/j.1525-139x.1999.99052-3.x"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sesso-1998" MODIFIED="2009-11-04 15:57:51 +1100" MODIFIED_BY="[Empty name]" NAME="Sesso 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-11-04 15:57:51 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbosa D, Pignatari A, Draibe S, Sader H, Leme I, Manfredi S, et al</AU>
<TI>A randomized trial evaluating topic mupirocin for the prevention of infections related to central venous catheters for hemodialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Program &amp; Abstracts</NO>
<PG>152A</PG>
<IDENTIFIERS MODIFIED="2009-10-27 13:46:25 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 13:46:25 +1100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00444336"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-03 12:14:03 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sesso R, Barbosa D, Leme IL, Sader H, Canziani ME, Manfredi S, et al</AU>
<TI>Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>6</NO>
<PG>1085-92</PG>
<IDENTIFIERS MODIFIED="2009-05-25 13:48:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 13:48:56 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9621293"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-10-27 14:05:35 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Comerota-2004" MODIFIED="2009-10-27 14:05:35 +1100" MODIFIED_BY="[Empty name]" NAME="Comerota 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-10-27 14:05:35 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comerota AJ</AU>
<TI>Totally subcutaneous hemodialysis access: experience with the LifeSite Hemodialysis System</TI>
<SO>Vascular</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>4</NO>
<PG>256-62</PG>
<IDENTIFIERS MODIFIED="2009-10-27 14:05:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 14:05:35 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15704320"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahlberg-1986" MODIFIED="2009-05-25 13:55:21 +1000" MODIFIED_BY="[Empty name]" NAME="Dahlberg 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-05-25 13:55:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Dahlberg PJ, Yutuc WR, Newcomer KL</AU>
<TI>Subclavian hemodialysis catheter infections</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>5</NO>
<PG>421-7</PG>
<IDENTIFIERS MODIFIED="2009-05-25 13:55:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 13:55:21 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="3518423"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-11-03 12:15:07 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Mavromatidis-1999" MODIFIED="2009-11-03 12:15:07 +1100" MODIFIED_BY="[Empty name]" NAME="Mavromatidis 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-11-03 12:15:07 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mavromatidis K, Kontodemou A, Tsoulfa S, Tsorlini E, Sombolos K</AU>
<TI>The impact of vancomycin administration on prevention of hemodialysis catheter related infection</TI>
<SO>Dialysis and Transplantation</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>12</NO>
<PG>727-33</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:15:07 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:15:07 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1999429347"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-11-03 04:58:44 +1100" MODIFIED_BY="Margaret McCann"/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-02-17 02:36:27 +1100" MODIFIED_BY="Margaret McCann"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-11-06 10:37:57 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-11-05 11:50:54 +1100" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Allon-2003" MODIFIED="2009-11-03 12:15:17 +1100" MODIFIED_BY="[Empty name]" NAME="Allon 2003" TYPE="JOURNAL_ARTICLE">
<AU>Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, et al</AU>
<TI>Impact of dialysis dose and membrane on infection related hospitalization and death: results of the HEMO study</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>7</NO>
<PG>1863-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12819247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alomari-2007" MODIFIED="2009-03-30 11:50:09 +1100" MODIFIED_BY="[Empty name]" NAME="Alomari 2007" TYPE="JOURNAL_ARTICLE">
<AU>Alomari AI, Falk A</AU>
<TI>The natural history of tunneled hemodialysis catheters removed or exchanged: A single institution experience</TI>
<SO>Journal of Vascular &amp; Intervention Radiology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>2</NO>
<PG>227-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17327555"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ash-2001" MODIFIED="2009-03-30 11:50:11 +1100" MODIFIED_BY="[Empty name]" NAME="Ash 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ash SR</AU>
<TI>The evolution and function of central venous catheters for dialysis</TI>
<SO>Seminars in Dialysis</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>6</NO>
<PG>416-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11851926"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Astor-2005" MODIFIED="2009-03-30 11:50:16 +1100" MODIFIED_BY="[Empty name]" NAME="Astor 2005" TYPE="JOURNAL_ARTICLE">
<AU>Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J</AU>
<TI>Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcome in Caring for ESRD (CHOICE) Study</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>5</NO>
<PG>1449-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15788468"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brandt-1996" MODIFIED="2009-05-25 14:32:10 +1000" MODIFIED_BY="[Empty name]" NAME="Brandt 1996" TYPE="OTHER">
<AU>Brandt T, J D, Irwin M, Shogan J, Lucke J</AU>
<TI>Comparison of central venous catheter dressings in bone marrow transplant recipients</TI>
<SO>Oncology Nursing Forum</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>5</NO>
<PG>829-36</PG>
<IDENTIFIERS MODIFIED="2009-05-25 14:32:10 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 14:32:10 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8792352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Butterly-2001" MODIFIED="2009-03-30 11:50:21 +1100" MODIFIED_BY="[Empty name]" NAME="Butterly 2001" TYPE="JOURNAL_ARTICLE">
<AU>Butterly DW, Schwab SJ</AU>
<TI>Catheter access for hemodialysis: an overview</TI>
<SO>Seminars in Dialysis</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>6</NO>
<PG>411-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11851925"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CARI-2000" MODIFIED="2009-10-27 14:45:02 +1100" MODIFIED_BY="[Empty name]" NAME="CARI 2000" TYPE="OTHER">
<AU>CARI Guidelines (Caring for Australasians with Renal Impairment)</AU>
<TI>Dialysis vascular access guidelines (2000)</TI>
<SO>http://www.cari.org.au/dialysis_va_list_published.php</SO>
<YR>(accessed May 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2002" NAME="CDC 2002" TYPE="OTHER">
<AU>CDC (Centers for Disease Control and Prevention)</AU>
<TI>Guidelines for the prevention of intravascular catheter-related infections (2002)</TI>
<SO>http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm</SO>
<YR>(accessed October 2007)</YR>
<PG>1-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalyakunapruk-2002" MODIFIED="2009-11-03 12:15:49 +1100" MODIFIED_BY="[Empty name]" NAME="Chalyakunapruk 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chalyakunapruk N, Veenstra D, Lipsky B, Saint S</AU>
<TI>Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: A meta-analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002</YR>
<VL>136</VL>
<NO>11</NO>
<PG>792-801</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:15:49 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:15:49 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12044127"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chatzinikolaou-2003" MODIFIED="2009-03-30 11:50:25 +1100" MODIFIED_BY="[Empty name]" NAME="Chatzinikolaou 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chatzinikolaou I, Finkel K, Hanna H, Boktour M, Foringer J, Ho T et al</AU>
<TI>Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: A prospective, randomized study</TI>
<SO>American Journal of Medicine</SO>
<YR>2003</YR>
<VL>115</VL>
<NO>5</NO>
<PG>352-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14553869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CIHI-2006" NAME="CIHI 2006" TYPE="OTHER">
<AU>Canadian Institute for Health Information (CIWI)</AU>
<TI>CORR Reports - Treatment of end stage organ failure in Canada, 1995-2004 (2006 Annual Report)</TI>
<SO>http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=PG_710_E&amp;cw_topic=710&amp;cw_rel=AR_5_E</SO>
<YR>(accessed October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conly-1989" MODIFIED="2009-05-25 14:42:45 +1000" MODIFIED_BY="[Empty name]" NAME="Conly 1989" TYPE="OTHER">
<AU>Conly J, Grieves K, Peters B</AU>
<TI>A prospective, randomized study comparing transparent and dry gauze dressings for central venous catheters</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>159</VL>
<NO>2</NO>
<PG>310-9</PG>
<IDENTIFIERS MODIFIED="2009-05-25 14:42:45 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 14:42:45 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2644372"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cookson-1990" MODIFIED="2009-05-25 14:44:51 +1000" MODIFIED_BY="[Empty name]" NAME="Cookson 1990" TYPE="OTHER">
<AU>Cookson BD</AU>
<TI>Mupirocin resistence in staphylococci</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1990</YR>
<VL>25</VL>
<NO>4</NO>
<PG>497-503</PG>
<IDENTIFIERS MODIFIED="2009-05-25 14:44:49 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 14:44:49 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2112535"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Develter-2005" MODIFIED="2009-03-30 11:50:33 +1100" MODIFIED_BY="[Empty name]" NAME="Develter 2005" TYPE="JOURNAL_ARTICLE">
<AU>Develter W, De Cubber A, Van Biesen W, Vanholder R, Lameire N</AU>
<TI>Survival and complications of indwelling venous catheters for permanent use in hemodialysis patients</TI>
<SO>Artificial Organs</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>5</NO>
<PG>399-405</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15854216"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dhingra-2001" MODIFIED="2009-03-30 11:50:36 +1100" MODIFIED_BY="[Empty name]" NAME="Dhingra 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK</AU>
<TI>Type of vascular access and mortality in US hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>4</NO>
<PG>1443-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11576358"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DoH-2004" NAME="DoH 2004" TYPE="OTHER">
<AU>Department of Health (UK)</AU>
<TI>The National Service Framework for Renal Services, Part One: Dialysis and Transplantation</TI>
<SO>http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4070359</SO>
<YR>(accessed October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ERA_x002d_EDTA-2002" NAME="ERA-EDTA 2002" TYPE="JOURNAL_ARTICLE">
<AU>The European Renal Association - European Dialysis and Transplant Association</AU>
<TI>European best practice guidelines for haemodialysis (Part 1)</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 7</NO>
<PG>1-111</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frankel-2006" MODIFIED="2009-03-30 11:50:41 +1100" MODIFIED_BY="[Empty name]" NAME="Frankel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Frankel A</AU>
<TI>Temporary access and central venous catheters</TI>
<SO>European Journal of Vascular &amp; Endovascular Surgery</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>4</NO>
<PG>417-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16360326"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-French-2005" MODIFIED="2009-11-03 12:19:19 +1100" MODIFIED_BY="[Empty name]" NAME="French 2005" TYPE="OTHER">
<AU>French VM, Cooper RA, Molan PC</AU>
<TI>The antibacterial activity of honey against coagulase-negative staphylococci</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2005</YR>
<VL>56</VL>
<NO>1</NO>
<PG>228-31</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:19:19 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:19:19 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15941774"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gethin-2008" MODIFIED="2009-05-25 14:55:44 +1000" MODIFIED_BY="[Empty name]" NAME="Gethin 2008" TYPE="OTHER">
<AU>Gethin G, Cowman S</AU>
<TI>Bacteriological changes in sloughy venous leg ulcers treated with manuka honey or hydrogel: an RCT</TI>
<SO>Journal of Wound Care</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>6</NO>
<PG>241-4, 246-7</PG>
<IDENTIFIERS MODIFIED="2009-05-25 14:55:33 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 14:55:33 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18666717"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gilles-2003" MODIFIED="2009-11-04 15:58:18 +1100" MODIFIED_BY="[Empty name]" NAME="Gilles 2003" TYPE="COCHRANE_REVIEW">
<AU>Gilles D, Carr D, Frost J, O'Riordan R, O'Brien I</AU>
<TI>Gauze and tape and transparent polyurethane dressings for central venous catheters</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-10-27 14:51:07 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 14:51:07 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003827"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herwaldt-1998" MODIFIED="2009-05-25 15:01:05 +1000" MODIFIED_BY="[Empty name]" NAME="Herwaldt 1998" TYPE="OTHER">
<AU>Herwaldt L</AU>
<TI>Reduction of staphylococcus aureus nasal carriage and infection in dialysis patients</TI>
<SO>Journal of Hospital Infection</SO>
<YR>1998</YR>
<VL>40</VL>
<NO>Supp B</NO>
<PG>S13-23</PG>
<IDENTIFIERS MODIFIED="2009-05-25 15:01:05 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:01:05 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9777529"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins J, Thompson S, Deeks J, Altman D</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jaffer-2008" MODIFIED="2009-11-03 12:20:42 +1100" MODIFIED_BY="[Empty name]" NAME="Jaffer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jaffer Y, Selby NM, Taal MW, Fluck RJ, McIntyre CW</AU>
<TI>A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter related infection</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>208</YR>
<VL>51</VL>
<NO>2</NO>
<PG>233-241</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:20:42 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:20:42 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18215701"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-James-2008" MODIFIED="2009-11-03 12:22:12 +1100" MODIFIED_BY="[Empty name]" NAME="James 2008" TYPE="JOURNAL_ARTICLE">
<AU>James MT, Conley J, Tonelli M, Manns BJ, MacRae J, Hennelgarn BR</AU>
<TI>Meta-analysis: Antibiotics for prophylaxis against hemodialysis catheter related infections</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2008</YR>
<VL>148</VL>
<NO>8</NO>
<PG>596-605</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:21:56 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:21:56 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18413621"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jindal-2006" MODIFIED="2009-11-03 12:22:24 +1100" MODIFIED_BY="[Empty name]" NAME="Jindal 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al</AU>
<TI>Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>3 Suppl 1</NO>
<PG>S1-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16497879"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jull-2008a" MODIFIED="2009-11-04 15:58:06 +1100" MODIFIED_BY="[Empty name]" NAME="Jull 2008a" TYPE="COCHRANE_REVIEW">
<AU>Jull AB, Rodgers A, Walker N</AU>
<TI>Honey as a topical treatment for wounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-05-25 15:23:26 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:23:26 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005083.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jull-2008b" MODIFIED="2009-11-03 12:24:22 +1100" MODIFIED_BY="[Empty name]" NAME="Jull 2008b" TYPE="OTHER">
<AU>Jull A, Walker N, Parag V, Molan P, Rogers A. Honey as Adjuvant Leg Ulcer Therapy trial collaborators</AU>
<TI>Randomized clinical trial of honey-impregnated dressings for venous leg ulcers</TI>
<SO>British Journal of Surgery</SO>
<YR>2008</YR>
<VL>95</VL>
<NO>2</NO>
<PG>175-82</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:23:40 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:23:40 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18161896"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kairaitis-1999" MODIFIED="2009-03-30 11:50:51 +1100" MODIFIED_BY="[Empty name]" NAME="Kairaitis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kairaitis LK, Gottlieb T</AU>
<TI>Outcome and complications of temporary haemodialysis catheters</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>7</NO>
<PG>1710-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10435881"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDOQI-2006" NAME="KDOQI 2006" TYPE="OTHER">
<AU>National Kidney Foundation</AU>
<TI>Clinical practice guidelines and clinical practice for vascular access, update 2006</TI>
<SO>http://www.kidney.org/professionals/kdoqi/guideline_upHD_PD_VA/index.htm</SO>
<YR>(accessed October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klevens-2005" MODIFIED="2009-03-30 11:50:54 +1100" MODIFIED_BY="[Empty name]" NAME="Klevens 2005" TYPE="JOURNAL_ARTICLE">
<AU>Klevens RM, Tokars JI, Andrus M</AU>
<TI>Electronic reporting of infections associated with hemodialysis</TI>
<SO>Nephrology News &amp; Issues</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>7</NO>
<PG>37-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16008022"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Labriola-2008" MODIFIED="2009-11-03 12:26:11 +1100" MODIFIED_BY="[Empty name]" NAME="Labriola 2008" TYPE="JOURNAL_ARTICLE">
<AU>Labriola L, Crott R, Jadoul M</AU>
<TI>Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>5</NO>
<PG>1666-72</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:26:11 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:26:11 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18065789"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laupland-2003" MODIFIED="2009-05-25 15:20:38 +1000" MODIFIED_BY="[Empty name]" NAME="Laupland 2003" TYPE="JOURNAL_ARTICLE">
<AU>Laupland KB, Conly JM</AU>
<TI>Treatment of staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: An evidence based review</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>7</NO>
<PG>933-8</PG>
<IDENTIFIERS MODIFIED="2009-05-25 15:07:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:07:39 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="13130405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Le-Corre-2003" MODIFIED="2009-05-25 15:45:49 +1000" MODIFIED_BY="[Empty name]" NAME="Le Corre 2003" TYPE="JOURNAL_ARTICLE">
<AU>Le Corre I, Delorme M, Cournoyer S</AU>
<TI>A prospective, randomized trial comparing a transparent dressing and a dry gauze on the exit site of long term central venous catheters of hemodialysis patients</TI>
<SO>Journal of Vascular Access</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>2</NO>
<PG>56-61</PG>
<IDENTIFIERS MODIFIED="2009-05-25 15:45:49 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:45:49 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2003309224"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-2002" MODIFIED="2009-03-30 11:50:58 +1100" MODIFIED_BY="[Empty name]" NAME="Lee 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D et al</AU>
<TI>Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>3</NO>
<PG>611-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12200814"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2009-11-04 15:16:12 +1100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org</TI>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Letourneau-2003" MODIFIED="2009-03-30 11:51:03 +1100" MODIFIED_BY="[Empty name]" NAME="Letourneau 2003" TYPE="JOURNAL_ARTICLE">
<AU>Letourneau I, Ouimet D, Dumont M, Pichette V, Leblanc M</AU>
<TI>Renal replacement in end-stage renal disease patients over 75 years old</TI>
<SO>American Journal of Nephrology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>2</NO>
<PG>71-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12481144"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marr-1998" MODIFIED="2009-11-03 12:26:43 +1100" MODIFIED_BY="[Empty name]" NAME="Marr 1998" TYPE="JOURNAL_ARTICLE">
<AU>Marr KA, Kong L, Fowler VG, Gopal A, Sexton DJ, Conlon PJ, et al</AU>
<TI>Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>1998</YR>
<VL>54</VL>
<NO>5</NO>
<PG>1684-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9844145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Master-List-2009" MODIFIED="2009-05-25 15:09:35 +1000" MODIFIED_BY="[Empty name]" NAME="Master List 2009" TYPE="OTHER">
<AU>US Cochrane Center</AU>
<TI>Master list of journals being searched</TI>
<SO>http://apps1.jhsph.edu/cochrane/masterlist.asp</SO>
<YR>(accessed February 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McIntyre-2004" MODIFIED="2009-03-30 11:51:09 +1100" MODIFIED_BY="[Empty name]" NAME="McIntyre 2004" TYPE="JOURNAL_ARTICLE">
<AU>McIntyre CW, Hulme LJ, Taal M, Fluck RJ</AU>
<TI>Locking of tunneled hemodialysis catheters with gentamicin and heparin</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>6</NO>
<PG>801-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15253736"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mendelssohn-2006" MODIFIED="2009-03-30 11:51:11 +1100" MODIFIED_BY="[Empty name]" NAME="Mendelssohn 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mendelssohn DC, Ethier J, Elder SJ, Saran R, Port FK, Pisoni RL</AU>
<TI>Haemodialysis vascular access problems in Canada: results from the dialysis outcomes and practice patterns study (DOPPS II)</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>3</NO>
<PG>721-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16311264"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mokrzycki-2006" MODIFIED="2009-03-30 11:51:18 +1100" MODIFIED_BY="[Empty name]" NAME="Mokrzycki 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO</AU>
<TI>Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>4</NO>
<PG>1024-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16449293"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oliver-2000" MODIFIED="2009-10-27 14:55:56 +1100" MODIFIED_BY="[Empty name]" NAME="Oliver 2000" TYPE="JOURNAL_ARTICLE">
<AU>Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN</AU>
<TI>Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: A prospective study</TI>
<SO>Kidney International</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>6</NO>
<PG>2543-5</PG>
<IDENTIFIERS MODIFIED="2009-10-27 14:55:54 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 14:55:54 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11115089"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oliver-2001" MODIFIED="2009-03-30 11:51:25 +1100" MODIFIED_BY="[Empty name]" NAME="Oliver 2001" TYPE="JOURNAL_ARTICLE">
<AU>Oliver MJ</AU>
<TI>Acute dialysis catheters</TI>
<SO>Seminars in Dialysis</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>6</NO>
<PG>432-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11851928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pastan-2002" MODIFIED="2009-03-30 11:51:27 +1100" MODIFIED_BY="[Empty name]" NAME="Pastan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pastan S, Soucie JM, McClellan WM</AU>
<TI>Vascular access and increased risk of death among hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>2</NO>
<PG>620-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12110026"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Percival-2005" MODIFIED="2009-03-30 11:51:31 +1100" MODIFIED_BY="[Empty name]" NAME="Percival 2005" TYPE="JOURNAL_ARTICLE">
<AU>Percival SL, Kite P, Eastwood K, Murga R, Carr J, Arduino MJ et al</AU>
<TI>Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>6</NO>
<PG>515-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16018425"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pisoni-2002" MODIFIED="2009-03-30 11:51:33 +1100" MODIFIED_BY="[Empty name]" NAME="Pisoni 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B et al</AU>
<TI>Vascular access use in Europe and the United States: Results from the DOPPS</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>1</NO>
<PG>305-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11786113"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Polkinghorne-2004" MODIFIED="2009-03-30 11:51:36 +1100" MODIFIED_BY="[Empty name]" NAME="Polkinghorne 2004" TYPE="JOURNAL_ARTICLE">
<AU>Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG</AU>
<TI>Vascular access and all cause mortality: a propensity score analysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>2</NO>
<PG>477-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14747396"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ponikvar-2005" MODIFIED="2009-10-27 14:58:09 +1100" MODIFIED_BY="[Empty name]" NAME="Ponikvar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ponikvar R</AU>
<TI>Hemodialysis catheters</TI>
<SO>Therapeutic Apheresis &amp; Dialysis: Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>3</NO>
<PG>218-22</PG>
<IDENTIFIERS MODIFIED="2009-10-27 14:58:09 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 14:58:09 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15966993"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pratt-2007" MODIFIED="2009-10-27 14:58:53 +1100" MODIFIED_BY="[Empty name]" NAME="Pratt 2007" TYPE="OTHER">
<AU>Pratt RJ, Pellowe CM, Wilson JA, Loveday HP, Harper PJ, Jones SR, et al</AU>
<TI>epic 2: National evidence-based guidelines for preventing healthcare-associated infections in NHS Hospitals in England</TI>
<SO>Journal of Hospital Infection</SO>
<YR>2007</YR>
<VL>65</VL>
<NO>Suppl 1</NO>
<PG>S1-64</PG>
<IDENTIFIERS MODIFIED="2009-10-27 14:58:53 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 14:58:53 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17307562"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Renal-Group-2009" MODIFIED="2009-11-03 12:28:05 +1100" MODIFIED_BY="[Empty name]" NAME="Renal Group 2009" TYPE="OTHER">
<AU>Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC</AU>
<TI>Cochrane Renal Group</TI>
<TO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 4. Art. No.: RENAL</TO>
<SO>http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/RENAL/frame.html</SO>
<YR>(accessed November 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richet-1990" MODIFIED="2009-05-25 15:19:38 +1000" MODIFIED_BY="[Empty name]" NAME="Richet 1990" TYPE="JOURNAL_ARTICLE">
<AU>Richet H, Hubert B, Nitemberg G, Andremont A, Buu-Hoi A, Ourbak P, et al</AU>
<TI>Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1990</YR>
<VL>28</VL>
<NO>11</NO>
<PG>2520-5</PG>
<IDENTIFIERS MODIFIED="2009-05-25 15:19:38 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:19:38 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2254429 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saeed-2002" MODIFIED="2009-03-30 11:51:43 +1100" MODIFIED_BY="[Empty name]" NAME="Saeed 2002" TYPE="JOURNAL_ARTICLE">
<AU>Saeed Abdulrahman I, Al-Mueilo SH, Bokhary HL, GO, Al-Rubaish A</AU>
<TI>A prospective study of hemodialysis access related bacterial infections</TI>
<SO>Journal of Infection &amp; Chemotherapy</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>242-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12373488"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saxena-2005" MODIFIED="2009-03-30 11:51:45 +1100" MODIFIED_BY="[Empty name]" NAME="Saxena 2005" TYPE="JOURNAL_ARTICLE">
<AU>Saxena AK, Panhotra BR</AU>
<TI>Haemodialysis catheter-related bloodstream infections: current treatment options and strategies for prevention</TI>
<SO>Swiss Medicine Weekly</SO>
<YR>2005</YR>
<VL>135</VL>
<NO>9-10</NO>
<PG>127-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15832231"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shivnan-1991" MODIFIED="2009-11-03 12:28:33 +1100" MODIFIED_BY="[Empty name]" NAME="Shivnan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Shivnan JC, McGuire D, Freedman S, Sharkazy E, Bosserman G, Larson E, et al</AU>
<TI>A comparison of transparent adherent and dry sterile gauze dressings for long term central catheters in patients undergoing bone marrow transplant</TI>
<SO>Oncology Nursing Forum</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>8</NO>
<PG>1349-56</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:28:33 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:28:33 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1762975"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stevenson-2000" MODIFIED="2009-03-30 11:51:47 +1100" MODIFIED_BY="[Empty name]" NAME="Stevenson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Stevenson KB, Adcox MJ, Mallea MC, Narasimhan N, Wagnild JP</AU>
<TI>Standardized surveillance of hemodialysis vascular access infections: 18 month experience at an outpatient, multi-facility hemodialysis center</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>3</NO>
<PG>200-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10738990"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2004" MODIFIED="2009-05-25 15:30:39 +1000" MODIFIED_BY="[Empty name]" NAME="Strippoli 2004" TYPE="COCHRANE_REVIEW">
<AU>Strippoli G, Tong A, Johnson D, Schena F, Craig J</AU>
<TI>Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-05-25 15:30:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:30:27 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004679.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tacconelli-2003" MODIFIED="2009-11-03 12:28:51 +1100" MODIFIED_BY="[Empty name]" NAME="Tacconelli 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EM</AU>
<TI>Mupirocin prophylaxis to prevent staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>12</NO>
<PG>1629-38</PG>
<IDENTIFIERS MODIFIED="2009-11-03 12:28:51 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 12:28:51 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="14689344"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tordoir-2007" MODIFIED="2009-10-27 15:04:33 +1100" MODIFIED_BY="[Empty name]" NAME="Tordoir 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, et al</AU>
<TI>EBPG on Vascular Access</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>Suppl 2</NO>
<PG>ii88-117</PG>
<IDENTIFIERS MODIFIED="2009-10-27 15:04:33 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-27 15:04:33 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17507428"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Treston_x002d_Aurand-1997" MODIFIED="2009-05-25 15:37:16 +1000" MODIFIED_BY="[Empty name]" NAME="Treston-Aurand 1997" TYPE="JOURNAL_ARTICLE">
<AU>Treston-Aurand J, Olmsten RN, Allen-Bridson K, Craig CP</AU>
<TI>Impact of dressing materials on central venous catheter infection rates</TI>
<SO>Journal of Intravenous Nursing</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>4</NO>
<PG>201-6</PG>
<IDENTIFIERS MODIFIED="2009-05-25 15:37:16 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:37:16 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9281961"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-UK-Renal--Association-2007" MODIFIED="2009-05-25 15:46:39 +1000" MODIFIED_BY="[Empty name]" NAME="UK Renal  Association 2007" TYPE="OTHER">
<AU>UK Renal Association</AU>
<TI>Clinical Practice Guideline for Haemodialysis, 4th edition</TI>
<SO>www.renal.org/guidelines (accessed January 2009)</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2009-05-25 15:44:55 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-UKRR-2005" NAME="UKRR 2005" TYPE="OTHER">
<AU>UK Renal Registry</AU>
<TI>UK Renal Registry Report 2005-The Eight Annual Report</TI>
<SO>www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=60277</SO>
<YR>(accessed October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-USRDS-2006" MODIFIED="2009-05-25 15:47:22 +1000" MODIFIED_BY="[Empty name]" NAME="USRDS 2006" TYPE="OTHER">
<AU>USRDS</AU>
<TI>US Renal Data System 2006 Annual Data Report: Atlas of End Stage Renal Disease in the United States</TI>
<SO>http://www.usrds.org/adr.htm</SO>
<YR>(accessed October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Rijen-2008" MODIFIED="2009-11-04 15:58:39 +1100" MODIFIED_BY="[Empty name]" NAME="Van Rijen 2008" TYPE="COCHRANE_REVIEW">
<AU>Van Rijen M, Bonten M, Wenzel R, Kluytmans J</AU>
<TI>Mupirocin ointment for preventing staphylococcus aureus infections in nasal carriers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-05-25 15:49:08 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:49:08 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006216.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weijmere-2004" MODIFIED="2009-03-30 11:51:52 +1100" MODIFIED_BY="[Empty name]" NAME="Weijmere 2004" TYPE="JOURNAL_ARTICLE">
<AU>Weijmere MC, Vervloet MG, ter Wee PM</AU>
<TI>Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>3</NO>
<PG>670-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14767025"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wille-1993" MODIFIED="2009-05-25 15:51:26 +1000" MODIFIED_BY="[Empty name]" NAME="Wille 1993" TYPE="JOURNAL_ARTICLE">
<AU>Wille JC, Blusse van Oud Alblas A, Thewessen EA</AU>
<TI>A comparison of two transparent film type dressings in central venous therapy</TI>
<SO>Journal of Hospital Infection</SO>
<YR>1993</YR>
<VL>23</VL>
<NO>2</NO>
<PG>113-21</PG>
<IDENTIFIERS MODIFIED="2009-05-25 15:50:54 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-25 15:50:54 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8097215"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yahav-2008" MODIFIED="2009-10-30 01:49:35 +1100" MODIFIED_BY="Margaret McCann" NAME="Yahav 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M</AU>
<TI>Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta analysis of randomised controlled trials</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>1</NO>
<PG>83-93</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-11-06 10:37:57 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-McCann-2008" MODIFIED="2009-11-06 10:37:57 +1100" MODIFIED_BY="[Empty name]" NAME="McCann 2008" TYPE="COCHRANE_PROTOCOL">
<AU>McCann M, Moore ZEH</AU>
<TI>Interventions for preventing infectious complications in haemodialysis patients with central venous lines</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-11-06 10:37:55 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-06 10:37:55 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006894"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-11-05 14:18:43 +1100" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-11-05 14:18:43 +1100" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-11-05 13:22:32 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Atapour-2006">
<CHAR_METHODS MODIFIED="2009-11-04 13:56:31 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Timeframe: NS</LI>
<LI>Completeness of follow-up: 96.7% (1 participant was excluded from the treatment group because of poor co-operation with clinicians)</LI>
<LI>Follow-up period: Once a week but did not state the length of this follow-up period</LI>
<LI>Loss to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 13:22:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Iran</LI>
<LI>Setting: NS</LI>
<LI>Patients without any vascular access requiring emergency HD either for AKI or ESKD; aetiology of kidney failure: NS</LI>
<LI>Number (treatment/control): 14/15 ((1 participant from treatment group was excluded because of poor co-operation with clinicians)</LI>
<LI>Age (mean ± SD)</LI>
<UL>
<LI>Treatment group: 49.37 ± 15.37</LI>
<LI>Control group: 52.66 ± 15.10</LI>
</UL>
</UL>
<UL>
<LI>Sex (M/F): NS</LI>
<LI>Ethnicity: NS</LI>
<LI>Differences between the groups: NS, however age of participants appear similar</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Patients who were admitted to ICU; acute pulmonary oedema; patients with decreased level of consciousness; coagulation disturbances; previous access failed due to infection during recent two days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 13:57:56 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Tunnelled CVC</LI>
<LI>Duration: Followed up once a week. Did not state the length of this follow-up period.</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Non-tunnelled CVC</LI>
<LI>Duration: Followed up once a week. Did not state the length of this follow-up period.</LI>
</UL>
<P>
<B>Co-interventions</B>: None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 13:59:24 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Exit site infections</LI>
<LI>Catheter-related bacteraemia</LI>
<LI>Life time of catheter</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>Entrance site infection: Once a week exit site was checked for presence of inflammation, redness, pus formation, bleeding and quality of sutures.</LI>
<LI>Catheter-related infection: Febrile patients with no clear cause of fever (history, physical examination, lab and imaging studies) were treated as catheter-related infection using appropriate antibiotic and removal of CVC.</LI>
<LI>Life time of catheter: Determined as the time from insertion to time of extraction in weeks.</LI>
</UL>
<P>Results relating to the following:</P>
<UL>
<LI>4/14 (28.6%) participants in the tunnelled group had a fever before the procedure versus 5/15 (33.3%) in the non-tunnelled group. The authors reported no statistical relationship between life time of the catheter and the presence of a fever before procedure (P = 0.49 and 0.24 in treatment and control group).</LI>
<LI>Removal of catheter due to fever-related catheter infection was 11/14 in tunnelled group and 12/15 in the non-tunnelled group.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 13:59:43 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Attempt made to contact author for further details on blinding and clarification on results reported in study, no reply received.</LI>
<LI>Procedure for both groups: the same type of CVC was used in all patients and the same clinician inserted all CVC in similar situations. The jugular vein was used and catheter lumen were washed with normal saline and filled with heparin (5000/mL). Mupirocin was applied at the entrance site and dry dressing used. Did not indicate if this was done after each dialysis.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 13:22:38 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-HIPPO-Study">
<CHAR_METHODS MODIFIED="2009-11-05 11:35:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: November 1999 and November 2000.</LI>
<LI>Completeness of follow-up: 58% (94/162 (58%) of participants remained in the study for at least 6 months.</LI>
<LI>Follow-up period: Primary end point was the proportion of patients with a catheter-related infection within 6 months after entry into the study. Study ended when the last enrolled subject completed the minimum 6 month study period</LI>
<LI>Loss to follow-up: None</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 13:22:38 +1100" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Canada</LI>
<LI>Setting: Multi-centre study in 2 teaching hospitals in Toronto</LI>
<LI>Individuals with ESKD who required HD using a permanent tunnelled cuffed catheter in the internal jugular vein as their vascular access for dialysis. Need for a cuffed catheter as the primary source of vascular access for one of the following reasons: ESKD without permanent vascular access; recent conversion from PD to HD; recent loss of AVF or graft</LI>
</UL>
<UL>
<LI>Number</LI>
<UL>
<LI>Treatment group: 83/162 (86 randomised to group but 3 did not start the study leaving a total number who started study at 83). Reasons for not starting the study include: recovery of kidney function not requiring dialysis (1), kidney transplant (1); requiring long term antibiotics for nondialysis-related medical reasons (1)</LI>
<LI>Control group: 79/162 (86 randomised to group but 3 did not start the study leaving a total number who started study at 83). Reasons for not starting the study include: recovery of kidney function not requiring dialysis (1); changed mind shortly after randomisation (1), requiring long-term antibiotics for non-dialysis related medical reasons (2).</LI>
</UL>
<LI>Age &gt; 18 years</LI>
<UL>
<LI>Treatment group: median 68 (range 24- 89)</LI>
<LI>Control group: median 64 (range 25- 87)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 52/31</LI>
<LI>Control group: 53/26</LI>
</UL>
<LI>Ethnicity</LI>
<UL>
<LI>Treatment group: white (47), Asian (12) , south east Asian (17), black (7)</LI>
<LI>Control group: white (50), Asian (5), south east Asian (14), black (10)</LI>
</UL>
<LI>Nasal colonisation with <I>S. aureus</I> (treatment/control): 11/12</LI>
<LI>Exit site colonisation with <I>S. aureus </I>(treatment/control): 3/4</LI>
<LI>Catheter status at randomisation (treatment/control): Prevalent (57/52); incident: (26/27); duration on HD (mean years) (1.9/1.8)</LI>
<LI>Aetiology of kidney failure (treatment/control): Diabetes (24/27); glomerulonephritis (16/11); interstitial nephritis (1/2); hypertension (18/17); other (24/24)</LI>
<LI>Difference between groups: Did not identify if any difference in baseline characteristics although no major difference noted except between Asian ethnicity.</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>AKI; antibiotic use by any route in the week before enrolling the study; known allergy to any component of polysporin ointment; use of a temporary CVC non cuffed; use of a CVC for purposes other than access for HD</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 14:04:53 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Topical polysporin triple ointment (500 µ/g bacitracin, 0.25mg/g gramicidin and 10,000 µ/g polymyxin B) applied to catheter entry site at the end of each dialysis session for 2 consecutive weeks (6 sessions), then applied with patients weekly dressing change and when dressing changes were clinically indicated.</LI>
<LI>Ointment contained in brown opaque 50 g glass jars marked only with patients name and study number. A 1 cm cotton swab application of study ointment was applied to the CVC exit site followed by the application of a 2 x 2 in dry gauze dressing secured with a porous nontransparent adhesive (hypafix).</LI>
<LI>Duration: Primary end point was the proportion of patients with a catheter-related infection within 6 months after entry into the study. Study ended when the last enrolled subject completed the minimum 6 month study period.</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Placebo ointment was applied at the end of each dialysis session for 2 consecutive weeks (6 sessions) and then with the patients weekly dressing change and when dressing changes were clinically indicated.</LI>
<LI>Placebo ointment was matched to intervention ointment with respect to appearance and consistency and contained in brown opaque 50 g glass jars marked only with patients name and study number. A 1 cm cotton swab application of study ointment was applied to the CVC exit site followed by the application of a 2 x 2 in dry gauze dressing secured with a porous nontransparent adhesive (hypafix).</LI>
<LI>Duration: Primary end point was the proportion of patients with a catheter-related infection within 6 months after entry into the study. Study ended when the last enrolled subject completed the minimum 6 month study period.</LI>
</UL>
<P>
<B>Co-interventions</B>: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 14:08:59 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Incidence of infections</LI>
<LI>Exit site</LI>
<LI>Tunnel infection</LI>
<LI>Bacteraemia</LI>
<LI>Patient mortality</LI>
<LI>Time to development of infection</LI>
<LI>Morbidity related to infection</LI>
<LI>Episodes of hospitalisation</LI>
<LI>Catheter removal due to infection</LI>
<LI>
<I>S. aureus</I> nasal and exit site carriage</LI>
<LI>Causative organism</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>Exit site infections</LI>
<UL>
<LI>Definite: Purulent discharge at exit site or erythema, tenderness, induration (2-3) at exit site with a positive culture or serous discharge.</LI>
<LI>Probable: Erythema, tenderness, induration (2-3) at exit site without a positive culture or serous discharge or above with discharge but lack of alternative explanation.</LI>
</UL>
<LI>Tunnel infection</LI>
<UL>
<LI>Definite: Purulent discharge or aspirate from a tunnel or pocket site not contiguous with exit site or erythema, tenderness, induration (2-3) at a tunnel or pocket site not contiguous with exit site with a positive culture of serous discharge or aspirate from that site.</LI>
<LI>Probable: Erythema, tenderness, induration (2-3) at a tunnel or pocket site not contiguous with exit site and serous discharge or aspirate from that site without a positive culture.</LI>
</UL>
<LI>Catheter-related bacteraemia</LI>
<UL>
<LI>Definite: Confirmation of septic thrombophlebitis with a single positive blood culture or single positive blood culture and positive culture of catheter segment with identical organism or &gt; 10-fold colony count difference in blood cultures drawn from device and peripheral blood or single positive blood culture and positive culture from discharge or aspirate from exit site, tunnel or pocket with identical organism.</LI>
<LI>Probable: two or more positive blood cultures with no evidence for source other than the device or single positive blood culture for <I>S. aureus</I> or candida with no evidence for source other than device or single positive blood culture for coagulase negative staphylococci, bacillus, <I>C. jeikeium</I>, enterococcus, trichophyton or malassezia in immunocompromised or neutropenic host or in patient receiving total parenteral nutrition with no evidence for source other than a centrally placed device.</LI>
</UL>
</UL>
<P>Results in relation to the following:</P>
<UL>
<LI>
<I>S. aureus</I> nasal carriage at baseline: 11/83 polysporin group versus 12/79 in placebo group. Authors report that prevalence of nasal carriage remained stable over time and similar between the two group, however, this data was not included in study report</LI>
<LI>
<I>S. aureus</I> exit site carriage at baseline: 3/83 polysporin group versus 4/79 in placebo group. Authors report that the prevalence of exit site carriage dropped markedly in the first few months for both groups. This data was not included in study report</LI>
<LI>Authors reported a consistent 22-25% colonisation of non <I>S. aureus</I> organisms at the exit site in the placebo treated group compared to 10-11% in the polysporin group within the first 6 months.</LI>
</UL>
<UL>
<LI>Causative organisms</LI>
<UL>
<LI>Exit site (treatment/control group): Coagulase-negative staphylococci (3/13); S<I>. aureus</I> (2/1); Enteroccocus (0/1); Enterobacter species (0/2)</LI>
<LI>Bacteraemia (treatment/control group): Coagulase-negative staphylococci (3/11); S<I>. aureus</I> (1/6); Stenotrophemonous species (2/0); Candida (2/1); Corynebacterium species (0/1); Enteroccocus (0/2); Alcaligenes species (0/2); Enterobacter species (0/1); <I>P mirabilis</I> (0/1); Micrococcus species: 0/0</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 14:09:24 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>59 (71%) of participants in the treatment group and 35 (44%) of participants in the control group remained in the study for at least 6 months.</LI>
<LI>Polysporin triple and matching placebo were provided by Pfizer Consumer Healthcare Canada and the study was supported in part by Physicians Services Incorporated grant R00-08.</LI>
<LI>The CVC for both groups were placed by interventional radiologist using aseptic technique (sterile gowns, gloves, mark, cap and drape). At the time of dressing changes cleansing around the exit site for both groups was carried out using chlorhexidine gluconate (0.5% in 70% alcohol) applicator. Both groups used a dry dressing.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 13:24:49 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Huraib-1994">
<CHAR_METHODS MODIFIED="2009-11-04 14:09:41 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Completeness of follow-up: 100%</LI>
<LI>Follow-up period: NS</LI>
<LI>Loss to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 13:24:49 +1100" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Saudi Arabia</LI>
<LI>Setting: Single centre in teaching hospital in Riyadh</LI>
<LI>Adult patients with Quinton double lumen non-tunnelled subclavian catheter for HD for maintenance and AKI.</LI>
<LI>Reason for HD (treatment/control): AKI (3/4); CKD (17/16); diabetic kidney disease (7/4); glomerulonephritis (5/6); interstitial nephritis (1/3); amyloidosis (1/0); hypertension (0/2); unknown (3/1); RPGN (1/2); acute tubular necrosis (2/2)</LI>
<LI>Number (treatment/control): 20/20</LI>
<LI>Age: mean ± SD (range)</LI>
<UL>
<LI>Treatment group: 47.5 ± 19.5 (20-80)</LI>
<LI>Control group: 34.85 ± 15.2 (17-76)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 12/8</LI>
<LI>Control group: 11/9</LI>
</UL>
<LI>Ethnicity: NS</LI>
<LI>Differences between the groups: NS, however appear similar</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-03 16:24:48 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Catheter care done by dialysis nurses using heparin 1 mL of 2500 units in each lumen only after dialysis three times/week with changing of dressing once/week after dialysis and as required to prevent the integrity of the seal mass from being compromised. Used an OpSite.</LI>
<LI>Duration: NS</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Catheter care done by hospital intravenous (IV) team using heparin flushing 500 units in 5 mL normal saline in each port of the catheter three times/day and changing the dressing three times/week. Did not indicate type of dressing. This was standard practice.</LI>
<LI>Duration: NS</LI>
</UL>
<P>
<B>Co-interventions</B>: None.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 14:10:22 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Incidence of infection</LI>
<LI>Exit site infection</LI>
<LI>Bacteraemia</LI>
<LI>Causative organism</LI>
<LI>Duration of catheter function</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>Catheter was considered infectious if the blood culture were positive or if purulent material from the insertion site was observed.</LI>
<LI>Catheterisation period was defined as the length of time the catheter (one or more) occupied the same insertion site.</LI>
<LI>Catheterisation period was defined as the length of time the catheter (one or more) occupied the same insertion site.</LI>
<LI>Brief description of how a catheter was considered infectious but not linked to any standard definition or lab result.</LI>
</UL>
<P>Results in relation to the following</P>
<UL>
<LI>Duration of catheter function in tunnelled group ranged from 10-150 days with mean 41.5 ± 32.5 days versus non-tunnelled group with range 7-70 days and a mean 28.1 ±15.3 days.</LI>
<LI>In the tunnelled group the causative organisms of bacteraemia was <I>S. epidermidis</I> (1) and the causative organism for exit site infection was <I>S. epidermidis</I> (1) and <I>S. fecalis</I> (1).</LI>
<LI>In the non-tunnelled group the causative organisms of bacteraemia was <I>S. aureus</I> (2), S. epidermidis (1) and the causative organism for exit site infection was S. epidermidis (3).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-03 16:29:27 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Unable to contact author to clarify issues in relation to randomisation method and allocation concealment.</LI>
<LI>Catheter inserted by designated members of the nephrology staff</LI>
<LI>Study compared the outcome of two protocols concerning post insertion catheter care. However, unclear as to what the intervention was</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 11:35:13 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Johnson-2002">
<CHAR_METHODS MODIFIED="2009-11-04 14:10:58 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Completeness of follow-up: 100%</LI>
<LI>Follow-up period: Until catheter was removed, however, did not provide exact timelines</LI>
<LI>Loss to follow-up: None</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 09:28:11 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Australia</LI>
<LI>Setting: Single site hospital in Brisbane</LI>
<LI>Adult patients with AKI or CKD who required HD via a newly inserted tunnelled cuffed CVC.</LI>
<LI>Reason for HD (treatment/control): acute temporary dialysis (5/5); commencing chronic dialysis (9/6); diabetes (10/10); symptomatic vascular disease (11/11); prior immunosuppression (6/5); prior catheter use (3/3); nasal staphylococcal carriage (6/6)</LI>
<LI>Number (treatment/control): 27/23</LI>
<LI>Age: mean ± SD</LI>
<UL>
<LI>Treatment group: 53.8 ± 3.6</LI>
<LI>Control group: 56.6 ± 2.9</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 15/12</LI>
<LI>Control group: 9/14</LI>
</UL>
<LI>Ethnicity (treatment/control): Caucasoid race (24/19)</LI>
<LI>Difference between groups: None of the differences between the groups was statistically different</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 14:12:11 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Calcium mupirocin ointment (2%) applied to the insertion site. This involved an application of 10 mm of ointment from a 15 G tube with an outlet diameter of 5 mm.</LI>
<LI>Applied immediately after catheter insertion and three times/week at the end of each dialysis session using primapore dressings - opaque, air permeable non woven fabric dressing.</LI>
<LI>Duration: Until catheter was removed, time frame was not stated</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>No ointment used. A primapore dressings applied immediately after catheter insertion and three times/week at the end of each dialysis session.</LI>
<LI>Duration: Until catheter was removed, however, time frame not stated</LI>
</UL>
<P>
<B>Co-interventions</B>: None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-05 11:35:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exit site infection</LI>
<LI>Catheter-related bacteraemia</LI>
<LI>Adverse reactions and costs</LI>
<LI>Catheter survival</LI>
<LI>Time to development of infection</LI>
<LI>Causative organism</LI>
<LI>
<I>S. aureus</I> colonisation</LI>
<LI>Mupirocin resistance</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>Catheter-related definitions were defined according to standard guidelines.</LI>
<LI>Exit site infection was defined as purulent exit site discharge or two out of three exit site erythema, tenderness or induration with a positive culture.</LI>
<LI>Catheter-associated bacteraemia was defined as either</LI>
<OL>
<LI>a single positive blood culture together with a positive culture of the catheter tip or exit site with an identical organism, or</LI>
<LI>two or more positive blood cultures (or a single positive blood culture for <I>S. aureus</I>) with no evidence of infection source other than the device.</LI>
</OL>
</UL>
<P>Results relating to the following</P>
<UL>
<LI>Median catheter survival for end of treatment in control group was 31 days and for the mupirocin group 108 days (log rank score 5.9, P &lt; 0.05)</LI>
<LI>Causative organism for exit site infection</LI>
<UL>
<LI>Control group: <I>S. aureus</I> (4), <I>P. aeruginosa</I> (1)</LI>
</UL>
<LI>Causative organism for bacteraemia</LI>
<UL>
<LI>Treatment group: <I>P. aeruginosa</I> (1); Rhodococcus species (1), <I>S. aureus</I> (0).</LI>
<LI>Control group: <I>S. aureus</I> (4); <I>E. cloacae</I> (1); <I>E. aerogenes</I> (1); <I>P. aeruginosa</I> (1); <I>S. epidermidis</I> (1).</LI>
</UL>
<LI>
<I>S. aureus</I> nasal carriage at baseline: 6/27 in mupirocin group (6/27), control group (6/23). Mupirocin use was associated with reduced occurrence of catheter-related sepsis in nasal staphylococcal carriers (0% mupirocin versus 50% controls, P = 0.09) and a prolonged time to first infection (log rank score 3.2, P = 0.07).</LI>
<LI>Participants who did not have nasal colonisation with <I>S. aureus</I> at baseline exhibited a lower frequency of catheter-associated infection (10 versus 26%, P = 0.06) and a significantly increased time to first infection (log rank score 6.3, P = 0.001) if they were allocated to the mupirocin rather than control group.</LI>
<LI>Odds ratio for staphylococcal infections in patients who were not nasal carriers was 0.26.</LI>
<LI>No local or systemic adverse reactions to mupirocin was noted. Mupirocin resistant staphylococcal isolate were not detected.</LI>
<LI>Costs: The authors reported the median cost of exit site application of mupirocin for the average life of a catheter was USD 7.50/patient which compared favourably to the median costs of reinserting a new CVC USD 824/catheter and therapy for catheter-related septicaemia USD 1744/episode.</LI>
<LI>Premature removal of CVC took place in 5 (19%) of mupirocin group and 13 (57%) of controls. Reasons for premature removal:</LI>
<UL>
<LI>Infection: 7% in mupirocin group and 39% in control</LI>
<LI>Catheter thrombosis: 7% in mupirocin group and 9% in control</LI>
<LI>Cracking: 0% in mupirocin group and 4% in control</LI>
<LI>Inadvertent patient removal: 4% in mupirocin group and 4% in control</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 14:41:10 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>In both the treatment and control group following each dialysis standard skin disinfection was achieved with 10% povidone-iodine. The site was covered by primapore dressings - opaque, air permeable non woven fabric dressing. Lumens of catheter were filled with heparin (1000 U/mL) after insertion and each dialysis session. Volume was equivalent to the priming volume of the catheter.</LI>
<LI>CVC insertion was carried out by dedicated vascular access surgeons using ultrasound guided placement of a subcutaneously tunnelled internal jugular venous HD catheter. Insertion was via the method described by Schwab et al.</LI>
<LI>No prophylactic pre-operative antibiotics were prescribed.</LI>
<LI>Dressings changed by trained HD staff and CVC was used only for dialysis.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 14:18:43 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Johnson-2005">
<CHAR_METHODS MODIFIED="2009-11-04 14:15:51 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: February 2002 to July 2004. Median follow-up was 95 (55-157 interquartile range) days</LI>
<LI>Completeness of follow-up: 100%</LI>
<LI>Loss to follow-up: No patient was lost to follow-up</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 13:22:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Australia</LI>
<LI>Setting: Single setting in teaching hospital in Brisbane</LI>
<LI>Adult patients who had AKI or CKD and required HD via a newly inserted tunnelled cuffed CVC</LI>
<LI>Aetiology of kidney failure (treatment/control): acute-on-CKD (4/6); diabetes (13/15); glomerulonephritis (15/9); polycystic kidney disease (4/4); chronic tubulointerstitial nephritis (5/5); other (10/11)</LI>
<LI>Number (treatment/control): 51/50</LI>
<LI>Age: mean ± SD</LI>
<UL>
<LI>Treatment group: 54.2 ± 6.8</LI>
<LI>Control group: 60.9 ± 12.6</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 29/22</LI>
<LI>Control group: 32/18</LI>
</UL>
<LI>Ethnicity (treatment/control): White (43/45)</LI>
<LI>Nasal Staphylococcal carriage (treatment/control): 9/6</LI>
<LI>Infection at time of catheter insertion (treatment/control): None (46/42); skin (2/2); PD peritonitis (3/5); URTI (0/1)</LI>
<LI>Differences between groups: No significant difference between the two groups with respect to their baseline characteristics except for a higher mean age and a trend toward a greater frequency of HD in the treatment group.</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 14:18:05 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Medihoney. 3 mL of topical Medihoney (Medihoney Pty Ltd Brisbane Australia) applied three times/week to exit site at each HD session when dressing was changed.</LI>
<LI>Duration: Patients were followed up until catheter was removed.</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Calcium mupirocin ointment. 10 mm of topically standard 2% calcium mupirocin ointment (Bactroban Sydney) was applied directly onto exit site from a 15 G tube with an outlet diameter of 5 mm three times/week at each HD session each dressing was changed.</LI>
<LI>Duration: Patients were followed up until catheter was removed.</LI>
</UL>
<P>
<B>Co-interventions</B>: None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-05 14:18:43 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Catheter-related bacteraemia</LI>
<LI>Catheter exit infection</LI>
<LI>Causative organism</LI>
<LI>Adverse reactions and cost</LI>
<LI>Mupirocin resistance among staphylococcus isolates</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>Catheter-related infections were defined according to standard guidelines.</LI>
<LI>Catheter-associated bacteraemia was defined as either a single positive blood culture together with a positive culture of the catheter tip or exit site with an identical organism or two or more positive blood cultures or a single positive blood culture for a <I>S. aureus</I> with no evidence of infection source other than the device.</LI>
<LI>Exit site infection was defined as purulent exit site discharge or two of three of the following: exit site erythema, tenderness, and induration with a positive culture.</LI>
</UL>
<P>Results in relation to the following:</P>
<UL>
<LI>Mean ± SE actuarial bacteraemia-free survival periods for Medihoney was 367 ± 42 days and for mupirocin 334 ± 17 days, (Log rank 0.01, P = 0.92).</LI>
<LI>Type of prophylaxis administered was not significantly associated with bacteraemia-free survival (unadjusted hazard ratio for Medihoney 0.94, 95% CI, 0.27 to 3.24, P = 0.92).</LI>
<LI>Causative organism for bacteraemia</LI>
<UL>
<LI>Medihoney group: <I>S. aureus</I> (1), coagulase-negative staph (2), Micrococcus (1), <I>S. marcescens</I> (2)</LI>
<LI>Mupirocin group: <I>S. aureus</I> (1), coagulase-negative staph (1), <I>K pneumoniae</I> (1), <I>S maltophilia</I> (2).</LI>
</UL>
<LI>Adverse reactions</LI>
<UL>
<LI>Medihoney group: Transient mild local skin discomfort (1) which resolved within few days. Administration of intervention was not discontinued.</LI>
<LI>Mupirocin group: Similar symptoms to patient in Medihoney group (1). Administration of intervention was not discontinued.</LI>
</UL>
<LI>Cost: Median cost of exit site application for the average life of a catheter was AUD 13/patient in the Medihoney group and AUD 11.10/patient in the mupirocin group.</LI>
<LI>Mupirocin-resistant strains not detected in any staph isolates from patients with catheter-related bacteraemia.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 14:41:12 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Medihoney was provided by Medihoney Pty Ltd.</LI>
<LI>For both groups the subcutaneously tunnelled internal jugular CVC was inserted under ultrasound guided placement by dedicated vascular access surgeons according to method described by Schwab et al. Prophylactic pre-operative antibiotic cephazolin 1 gram IV was given to both groups.</LI>
<LI>For both groups 10% povidone-iodine was used for disinfection at the site of insertion with contact time 3-5 minutes followed by complete drying and sites were covered by opaque air permeable non woven fabric dressing.</LI>
<LI>CVC in both groups were dedicated to HD use only and not used for any other purposes. Sodium heparin 1000 U/mL was injected into each lumen in a volume equivalent to the priming volume of the catheter and subsequent catheter care was performed by trained HD registered nurse using a rigorous aseptic technique.</LI>
<LI>For both groups exit site was re-cleansed at each dialysis session with 10% povidone-iodine solution and a primapore dressing applied.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 13:27:23 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kamaliah-2004">
<CHAR_METHODS MODIFIED="2009-11-04 14:22:13 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: 1st July 1999 to 30th September 2000</LI>
<LI>Completeness of follow-up: 100%</LI>
<LI>Follow-up period: NS</LI>
<LI>Loss to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 14:23:06 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Malaysia</LI>
<LI>Setting: Multicentre study using 4 HD centres in north east Malaysia</LI>
<LI>Adult patients with acute-on-CKD or ESKD needing temporary HD using CVC</LI>
<LI>CVC insertion (treatment/control): subclavian (1/2); internal jugular vein (16/12)</LI>
<LI>Acute-on-CKD (treatment/control): 3/2</LI>
<LI>ESKD (treatment/control): 14/12</LI>
<LI>Comorbid conditions (treatment/control): hypertension (16/12); diabetes mellitus (4/6); ischaemic heart disease (1/1); gout (1/1)</LI>
<LI>Number (treatment/control): 1714</LI>
<LI>Age: Mean</LI>
<UL>
<LI>Treatment group: 47.18</LI>
<LI>Control group: 48.71</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 10/7</LI>
<LI>Control group: 7/7</LI>
</UL>
<LI>Ethnicity (treatment/control): Malay (15/12), Chinese (2/1)</LI>
<LI>Differences between the groups: Both group were comparable in terms of baseline characteristics and there was no significant differences between the 2 groups.</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Patients with AKI; CVC inserted into femoral vein; Pre-existing fever from any focus of infection at study onset; corticosteroid therapy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-05 11:35:15 +1100" MODIFIED_BY="Narelle S Willis">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Topical application of mupirocin ointment applied 3 times/week after each dialysis. Catheter exit site prepared with sterile povidone-iodine (10%) followed by topical application of mupirocin ointment. Dressed with OpSite and secured with porous tape.</LI>
<LI>Duration: The end point was catheter colonisation and catheter-related infection.</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>No ointment</LI>
<LI>Standard treatment where catheter exit site was prepared with sterile povidone-iodine (10%) dressed by sterile gauze 3 times/week after each dialysis.</LI>
<LI>Duration: The end point was catheter colonisation and catheter-related infection.</LI>
</UL>
<P>
<B>Co-interventions</B>: None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-05 13:27:23 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Incidence of infections</LI>
<LI>Exit site infection</LI>
<LI>Catheter-related bacteraemia</LI>
<LI>Bacterial colonisation</LI>
<LI>Duration of catheter placement</LI>
<LI>Survival rate of CVC</LI>
<LI>Mortality</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>Catheter-related infection was classified into 2 categories</LI>
<UL>
<LI>Exit site infection: Defined as infection localised to the exit site characterised by localised redness, crusting with exudate either serous or pus with positive culture from superficial swab from exit site taken from the skin and catheter surface.</LI>
<LI>Catheter-related bacteraemia: Defined as patient having systemic symptoms, fever with body temperature of 38C or higher and positive blood culture either from the catheter or peripheral vein yielding similar micro-organism.</LI>
</UL>
<LI>Colonisation was defined as positive culture from the superficial swabs (skin and catheter surface) or catheter tip but without the above signs and symptoms.</LI>
</UL>
<P>Results in relation to the following:</P>
<UL>
<LI>Survival of catheter (mean duration of catheter placement): Mupirocin group 48.53 days (range 6-154); control group 25.90 days (range 3-60 (P = 0.05).</LI>
<LI>Positive microbiological culture (isolated from peripheral swab, blood culture or catheter tip): Mupirocin group: 4/17 (23.5%); control group: 8/14 (57.1%) (P = 0.012)</LI>
<LI>Colonisation: Mupirocin group (3/17); control group (3/14).</LI>
<LI>Causative organisms for colonisation</LI>
<UL>
<LI>Mupirocin group: <I>S. epidermidis</I> (1); <I>B. subtilis</I> (1); Acinetobacter sp (1)</LI>
<LI>Control group: <I>S. aureus</I> (1); <I>S. epidermidis</I> (1); <I>K. aerugene</I>s (1)</LI>
</UL>
<LI>Causative organism for catheter-related infections</LI>
<UL>
<LI>Mupirocin group: <I>K. aerugenes</I> (1)</LI>
<LI>Control group: <I>S. aureus</I> (2); MRSA (2), <I>P. aeruginosa</I> (1)</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 14:27:46 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>University Sains Malaysia provided a short-term research grant.</LI>
<LI>Author initial supplied information on where to obtain full article but received no reply to follow-up requests seeking clarification on method of randomisation, allocation concealment, blinding, loss to follow-up, duration of follow-up, clarification on what dressing were used in both groups and data analysis.</LI>
<LI>Dressing used in the treatment group and control group are different. The exit site of the treatment group was dressed with OpSite and secured with porous tape while the dressing used in the control group was sterile gauze. CVC inserted into either internal jugular or subclavian vein by a medical doctor using sterile methods, wore face masks and sterile gloves. CVC used only for HD</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 13:28:24 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-le-Corre-2003">
<CHAR_METHODS MODIFIED="2009-11-04 14:31:39 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: Dates not specified</LI>
<LI>Completeness of follow-up: 55.2% (13/29 participants in the treatment group and 19/29 participants in the control group completed the total 6 months observation. 16 patients in the treatment group did not complete 6 months observation due to removal of catheter (7) or reaction to dressing (9). In the dry dressing group 10 participants did not complete 6 months observation due to removal of catheter).</LI>
<LI>Follow-up period: 6 month study</LI>
<LI>Loss to follow-up: None</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 13:27:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Canada</LI>
<LI>Setting: Single centre teaching hospital in Quebec</LI>
<LI>Required HD treatment for chronic terminal renal insufficiency; tunnelled CVC inserted in the jugular vein; competent and able to sign consent form</LI>
<LI>Previous number of days on HD</LI>
<UL>
<LI>Treatment group: Mean 581, median 483, range 1-2286</LI>
<LI>Control group: Mean 487, median 251, range 28-2403</LI>
</UL>
<LI>Previous number of bacteraemia (treatment/control): 5/6</LI>
<LI>Number of hospitalisations (treatment/control): 8/8</LI>
<LI>Aetiology of kidney failure: NS</LI>
<LI>Comorbidities (treatment/control): Diabetes (13/11); chemotherapy (1/0); vascular insufficiency (7/7)</LI>
<LI>Number (treatment/control): 29/29</LI>
<LI>Age: &#8805; 18 years</LI>
<UL>
<LI>Treatment group: Mean 74, median 76, range 36-87</LI>
<LI>Control group: Mean 71, median 74, range 50-88</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 13/16</LI>
<LI>Control group: 14/15</LI>
</UL>
<LI>Ethnicity: NS</LI>
<LI>Differences between the groups: Not stated but provided P values for differences in:</LI>
<UL>
<LI>number of females in treatment and control group (P = 0.79)</LI>
<LI>median age (P = 0.42)</LI>
<LI>previous median number of days on HD (P = 0.45)</LI>
</UL>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Any other type of permanent or temporary catheter; catheter inserted at a different site other than the jugular vein; systemic antibiotic therapy; history of bacteraemia during the last 3 months and catheter was not changed; known dermatitis at the exit site or known hypersensitivity to a component of either dressing</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 14:34:49 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Standard polyurethane transparent dressing (3 MTM TegadermTM 1635 Transparent IV) applied at exit site. Replaced every 7 days during scheduled visit to the HD unit.</LI>
<LI>Duration: 6 months</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>4 x 4 dry gauze attached with stretch bandage (Mefix® TendraTM) applied to the exit site. Replaced every 2/3 days depending on the scheduled visit for HD treatment usually 3 times/week.</LI>
<LI>Duration: 6 months</LI>
</UL>
<P>
<B>Co-interventions</B>: None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 14:35:59 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Incidence of infection</LI>
<LI>Exit site</LI>
<LI>Local infection</LI>
<LI>Bacteraemia</LI>
<LI>Quality of Life</LI>
<LI>Cost related to each type of dressing</LI>
<LI>Skin condition</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>During each dressing change the dressing condition was evaluated as well as the skin at the exit site for visible humidity, pain, pruritus, erythema and exudates. If infection was suspected the distal end of the catheter was cultured and infection confirmed. The skin condition at the exit site was evaluated using a scale from 0-5 (0: none and 5: severe). No definitive definitions provided only indicated what they would observe for when observing exit site.</LI>
</UL>
<P>Results in relation to the following:</P>
<UL>
<LI>Quality of Life: There was no significant difference (all P values were between 0.22 and 0.62) between the two groups as measured on 2 standardised scales; physical and mental of the SF-36TM, 3 times during the study. The score difference was 3.8 for the physical component and 6.4 for the mental component between the beginning and the end of the study. No precise figures provided.</LI>
<LI>Skin condition: 8 patients in the transparent dressing group experienced pruritus and erythema and were withdrawn from the study. This occurred at the beginning of the study and prior to the reinforcement of correct drying policy of disinfecting agent. Following implementation of the drying policy only 1 patient experienced pruritus and erythema. Did not indicate if this participant was withdrawn from the study.</LI>
<LI>Cost/patient/week was CAD 4.72 for the transparent dressing group and CAD 7.60 for the dry dressing group.</LI>
<LI>Total materials cost/week were CAD 30.34 for transparent group and CAD 51.09 for dry dressing group</LI>
<LI>Nursing cost/week with median salary CAD 21/hour; CAD 0.006/sec: transparent group CAD 10.83 and dry group CAD 24.88</LI>
<LI>Non-scheduled dressing changes (during observation period) were CAD 6.01 for the transparent dressing group. No figure was provided for the dry dressing group</LI>
<LI>Total cost/week for 10 patients were CAD 47.18 transparent group and CAD 75.97 for dry dressing group.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-05 13:28:24 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funded in part by research grants from 3M Canada Company, CR Bard Canada and SoluMed Canada.</LI>
<LI>Attempt made to contact author for further detail on randomisation, allocation concealment and data analysis, however, received no reply.</LI>
<LI>Four participants were excluded before the first day of the study: voluntary withdrawal (2), died (1) catheter removed just prior to onset of study (1), leaving a total of 58 participants in the study.</LI>
<LI>A standardised questionnaire on quality of life (SF-36tm, QualityMetric Inc) was performed on all patients at start of study, at 3 months and at the study end (6 months) to evaluate the impact of the different dressing.</LI>
<LI>Only 13 subjects in treatment group completed the 6 months observation versus 19 in the control group as a result there was statistically less catheter days of observation in the treatment group than in the control group (3348 versus 4286 catheter days, P &gt; 0.05).</LI>
<LI>Catheter used was double lumen tunnelled CVC inserted into intern jugular vein. Insertion was done by a vascular radiologist under sterile conditions (gown, gloves, mask and sterile field). Aqueous solution of 2% chlorhexidine was used for skin asepsis. 5000 U of heparin (1 mL = 10, 000 U) was diluted in NaCl 0.9% solution and inserted into each lumen and distal end of the Y which was covered with a dry gauze. The exit site was covered temporarily with dry gauze until the next dressing change. During dressing change the exit site was sanitized with aqueous solution of 2% chlorhexidine which was applied on a 10 cm² skin surface around the site. No ointments or topical antimicrobial creams were used.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 13:23:07 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Levin-1991">
<CHAR_METHODS MODIFIED="2009-11-04 09:13:25 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Completeness of follow-up: 99% (1 excluded from control group as he was accidentally changed to the treatment group).</LI>
<LI>Follow-up period: NS</LI>
<LI>Loss to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 13:23:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Canada</LI>
<LI>Setting: Single centre clinical dialysis unit situated in a hospital in Toronto</LI>
<LI>Patients with either AKI or CKD requiring non-tunnelled subclavian catheters for HD access; aetiology of kidney failure: NS</LI>
<UL>
<LI>AKI (treatment/control): 19/12</LI>
<LI>CKD (treatment/control): 44/54</LI>
</UL>
<LI>Number</LI>
<UL>
<LI>Treatment group: 63 (75 catheter tips)</LI>
<LI>Control group: 66 (73 catheter tips)</LI>
</UL>
<LI>Age: Mean ± SD</LI>
<UL>
<LI>Treatment group: 49.8 ± 2.1</LI>
<LI>Control group: 53.0 ± 1.9</LI>
</UL>
<LI>Sex (M/F): NS</LI>
<LI>Difference between groups: Groups were similar and these similarities were stated</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>CVC were not inserted into patients who were actively infected.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 14:44:10 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Povidone-iodine ointment. 1 g of 10% sterile povidone-iodine ointment (Betadine) applied to gauze adjacent to the skin entry site.</LI>
<LI>Applied immediately after catheter insertion and three times/week at the end of each dialysis session.</LI>
<LI>Duration: NS</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>No ointment used sterile gauze dressing only.</LI>
<LI>Applied immediately after catheter insertion and three times/week at the end of each dialysis session.</LI>
<LI>Duration: NS</LI>
</UL>
<P>
<B>Co-interventions</B>: None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-05 11:35:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Incidence of catheter-related infections</LI>
<LI>Exit site infection</LI>
<LI>Septicaemia</LI>
<LI>Morbidity</LI>
<LI>Mortality</LI>
<LI>Catheter tip colonisation</LI>
<LI>Incidence of <I>S. aureus</I> nasal carrier</LI>
<LI>Catheter duration</LI>
<LI>Catheter-days at risk</LI>
<LI>Catheter-days at risk in <I>S. aureus</I> nasal carriers</LI>
<LI>Causative organism for catheter-related bacteraemia</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>Exit site and tip cultures were defined as positive if at least 15 colonies of one organism were grown.</LI>
<LI>Line-related sepsis was defined as present if peripheral blood cultures were positive with no other focus of infection demonstrable.</LI>
<LI>Coagulase negative staphylococci defined as growth in two or more blood culture bottles was required to indicate significant bacteraemia.</LI>
<LI>Duration of catheter-days reflects the number of uses for dialysis (3 treatments/week)</LI>
</UL>
<P>Results in relation to the following:</P>
<UL>
<LI>Number of catheter tips colonised in povidone-iodine ointment group were 13/75 (17%) versus 27/73 (37%) in control group (P &lt; 0.01, 95% CI 7-33%). RRR for tip colonisation due to povidone-iodine was 52%.</LI>
<LI>Incidence of catheter colonisation based on the number of sites which developed a colonised catheter was 11/63 (17%) for povidone-iodine ointment group compared to 25/66 (38%) for the control group (P = 0.012, 95% CI 6-37%, RRR 54%).</LI>
<LI>Total catheter-days at risk for the povidone-iodine ointment group was 2437 days (mean 8.6 ± 5.1, range 2-210) versus control group of 2397 days (mean 36.2 ± 4.6, range 2-214).</LI>
<LI>Rate of septicaemia/100 days at risk is 0.04 for povidone-iodine ointment group and 0.046 (P &lt; 0.01) for control group.</LI>
<LI>The rate of <I>S. aureus</I> nasal carriers was 14/63 (22%) in the povidone-iodine ointment group. Of these none developed exit site infection or septicaemia. The rate of <I>S. aureus</I> nasal carriers in the control group was 21/66 (32%) of these 6 developed septicaemia due to <I>S. aureus</I> and 5 developed exit site infections.</LI>
<LI>Overall rate of <I>S. aureus</I> nasal carriage was 35 (26%) with the RR/day of developing septicaemia with any organism in the control group been three times greater in those who were <I>S. aureus</I> nasal carriers (6/21, 644 days at risk) than in the non <I>S. aureus</I> carriers (5/45, 1753 days at risk) (P &lt; 0.05).</LI>
<LI>Mean number of catheter-days at risk in <I>S. aureus</I> nasal carriers was 40.3 ± 6.1 days in treatment group and 30.6 ± 7.7 days (P &lt; 0.01) in control group.</LI>
<LI>There were no exit site infections in <I>S. aureus</I> nasal carriers in treatment group compared to 5 exit site infections in control group (P &lt; 0.05, 95% CI 6-32%, RRR 100%).</LI>
<LI>There were no episodes of septicaemia in <I>S. aureu</I>s nasal carriers in treatment group compared to 6 episodes in the control group (P &lt; 0.05, 95% CI 10-48%, RRR 100%). These 6 episodes were caused by <I>S. aureus</I>.</LI>
<LI>There were 2 catheter tip colonisation in <I>S. aureus</I> nasal carriers in the treatment group and these were not caused by <I>S. aureus</I> versus 11 episodes of tip colonisation in the control group (P &lt; 0.05, 95% CI 6-54%, RRR 71%). 7 of these were caused by <I>S. aureus</I>.</LI>
<LI>Causative organism of septicaemia in treatment group was <I>S. epidermidis</I> (1/1) versus <I>S. epidermidis</I> (3/11), <I>S. aureus</I> (8/11) in the control group. 6/8 in the <I>S. aureus</I> group were found in the <I>S. aureus</I> nasal carrier group within the control group.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 14:39:22 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>For both treatment and control group CVC inserted by staff nephrologist or senior nephrology trainees, who wore masks, sterile gowns and gloves. Both patient and assistant nurse wore masks. Strict protocol included skin preparation with povidone-iodine surgical scrub, removed with sterile water and followed by povidone-iodine solution. Head, neck and anterior chest were draped with sterile towels, lidocaine (2%) was given as LA. Catheter filled with 7 to 10, 000 units of heparin depending on catheter length after insertion and each dialysis session. Skin including exit site and catheter hub were disinfected with povidone-iodine solution after each dialysis. Sterile gauze dressing used. Dressing changed by trained haemodialysis staff. CVC only used for dialysis.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-04 14:51:06 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quadri-1999">
<CHAR_METHODS MODIFIED="2009-11-04 14:49:00 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Completeness of follow-up: 100%</LI>
<LI>Follow-up period: Study took place over 21 month period</LI>
<LI>Loss to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 14:49:18 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Saudi Arabia</LI>
<LI>Setting: Single setting in teaching hospital</LI>
<LI>HD patients with temporary CVC</LI>
<LI>Number (treatment/control): 23/26</LI>
<LI>No further details provided on participants</LI>
<LI>Differences between the groups: NS</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 14:50:42 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Manuka honey in sterile syringes 3 mL applied to exit site after each dialysis treatment three times/week. Exit site area was covered with sterile 2X2 inch gauze and Tegaderm dressing</LI>
<LI>Duration: Study took place over 21 month period. End points were uneventful removal of temporary catheter following AV fistula maturation, temperature greater than 38 C with a clinical diagnosis of line sepsis, appearance of purulent material at exit sites with positive exit site culture, positive blood culture.</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Povidone-iodine ointment packaged in pharmacy under laminar flow applied to exit site after each dialysis treatment three times/week. Exit site area was covered with sterile 2 x 2 inch gauze and Tegaderm dressing.</LI>
<LI>Duration: Study took place over 21 month period. End points were uneventful removal of temporary catheter following AV fistula maturation, temperature greater than 38 C with a clinical diagnosis of line sepsis, appearance of purulent material at exit sites with positive exit site culture, positive blood culture.</LI>
</UL>
<P>
<B>Co-interventions</B>: None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 14:51:06 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Catheter-related bacteraemia</LI>
<LI>Catheter exit infection</LI>
<LI>Catheter-days</LI>
<LI>Adverse effects</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>Infection defined either</LI>
<OL>
<LI>blood stream infection plus blood cultures, or </LI>
<LI>purulent exit site drainage with positive cultures, or </LI>
<LI>temperatures &gt; 38 C felt to be due to line sepsis.</LI>
</OL>
</UL>
<P>Results in relation to the following:</P>
<UL>
<LI>Total catheter days in honey group was 495 days (mean 21.5 ± 9.3) versus povidone-iodine group of 535 days (mean 20.6 ± 8.9, P = 0.53).</LI>
<LI>No adverse reactions were reported in either honey or povidone-iodine group.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 14:39:25 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Contacted author for further information on randomisation method, allocation concealment, blinding, clarification on control used in study. Received written reply author has no access to files but gave some information based on recall.</LI>
<LI>For both groups CVC were placed using standard povidone-iodine with standard asepsis technique including gloves, gowns, drapes and masks</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 13:22:42 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sesso-1998">
<CHAR_METHODS MODIFIED="2009-11-04 14:51:44 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: From June 1994 to December 1996</LI>
<LI>Completeness of follow-up: 100%</LI>
<LI>Follow-up period: Participants were followed up until catheter was removed</LI>
<LI>Loss to follow-up: None</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 13:22:42 +1100" MODIFIED_BY="Narelle S Willis">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: Brazil</LI>
<LI>Setting: Single centre tertiary referral centre in Sao Paula</LI>
<LI>Patients with ESKD requiring subclavian or internal jugular non-tunnelled CVC for maintenance HD access; new ESRD patients without permanent venous access; patients with PD problems requiring urgent transfer to HD; patients with sudden loss of AVF.</LI>
<LI>Aetiology of kidney failure (treatment/control): glomerulonephritis (12/9); hypertension (28/27); diabetes mellitus (11/14); interstitial nephritis (2/4); other/unknown (16/13)</LI>
<LI>Number (treatment/control): 69/67</LI>
<LI>Age: mean (SEM), range</LI>
<UL>
<LI>Treatment group: 48.4 (2.0), 16-80</LI>
<LI>Control group: 4.6 (1.9), 16-74</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 34/35</LI>
<LI>Control group: 46/21</LI>
</UL>
<LI>Ethnicity (treatment/control): white 41/50; non white 28/17</LI>
<LI>Education (treatment/control): illiterate/primary school (55/44); secondary/high school/college (14/23)</LI>
</UL>
<UL>
<LI>Differences between the groups: Greater number of female patients in treatment group compared to the control group P &lt; 0.05. The treatment group had a greater but non significant proportion of non white individuals and of patients with lower educational level</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Patients with AKI; used a CVC within one month of the beginning of the study; patients who presented with septicaemia or a life threatening infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 14:53:52 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>Calcium mupirocin ointment (2%) applied to the insertion site. This involved an application of 10 mm of ointment from a 15 g tube with an outlet diameter of 5 mm.</LI>
<LI>Applied three times/week at the end of each dialysis session. Gauze dressing was used to cover site.</LI>
<LI>Duration: Until catheter was removed</LI>
</UL>
<UL>
<LI>
<B>Control group</B>
</LI>
<LI>No ointment</LI>
<LI>Sterile gauze dressing</LI>
<LI>Applied three times/week at the end of each dialysis session</LI>
<LI>Duration: Until catheter was removed</LI>
</UL>
<P>
<B>Co-interventions</B>: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 14:55:43 +1100" MODIFIED_BY="[Empty name]">
<P>Outcomes focused only on <I>S. aureus</I> colonisation and infection</P>
<UL>
<LI>
<I>S. aureus</I> colonisation</LI>
<LI>
<I>S. aureus</I> infection</LI>
<LI>Exit site colonisation and infection due to <I>S. aureus</I>
</LI>
<LI>Bacteraemia due to <I>S. aureus</I>
</LI>
<LI>Duration of CVC</LI>
<LI>Episodes of hospitalisations</LI>
<LI>Causes for removal of catheter</LI>
</UL>
<P>
<B>Outcome definitions</B>
</P>
<UL>
<LI>
<I>S. aureus</I> catheter-associated bacteraemia was considered confirmed (definite) if the following was present</LI>
<OL>
<LI>One or more blood cultures yielded <I>S. aureus</I> while the catheter was in place,</LI>
<LI>Fever &gt; 37.8 C was accompanied by rigor's, </LI>
<LI>Clinical examination, chest radiography, laboratory investigation and microbiologic data that did not suggest another source of <I>S. aureus</I> and</LI>
<LI>Recovery of <I>S. aureus</I> on catheter tip culture.</LI>
</OL>
<LI>
<I>S. aureus</I> catheter associated bacteraemia was considered probable if criteria 2, 3, and 4 were met but the blood culture revealed no growth and in addition no other source of infection that could have explained the fever is detected.</LI>
<LI>Catheter exit site <I>S. aureus</I> infection was defined if there were objective signs of pericatheter skin infection on physical examination (erythema, drainage or purulent exudate) at the catheter site and recover of <I>S. aureus</I> from the material expressed from the catheter exit site.</LI>
</UL>
<P>Results relating to the following:</P>
<UL>
<LI>Skin colonisation with <I>S. aureus</I>: 5/69 (7.2%), 1.76 episodes/1000 patient-days in mupirocin group versus 24/67 (35.8%), 14.27 episodes/1000 patient-days (P &lt; 0.001) in the control group. RR 1 - 7.7 (95% CI 2.9 to 20.9, P &lt; 0.001).</LI>
<LI>After 30 days of catheter placement the cumulative probability of not having <I>S. aureus</I> recovered from samples of the skin around CVC was 96.4% (95% CI 91.5 to 100) in the mupirocin group and 62% (95% CI 47.9 to 76.1) in the control group (P &lt; 0.001).</LI>
<LI>The risk of <I>S. aureus</I> colonisation in skin was 7.7 times greater in patient not receiving mupirocin ointment</LI>
<LI>Catheter surface colonisation with <I>S. aureus</I> was seen in 9/69 participants in the mupirocin group (3.17 episodes/1000 patient-days) in comparison to 24/67 participants in the control group (14.27 episodes/1000 patient-days, P &lt; 0.001), RR 1-4.5 (95% CI 2.0 to 10.0, P &lt; 0.001)</LI>
<LI>The risk of <I>S. aureus</I> colonisation in the catheter was 4.5 times greater in patients not receiving mupirocin ointment. <I>S. aureus</I> colonisation in the catheter was associated with bacteraemia in 2 (2.9%) participants in the mupirocin group compared to 15 (22.4%, P &lt; 0.001) in the control group.</LI>
<LI>
<I>S. aureus</I> colonisation of skin or catheter or blood was 13 (18.8%) in the mupirocin group versus 30 (44.8%, P &lt; 0.01) in the control group. Incidence rate/1000 patient-days was 1 episode in the mupirocin group compared to 17.84 episodes in the control group RR 1-4.3 (95% CI 2.2 to 8.5, P &lt; 0.001).</LI>
<LI>Hospitalisation: median duration of hospitalisation was 6 days (1-46) for mupirocin group and 5 days (2-56) for the control group</LI>
<LI>Median duration of catheter placement in mupirocin group was 37 days (4-142) and 20 days (3-136) in the control group (P &lt; 0.01)</LI>
<LI>Number of cumulative days catheter in place: mupirocin group 2836 days versus 1682 days in control group</LI>
<LI>Median number of dialysis sessions was 16 (range 2-65) for mupirocin group and 9 (range 2-44) (P &lt; 0.001) for the control group.</LI>
<LI>Number of cumulative dialysis sessions: mupirocin 1270 sessions versus 735 sessions for the control group.</LI>
<LI>Causes of catheter removal</LI>
<UL>
<LI>Mupirocin group: local skin infection (6, 8.7%); local skin infection and fever (3, 4.3%); fever without known source of infection (9, 13%); inadequate blood flow (17, 24.6%); inadvertent withdrawal (1, 1.4%) and no longer needed (33, 47.8%)</LI>
<LI>Control group: local skin infection (25, 37.3%); local skin infection and fever (15, 22.4%); fever without known source of infection (6. 9%); inadequate blood flow (5, 7.5%); inadvertent withdrawal (1, 1.5%) and no longer needed (15, 22.4%)</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 14:39:25 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>For both treatment and control group either internal jugular or subclavian CVC was inserted by nephrology staff physicians according to the aseptic Seldinger technique. Standard skin disinfection for both groups during dressing change was achieved using 10% povidone-iodine. Cannulation site, cannula hub and site connections were covered with sterile occlusive gauze dressing. Catheter filled with 2500 to 3000 units of heparin after insertion and after each dialysis session. Dressing changed by trained HD staff and CVC only used for dialysis.</LI>
<LI>Author was recipient of a research grant from the Brazilian Research Council while second author Dr Barbosa was supported by a doctoral fellowship grant from the Fundacao de Amparo a Pesquisa do Estado de Sao Paula.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AKI - acute kidney injury; CVC - central venous catheter; ESKD - end-stage kidney disease; HD - haemodialysis; NS - not stated; PD - peritoneal dialysis; RPGN - rapidly progressive glomerulonephritis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-04-15 19:31:32 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Comerota-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-15 19:31:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dahlberg-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-15 19:31:32 +1000" MODIFIED_BY="[Empty name]">
<P>Used CVC for purposes other than haemodialysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-11-05 13:29:48 +1100" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-11-05 13:29:48 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mavromatidis-1999">
<CHAR_METHODS MODIFIED="2009-11-04 12:30:47 +1100" MODIFIED_BY="[Empty name]">
<P>Randomisation via coin toss. Four groups A, A1, B and B1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-04 12:31:16 +1100" MODIFIED_BY="[Empty name]">
<P>AKI and CKD patients requiring placement of a double lumen CVC</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 12:31:35 +1100" MODIFIED_BY="[Empty name]">
<P>Vancomycin versus no antibiotic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-05 13:29:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>Insitu duration of initial catheter; catheter tip culture; systemic infection related to catheter; exit site infection</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 12:33:18 +1100" MODIFIED_BY="[Empty name]">
<P>Study identified prior to publication and will be included in review update</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-02-17 02:36:27 +1100" MODIFIED_BY="Margaret McCann" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-11-05 13:29:03 +1100" MODIFIED_BY="Narelle S Willis">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-11-04 16:13:27 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 13:59:53 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Atapour-2006">
<DESCRIPTION>
<P>Every other case randomly assigned to one of two groups tunnelled or non-tunnelled CVC</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 15:18:32 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HIPPO-Study">
<DESCRIPTION>
<P>Patient randomisation was performed at an independent central randomisation facility via a computer generated random number list using blocked randomisation with a block size of 4. Patients stratified into two groups before randomisation on the basis of the time interval between CVC insertion and study enrolment &lt; 7 days was called incident catheter and others were called prevalent catheter</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 16:11:27 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huraib-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 16:30:38 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2002">
<DESCRIPTION>
<P> Computer generated random number list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 17:10:24 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2005">
<DESCRIPTION>
<P>Computer generated random number list with randomisation blocks of 10. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 17:39:35 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamaliah-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 16:13:27 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levin-1991">
<DESCRIPTION>
<P>Sequenced allocation using designation box</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 09:30:03 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quadri-1999">
<DESCRIPTION>
<P>In written communication the author reported that it was double blind, placebo controlled study and that randomisation was concealed. The author did not provide details on how randomisation and allocation concealment was achieved.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 11:49:43 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sesso-1998">
<DESCRIPTION>
<P>Computer generated blocked randomisation, blocking size varying from 4-6</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 08:41:00 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-le-Corre-2003">
<DESCRIPTION>
<P>Randomisation was computer generated 1:1 ratio</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-11-04 16:13:34 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 14:53:44 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Atapour-2006">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 15:17:57 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HIPPO-Study">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 16:11:30 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huraib-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 16:30:30 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2002">
<DESCRIPTION>
<P>Sequentially numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 17:10:22 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2005">
<DESCRIPTION>
<P>Sequentially numbered opaque sealed envelopes before catheter insertion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 17:39:40 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamaliah-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 16:13:34 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levin-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 09:30:09 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quadri-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 12:14:07 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sesso-1998">
<DESCRIPTION>
<P>Sealed, sequentially number envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 08:41:05 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-le-Corre-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-11-03 16:11:23 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-03 15:17:18 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atapour-2006">
<DESCRIPTION>
<P>Blinding of participants, investigators, outcome assessors and data analysts not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-15 19:29:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HIPPO-Study">
<DESCRIPTION>
<P>Blinded participants, investigations and outcome assessors </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-03 16:11:23 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huraib-1994">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-15 19:27:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2002">
<DESCRIPTION>
<P>Blinded outcome assessors only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-15 19:27:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2005">
<DESCRIPTION>
<P>Blinded outcome assessors only </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-15 19:28:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamaliah-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-15 19:28:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levin-1991">
<DESCRIPTION>
<P> Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-15 19:30:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quadri-1999">
<DESCRIPTION>
<P>Blinded participants and investigator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-15 19:30:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sesso-1998">
<DESCRIPTION>
<P>Blinded outcome assessors only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-15 19:28:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-le-Corre-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2009-11-05 13:29:03 +1100" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Intention-to-treat?</NAME>
<DESCRIPTION>
<P>Was intention-to-treat analysis performed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 14:51:45 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atapour-2006">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 15:19:17 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HIPPO-Study">
<DESCRIPTION>
<P>Yes, except for the exclusion of seven blinded subjects who never started treatments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 16:11:33 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huraib-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 13:25:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Johnson-2002">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 17:10:40 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2005">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-03 17:39:47 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamaliah-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 09:11:32 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levin-1991">
<DESCRIPTION>
<P>Unclear. Only 148/171 catheter tips analysed T=75 and C=73<BR/>Reasons for catheter tips loss - loss of catheter at home, failure of tips to reach microbiology and transfer of patient to another institution</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 09:30:18 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quadri-1999">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 13:29:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sesso-1998">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 08:41:21 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-le-Corre-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-11-05 14:18:44 +1100" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-11-05 13:31:19 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2009-11-03 14:42:00 +1100" MODIFIED_BY="[Empty name]">Topical antimicrobial ointments and survival time of central venous lines</TITLE>
<TABLE COLS="4" ROWS="8">
<TR>
<TH ALIGN="CENTER" ROWSPAN="2">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2">
<P>
<B>Description of survival time</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>
<B>Results as reported by study authors</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>
<B>Ointment</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>No ointment/placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Sesso-1998" TYPE="STUDY">Sesso 1998</LINK>
</P>
<P>
<I>S. aureus</I> only</P>
<P>Mupirocin ointment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Median duration of catheter placement</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>37 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 days</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Range</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 to 142 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 to 136 days (P &lt; 0.01)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cumulative days catheter in place</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2836</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1682 (P &lt; 0.01)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>
</P>
<P>Mupirocin ointment</P>
</TD>
<TD VALIGN="TOP">
<P>Median catheter survival censored for end of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>108 days</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 days</P>
<P>log rank score 5.9 (P &lt; 0.05)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Kamaliah-2004" TYPE="STUDY">Kamaliah 2004</LINK>
</P>
<P>Mupirocin ointment</P>
</TD>
<TD VALIGN="TOP">
<P>Mean duration of catheter placement</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48.53 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25.90 days</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Range</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6-154 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3-60 days (P = 0.05)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-11-04 15:52:38 +1100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-11-03 14:44:27 +1100" MODIFIED_BY="[Empty name]">Topical antimicrobial ointments and time to development of infection</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH ALIGN="CENTER" ROWSPAN="2">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2">
<P>
<B>Description of time to development of infection </B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>
<B>Results as reported by study authors</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>
<B>Ointment</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>No ointment/placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>
</P>
<P>Mupirocin ointment</P>
</TD>
<TD VALIGN="TOP">
<P>Median interval between catheter insertion and onset of catheter associated bacteraemia</P>
</TD>
<TD VALIGN="TOP">
<P>108 days</P>
</TD>
<TD VALIGN="TOP">
<P>55 days</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Time to first exit site infection</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Significantly shorter in those patients who did not use a topical antimicrobial ointment</P>
<P>log rank 7.3, (P &lt; 0.01)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Time to first infection</P>
</TD>
<TD VALIGN="TOP">
<P>Patients who did not have nasal colonisation with <I>S. aureus</I> at baseline exhibited a significantly increased time to first infection (log rank score 6.3, p=0.001) if they were allocated to receive mupirocin ointment</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-HIPPO-Study" TYPE="STUDY">HIPPO Study</LINK>
</P>
<P>Polysporin ointment</P>
</TD>
<TD VALIGN="TOP">
<P>Time to first infection</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Shorter for placebo group (P = 0.0002, log rank test)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Time to first bacteraemia</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Significantly shorter in the placebo group (P = 0.0056, log rank test)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-11-05 14:18:44 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<TITLE MODIFIED="2009-11-03 14:44:54 +1100" MODIFIED_BY="[Empty name]">Honey and bacteraemia-free survival period</TITLE>
<TABLE COLS="4" ROWS="4">
<TR>
<TH ALIGN="CENTER" ROWSPAN="2">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2">
<P>
<B>Description of bacteraemia-free survival period</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>
<B>Results as reported by study authors</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>
<B>Honey</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Mupirocin ointment</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Johnson-2005" TYPE="STUDY">Johnson 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean ± SE actuarial bacteraemia-free survival period</P>
</TD>
<TD VALIGN="TOP">
<P>367 ± 42 days</P>
</TD>
<TD VALIGN="TOP">
<P>334 ± 17 days for mupirocin</P>
<P>(Log rank 0.01, p=0.92)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Honey or mupirocin were not significantly associated with bacteraemia-free survival. Unadjusted hazard ratio for honey</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.94, 95% CI, 0.27 to 3.24 (P = 0.92).</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2009-11-05 13:33:00 +1100" MODIFIED_BY="Narelle S Willis" NO="4">
<TITLE MODIFIED="2009-11-03 14:46:54 +1100" MODIFIED_BY="[Empty name]">International guidelines on preventing central venous catheter-related infections</TITLE>
<TABLE COLS="3" ROWS="28">
<TR>
<TH ALIGN="CENTER" COLSPAN="3">
<P>
<B>International guidelines</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="3">
<P>
<B>1. Topical antimicrobial ointments </B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>
<B>Guideline</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Year</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Recommendation/s</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>European Best Practice Guidelines (EBPG)</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>United Kingdom Renal Association</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>Suggest that local protocols may incorporate infection control measures that previous RCTs have shown can lead to a reduction in catheter-related infection. These procedures can include the use of:</P>
<P>Topical mupirocin, Medihoney or antiseptic at the catheter exit site</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Canadian Society of Nephrology (<LINK REF="REF-Jindal-2006" TYPE="REFERENCE">Jindal 2006</LINK>)</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>Use either povidone-iodine, mupirocin or polysporin ointment at the catheter exit site</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>K/DOQI</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CARI</P>
<P>Guidelines currently been updated</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P>Mupirocin or povidone-iodine ointment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CDC</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P>Povidone-iodine ointment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Epic 2</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>Does not recommend the use of topical antimicrobial ointments</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3">
<P>
<B>2. CVC Dressing</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>Guideline</B>
</P>
</TH>
<TH>
<P>
<B>Year</B>
</P>
</TH>
<TH>
<P>
<B>Recommendation/s</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>European Best Practice Guidelines (EBPG)</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>United Kingdom Renal Association</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>Suggest that local protocols may incorporate infection control measures that previous RCTs have shown can lead to a reduction in catheter-related infection. These procedures can include the use of dry dressing<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>K/DOQI</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>No preference recommends the use of either transparent or dry gauze dressing</P>
<P>If exit site is oozing use dry gauze</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Canadian Society of Nephrology (<LINK REF="REF-Jindal-2006" TYPE="REFERENCE">Jindal 2006</LINK>)</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>Dry gauze dressing </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CARI</P>
<P>Guidelines currently been updated</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P>Dry gauze but transparent are preferred because of comfort and anchoring </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CDC</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P>No preference recommends the use of either transparent or dry gauze</P>
<P>If patient is diaphoretic or site is oozing use dry gauze<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Epic 2</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>Transparent semi permeable polyurethane dressing</P>
<P>If profuse perspiration or bleeding use sterile gauze dressing</P>
</TD>
</TR>
<TR>
<TH COLSPAN="3">
<P>
<B>3. Cleansing agents</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>Guideline</B>
</P>
</TH>
<TH>
<P>
<B>Year</B>
</P>
</TH>
<TH>
<P>
<B>Recommendation/s</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>European Best Practice Guidelines (EBPG)</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>United Kingdom Renal Association</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>Chlorhexidine solution (no strength given)<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>K/DOQI</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>Chlorhexidine 2% with 70% alcohol</P>
<P>Patients with sensitivities chlorhexidine 2% with 70% alcohol use chlorhexidine aqueous solution</P>
<P>Patients with sensitivities to chlorhexidine aqueous use povidone-iodine solution</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Canadian Society of Nephrology (<LINK REF="REF-Jindal-2006" TYPE="REFERENCE">Jindal 2006</LINK>)</P>
</TD>
<TD VALIGN="TOP">
<P>2006</P>
</TD>
<TD VALIGN="TOP">
<P>No guideline</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CARI</P>
<P>Guidelines currently been updated</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P>Chlorhexidine (no strength given) or povidone-iodine </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CDC</P>
</TD>
<TD VALIGN="TOP">
<P>2002</P>
</TD>
<TD VALIGN="TOP">
<P>2% chlorhexidine based preparation is preferred but tincture of iodine, an iodophor or 70% alcohol can also be used.<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Epic 2</P>
</TD>
<TD VALIGN="TOP">
<P>2007</P>
</TD>
<TD VALIGN="TOP">
<P>Single patient use application of alcoholic chlorhexidine gluconate solution (preferably 2% chlorhexidine gluconate in 70% isopropyl alcohol). Aqueous solution of chlorhexidine should be used if the manufacturers recommendations prohibit the use of alcohol with their product (CVC)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-11-05 13:37:20 +1100" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2009-11-05 13:37:20 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Topical antimicrobial ointment versus no ointment/placebo subgroup analysis</NAME>
<DICH_OUTCOME CHI2="0.9875355135414849" CI_END="0.5101345479146878" CI_START="0.21080297211019502" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3279296858726073" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.29231526368574945" LOG_CI_START="-0.6761232703002976" LOG_EFFECT_SIZE="-0.4842192669930235" METHOD="MH" MODIFIED="2009-11-03 13:42:21 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.804267971822223" P_Q="0.0" P_Z="7.596680500282475E-7" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="200" TOTAL_2="186" WEIGHT="300.0" Z="4.945453495345281">
<NAME>Central venous catheter infection</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.49376775677074247" CI_END="0.6125957467242884" CI_START="0.1755446058049543" DF="1" EFFECT_SIZE="0.3279296858726072" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="32" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.21282602284218533" LOG_CI_START="-0.7556125111438619" LOG_EFFECT_SIZE="-0.48421926699302364" MODIFIED="2009-11-03 13:38:19 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48225143979852414" P_Z="4.70585857015083E-4" STUDIES="2" TAU2="0.0" TOTAL_1="100" TOTAL_2="93" WEIGHT="100.0" Z="3.4969637026013625">
<NAME>Topical antimicrobial ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.6799420504140395" CI_START="0.18276733065611905" EFFECT_SIZE="0.3525211958946899" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" LOG_CI_END="-0.16752809943765432" LOG_CI_START="-0.7381014310515852" LOG_EFFECT_SIZE="-0.4528147652446198" ORDER="121" O_E="0.0" SE="0.33515759937356554" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.11233061641785144" WEIGHT="90.49719498852652"/>
<DICH_DATA CI_END="1.250532840404473" CI_START="0.02169317494523902" EFFECT_SIZE="0.16470588235294117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.09709510127977287" LOG_CI_START="-1.6636768813518823" LOG_EFFECT_SIZE="-0.7832908900360547" ORDER="120" O_E="0.0" SE="1.0342861785597175" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.0697478991596638" WEIGHT="9.502805011473479"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.250532840404473" CI_START="0.02169317494523902" DF="0" EFFECT_SIZE="0.16470588235294117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.09709510127977287" LOG_CI_START="-1.6636768813518823" LOG_EFFECT_SIZE="-0.7832908900360547" MODIFIED="2009-02-11 23:31:30 +1100" MODIFIED_BY="Margaret McCann" NO="2" P_CHI2="1.0" P_Z="0.08119301109152362" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="1.743805500124376">
<NAME>Mupirocin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="1.250532840404473" CI_START="0.02169317494523902" EFFECT_SIZE="0.16470588235294117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.09709510127977287" LOG_CI_START="-1.6636768813518823" LOG_EFFECT_SIZE="-0.7832908900360547" ORDER="2004" O_E="0.0" SE="1.0342861785597175" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.0697478991596638" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6799420504140394" CI_START="0.18276733065611905" DF="0" EFFECT_SIZE="0.3525211958946899" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-0.1675280994376544" LOG_CI_START="-0.7381014310515852" LOG_EFFECT_SIZE="-0.4528147652446198" MODIFIED="2009-02-11 23:31:53 +1100" MODIFIED_BY="Margaret McCann" NO="3" P_CHI2="1.0" P_Z="0.0018651290426205175" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="79" WEIGHT="100.0" Z="3.1109082124010916">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.6799420504140395" CI_START="0.18276733065611905" EFFECT_SIZE="0.3525211958946899" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" LOG_CI_END="-0.16752809943765432" LOG_CI_START="-0.7381014310515852" LOG_EFFECT_SIZE="-0.4528147652446198" ORDER="2005" O_E="0.0" SE="0.33515759937356554" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.11233061641785144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="102" EVENTS_2="410" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 13:53:13 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="0.0" Z="0.0">
<NAME>Central venous catheter infection/100,000 catheter-days</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="102" EVENTS_2="410" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-02-11 23:33:06 +1100" MODIFIED_BY="Margaret McCann" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="0.0" Z="0.0">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.30897473789840957" CI_START="0.20031324092516253" EFFECT_SIZE="0.24878048780487805" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="410" LOG_CI_END="-0.5100770275001424" LOG_CI_START="-0.6982903424154936" LOG_EFFECT_SIZE="-0.6041836849578179" ORDER="2007" O_E="0.0" SE="0.11055743285221195" STUDY_ID="STD-HIPPO-Study" TOTAL_1="100000" TOTAL_2="100000" VAR="0.012222945958871355" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5633096198951133" CI_END="0.30049453481122335" CI_START="0.13069709020005632" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19817608665236688" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="124" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.5221634222399836" LOG_CI_START="-0.8837340813110113" LOG_EFFECT_SIZE="-0.7029487517754973" METHOD="MH" MODIFIED="2009-11-04 16:27:46 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.999628844935036" P_Q="0.0" P_Z="2.5183404995670853E-14" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="641" TOTAL_2="614" WEIGHT="700.0" Z="7.620940482268018">
<NAME>Exit site infection</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6862469869179744" CI_END="0.448587658075618" CI_START="0.09281476002510483" DF="3" EFFECT_SIZE="0.204047925337437" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="34" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.348152679267071" LOG_CI_START="-1.0323829538702276" LOG_EFFECT_SIZE="-0.6902678165686493" MODIFIED="2009-11-03 13:42:45 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8764339474549973" P_Z="7.668948128172426E-5" STUDIES="4" TAU2="0.0" TOTAL_1="176" TOTAL_2="170" WEIGHT="99.99999999999999" Z="3.9545168063377933">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (all organisms)</NAME>
<DICH_DATA CI_END="1.3380466135710425" CI_START="0.004537846563872347" EFFECT_SIZE="0.07792207792207792" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.12647124322557168" LOG_CI_START="-2.343150192803248" LOG_EFFECT_SIZE="-1.1083394747888382" ORDER="122" O_E="0.0" SE="1.4506678563465965" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="2.1044372294372296" WEIGHT="7.676156139924518"/>
<DICH_DATA CI_END="6.331051965327361" CI_START="0.012187626045361447" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.801475878228832" LOG_CI_START="-1.9140808797634066" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="123" O_E="0.0" SE="1.5951314818673865" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="2.5444444444444443" WEIGHT="6.3487292069202175"/>
<DICH_DATA CI_END="0.8845865493918935" CI_START="0.07754368903251449" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.05325966859437161" LOG_CI_START="-1.1104535418849792" LOG_EFFECT_SIZE="-0.5818566052396754" ORDER="124" O_E="0.0" SE="0.6210009143649755" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="0.3856421356421356" WEIGHT="41.88854709284348"/>
<DICH_DATA CI_END="0.596318583918901" CI_START="0.05558730564105811" EFFECT_SIZE="0.18206521739130435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" LOG_CI_END="-0.2245216559105626" LOG_CI_START="-1.2550243760348199" LOG_EFFECT_SIZE="-0.7397730159726912" ORDER="125" O_E="0.0" SE="0.6053223988717223" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.36641520657581655" WEIGHT="44.08656756031177"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6317900760090492" CI_END="0.6401626690631096" CI_START="0.07784695734637156" DF="2" EFFECT_SIZE="0.22323690553601405" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.1937096552350045" LOG_CI_START="-1.1087583571935422" LOG_EFFECT_SIZE="-0.6512340062142734" MODIFIED="2009-11-04 16:27:38 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7291360249894312" P_Z="0.005274283029151198" STUDIES="3" TAU2="0.0" TOTAL_1="107" TOTAL_2="103" WEIGHT="100.0" Z="2.789786368650671">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (excluding Sesso 1998)</NAME>
<DICH_DATA CI_END="1.3380466135710425" CI_START="0.004537846563872347" EFFECT_SIZE="0.07792207792207792" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.12647124322557168" LOG_CI_START="-2.343150192803248" LOG_EFFECT_SIZE="-1.1083394747888382" ORDER="77" O_E="0.0" SE="1.4506678563465965" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="2.1044372294372296" WEIGHT="13.728644093178339"/>
<DICH_DATA CI_END="6.331051965327361" CI_START="0.012187626045361447" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.801475878228832" LOG_CI_START="-1.9140808797634066" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="78" O_E="0.0" SE="1.5951314818673865" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="2.5444444444444443" WEIGHT="11.354568893205332"/>
<DICH_DATA CI_END="0.8845865493918935" CI_START="0.07754368903251449" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.05325966859437161" LOG_CI_START="-1.1104535418849792" LOG_EFFECT_SIZE="-0.5818566052396754" ORDER="79" O_E="0.0" SE="0.6210009143649755" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="0.3856421356421356" WEIGHT="74.91678701361633"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5963185839189011" CI_START="0.055587305641058134" DF="0" EFFECT_SIZE="0.18206521739130438" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-0.22452165591056253" LOG_CI_START="-1.2550243760348196" LOG_EFFECT_SIZE="-0.7397730159726912" MODIFIED="2009-11-03 13:43:15 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.004892593739875013" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="2.8140216221189935">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.596318583918901" CI_START="0.05558730564105811" EFFECT_SIZE="0.18206521739130435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" LOG_CI_END="-0.2245216559105626" LOG_CI_START="-1.2550243760348199" LOG_EFFECT_SIZE="-0.7397730159726912" ORDER="87" O_E="0.0" SE="0.6053223988717223" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.36641520657581655" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4044650733419303" CI_END="0.47904266650226857" CI_START="0.06064539209704073" DF="2" EFFECT_SIZE="0.17044568149777803" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="22" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="-0.31962580391052575" LOG_CI_START="-1.2172021917117135" LOG_EFFECT_SIZE="-0.7684139978111196" MODIFIED="2009-02-17 03:37:21 +1100" MODIFIED_BY="Margaret McCann" NO="4" P_CHI2="0.8169050254128544" P_Z="7.912280826813074E-4" STUDIES="3" TAU2="0.0" TOTAL_1="113" TOTAL_2="104" WEIGHT="100.0" Z="3.355845321679354">
<NAME>Mupirocin ointment versus no ointment/placebo (all organisms)</NAME>
<DICH_DATA CI_END="1.3380466135710425" CI_START="0.004537846563872347" EFFECT_SIZE="0.07792207792207792" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.12647124322557168" LOG_CI_START="-2.343150192803248" LOG_EFFECT_SIZE="-1.1083394747888382" ORDER="2010" O_E="0.0" SE="1.4506678563465965" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="2.1044372294372296" WEIGHT="13.209368817862044"/>
<DICH_DATA CI_END="6.331051965327361" CI_START="0.012187626045361447" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.801475878228832" LOG_CI_START="-1.9140808797634066" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="2009" O_E="0.0" SE="1.5951314818673865" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="2.5444444444444443" WEIGHT="10.925091164152192"/>
<DICH_DATA CI_END="0.596318583918901" CI_START="0.05558730564105811" EFFECT_SIZE="0.18206521739130435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" LOG_CI_END="-0.2245216559105626" LOG_CI_START="-1.2550243760348199" LOG_EFFECT_SIZE="-0.7397730159726912" ORDER="2008" O_E="0.0" SE="0.6053223988717223" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.36641520657581655" WEIGHT="75.86554001798577"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3630945480220256" CI_END="1.1352304643740445" CI_START="0.016905374974350535" DF="1" EFFECT_SIZE="0.13853337750357964" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="0.055084037075930556" LOG_CI_START="-1.7719751918023698" LOG_EFFECT_SIZE="-0.8584455773632196" MODIFIED="2009-11-04 16:27:46 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5467928560016986" P_Z="0.06550704178392126" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="100.0" Z="1.841782015301788">
<NAME>Mupirocin ointment versus no ointment/placebo (excluding Sesso 1998)</NAME>
<DICH_DATA CI_END="1.3380466135710425" CI_START="0.004537846563872347" EFFECT_SIZE="0.07792207792207792" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.12647124322557168" LOG_CI_START="-2.343150192803248" LOG_EFFECT_SIZE="-1.1083394747888382" ORDER="80" O_E="0.0" SE="1.4506678563465965" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="2.1044372294372296" WEIGHT="54.73239851940372"/>
<DICH_DATA CI_END="6.331051965327361" CI_START="0.012187626045361447" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.801475878228832" LOG_CI_START="-1.9140808797634066" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="81" O_E="0.0" SE="1.5951314818673865" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="2.5444444444444443" WEIGHT="45.26760148059628"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5963185839189011" CI_START="0.055587305641058134" DF="0" EFFECT_SIZE="0.18206521739130438" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="-0.22452165591056253" LOG_CI_START="-1.2550243760348196" LOG_EFFECT_SIZE="-0.7397730159726912" MODIFIED="2009-11-03 13:43:34 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.004892593739875013" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="2.8140216221189935">
<NAME>Mupirocin ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.596318583918901" CI_START="0.05558730564105811" EFFECT_SIZE="0.18206521739130435" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" LOG_CI_END="-0.2245216559105626" LOG_CI_START="-1.2550243760348199" LOG_EFFECT_SIZE="-0.7397730159726912" ORDER="90" O_E="0.0" SE="0.6053223988717223" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.36641520657581655" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8845865493918935" CI_START="0.07754368903251449" DF="0" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-001.03.07" LOG_CI_END="-0.05325966859437161" LOG_CI_START="-1.1104535418849792" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2009-11-04 14:41:36 +1100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.030971130045356118" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="2.157443434451344">
<NAME>Povidone-iodine ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.8845865493918935" CI_START="0.07754368903251449" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.05325966859437161" LOG_CI_START="-1.1104535418849792" LOG_EFFECT_SIZE="-0.5818566052396754" ORDER="2011" O_E="0.0" SE="0.6210009143649755" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="0.3856421356421356" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 13:46:59 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Exit site infection/total infections</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="17" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-02-11 23:36:13 +1100" MODIFIED_BY="Margaret McCann" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="2.1236435810290217" CI_START="0.44566727277875845" EFFECT_SIZE="0.9728506787330317" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="0.32708162927328693" LOG_CI_START="-0.35098925681229765" LOG_EFFECT_SIZE="-0.011953813769505373" ORDER="2012" O_E="0.0" SE="0.3983021949916915" STUDY_ID="STD-HIPPO-Study" TOTAL_1="13" TOTAL_2="43" VAR="0.15864463853519944" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.044555950482797" CI_END="0.33773501948409446" CI_START="0.18284935745498396" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2485047913073572" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="198" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.4714239053693817" LOG_CI_START="-0.7379065614634548" LOG_EFFECT_SIZE="-0.6046652334164183" METHOD="MH" MODIFIED="2009-11-04 16:35:10 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8542384439976554" P_Q="0.0" P_Z="5.865480816856588E-19" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="890" TOTAL_2="851" WEIGHT="800.0" Z="8.894553195847136">
<NAME>Catheter-related bacteraemia</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3661752352751737" CI_END="0.4573727371074414" CI_START="0.14802320438968367" DF="4" EFFECT_SIZE="0.2601956535899934" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="57" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.33972972621084574" LOG_CI_START="-0.8296701984667484" LOG_EFFECT_SIZE="-0.5846999623387971" MODIFIED="2009-11-03 13:48:34 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49851633143683216" P_Z="2.8957066082524835E-6" STUDIES="5" TAU2="0.0" TOTAL_1="259" TOTAL_2="249" WEIGHT="100.0" Z="4.678082064416192">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (all organisms)</NAME>
<DICH_DATA CI_END="0.8624883764709519" CI_START="0.1862162252866492" EFFECT_SIZE="0.40076093849080535" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.06424674908777951" LOG_CI_START="-0.7299824810052561" LOG_EFFECT_SIZE="-0.3971146150465178" ORDER="129" O_E="0.0" SE="0.39105646437334696" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.1529251583281828" WEIGHT="54.1605290756569"/>
<DICH_DATA CI_END="0.9044799548327509" CI_START="0.05014287309700597" EFFECT_SIZE="0.21296296296296297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.04360105357143169" LOG_CI_START="-1.299790785367282" LOG_EFFECT_SIZE="-0.6716959194693568" ORDER="126" O_E="0.0" SE="0.7378920666963413" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="0.5444847020933978" WEIGHT="15.211644059399571"/>
<DICH_DATA CI_END="1.638116456454583" CI_START="0.025875781349718928" EFFECT_SIZE="0.20588235294117646" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2143447732472228" LOG_CI_START="-1.5871065273032194" LOG_EFFECT_SIZE="-0.6863808770279983" ORDER="127" O_E="0.0" SE="1.0581814112710843" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.1197478991596639" WEIGHT="7.3967609050651"/>
<DICH_DATA CI_END="0.7163555095474747" CI_START="0.012661722655431583" EFFECT_SIZE="0.09523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.14487139456788029" LOG_CI_START="-1.897507203571996" LOG_EFFECT_SIZE="-1.021189299069938" ORDER="128" O_E="0.0" SE="1.0295069498961917" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="1.0598845598845599" WEIGHT="7.814537353893608"/>
<DICH_DATA CI_END="0.5445925388432583" CI_START="0.030779191671231314" EFFECT_SIZE="0.1294685990338164" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.26392831298026004" LOG_CI_START="-1.5117427898759979" LOG_EFFECT_SIZE="-0.887835551428129" ORDER="130" O_E="0.0" SE="0.7329724005098349" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.5372485399091499" WEIGHT="15.416528605984809"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2311964082931253" CI_END="0.5456469412263127" CI_START="0.16002572701458706" DF="3" EFFECT_SIZE="0.29549542883609276" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="42" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.26308827501097365" LOG_CI_START="-0.7958101910797977" LOG_EFFECT_SIZE="-0.5294492330453856" MODIFIED="2009-11-04 16:27:59 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5258299152742087" P_Z="9.785631862398831E-5" STUDIES="4" TAU2="0.0" TOTAL_1="190" TOTAL_2="182" WEIGHT="100.00000000000003" Z="3.8958465837821694">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (excluding Sesso 1998)</NAME>
<DICH_DATA CI_END="0.8624883764709519" CI_START="0.1862162252866492" EFFECT_SIZE="0.40076093849080535" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.06424674908777951" LOG_CI_START="-0.7299824810052561" LOG_EFFECT_SIZE="-0.3971146150465178" ORDER="95" O_E="0.0" SE="0.39105646437334696" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.1529251583281828" WEIGHT="64.03204808580263"/>
<DICH_DATA CI_END="0.9044799548327509" CI_START="0.05014287309700597" EFFECT_SIZE="0.21296296296296297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.04360105357143169" LOG_CI_START="-1.299790785367282" LOG_EFFECT_SIZE="-0.6716959194693568" ORDER="93" O_E="0.0" SE="0.7378920666963413" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="0.5444847020933978" WEIGHT="17.984180370818752"/>
<DICH_DATA CI_END="1.638116456454583" CI_START="0.025875781349718928" EFFECT_SIZE="0.20588235294117646" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2143447732472228" LOG_CI_START="-1.5871065273032194" LOG_EFFECT_SIZE="-0.6863808770279983" ORDER="96" O_E="0.0" SE="1.0581814112710843" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.1197478991596639" WEIGHT="8.744924727206772"/>
<DICH_DATA CI_END="0.7163555095474747" CI_START="0.012661722655431583" EFFECT_SIZE="0.09523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.14487139456788029" LOG_CI_START="-1.897507203571996" LOG_EFFECT_SIZE="-1.021189299069938" ORDER="94" O_E="0.0" SE="1.0295069498961917" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="1.0598845598845599" WEIGHT="9.238846816171861"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5445925388432583" CI_START="0.030779191671231314" DF="0" EFFECT_SIZE="0.1294685990338164" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="-0.26392831298026004" LOG_CI_START="-1.5117427898759979" LOG_EFFECT_SIZE="-0.887835551428129" MODIFIED="2009-11-03 13:49:04 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.005285839766370127" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="2.7890776028218647">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.5445925388432583" CI_START="0.030779191671231314" EFFECT_SIZE="0.1294685990338164" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.26392831298026004" LOG_CI_START="-1.5117427898759979" LOG_EFFECT_SIZE="-0.887835551428129" ORDER="97" O_E="0.0" SE="0.7329724005098349" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.5372485399091499" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2685409676787822" CI_END="0.43160001183133656" CI_START="0.0692713532265493" DF="2" EFFECT_SIZE="0.17290898435926158" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="27" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="-0.3649185520839274" LOG_CI_START="-1.1594463282707301" LOG_EFFECT_SIZE="-0.7621824401773288" MODIFIED="2009-11-04 16:35:00 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8743535413699" P_Z="1.696777205669872E-4" STUDIES="3" TAU2="0.0" TOTAL_1="113" TOTAL_2="104" WEIGHT="100.0" Z="3.7603471575679617">
<NAME>Mupirocin ointment versus no ointment/placebo (all organisms)</NAME>
<DICH_DATA CI_END="0.9044799548327509" CI_START="0.05014287309700597" EFFECT_SIZE="0.21296296296296297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.04360105357143169" LOG_CI_START="-1.299790785367282" LOG_EFFECT_SIZE="-0.6716959194693568" ORDER="2016" O_E="0.0" SE="0.7378920666963413" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="0.5444847020933978" WEIGHT="40.0043935151568"/>
<DICH_DATA CI_END="1.638116456454583" CI_START="0.025875781349718928" EFFECT_SIZE="0.20588235294117646" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2143447732472228" LOG_CI_START="-1.5871065273032194" LOG_EFFECT_SIZE="-0.6863808770279983" ORDER="2015" O_E="0.0" SE="1.0581814112710843" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.1197478991596639" WEIGHT="19.452396652740994"/>
<DICH_DATA CI_END="0.5445925388432583" CI_START="0.030779191671231314" EFFECT_SIZE="0.1294685990338164" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.26392831298026004" LOG_CI_START="-1.5117427898759979" LOG_EFFECT_SIZE="-0.887835551428129" ORDER="2014" O_E="0.0" SE="0.7329724005098349" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.5372485399091499" WEIGHT="40.543209832102214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.871158054670532E-4" CI_END="0.6897672880470643" CI_START="0.06431268655188264" DF="1" EFFECT_SIZE="0.2106200070978847" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="-0.16129740573191992" LOG_CI_START="-1.1917033481331698" LOG_EFFECT_SIZE="-0.6765003769325448" MODIFIED="2009-11-04 16:35:05 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9790875322474837" P_Z="0.01006521985424602" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="100.0" Z="2.5735806049907946">
<NAME>Mupirocin ointment versus no ointment/placebo (excluding Sesso 1998)</NAME>
<DICH_DATA CI_END="0.9044799548327509" CI_START="0.05014287309700597" EFFECT_SIZE="0.21296296296296297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.04360105357143169" LOG_CI_START="-1.299790785367282" LOG_EFFECT_SIZE="-0.6716959194693568" ORDER="102" O_E="0.0" SE="0.7378920666963413" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="0.5444847020933978" WEIGHT="67.28313688342391"/>
<DICH_DATA CI_END="1.638116456454583" CI_START="0.025875781349718928" EFFECT_SIZE="0.20588235294117646" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2143447732472228" LOG_CI_START="-1.5871065273032194" LOG_EFFECT_SIZE="-0.6863808770279983" ORDER="104" O_E="0.0" SE="1.0581814112710843" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.1197478991596639" WEIGHT="32.71686311657609"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5445925388432583" CI_START="0.030779191671231314" DF="0" EFFECT_SIZE="0.1294685990338164" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" I2="0.0" ID="CMP-001.05.06" LOG_CI_END="-0.26392831298026004" LOG_CI_START="-1.5117427898759979" LOG_EFFECT_SIZE="-0.887835551428129" MODIFIED="2009-11-04 16:35:10 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.005285839766370127" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="2.7890776028218647">
<NAME>Mupirocin ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.5445925388432583" CI_START="0.030779191671231314" EFFECT_SIZE="0.1294685990338164" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.26392831298026004" LOG_CI_START="-1.5117427898759979" LOG_EFFECT_SIZE="-0.887835551428129" ORDER="106" O_E="0.0" SE="0.7329724005098349" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.5372485399091499" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8624883764709519" CI_START="0.1862162252866492" DF="0" EFFECT_SIZE="0.4007609384908054" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" I2="0.0" ID="CMP-001.05.07" LOG_CI_END="-0.06424674908777951" LOG_CI_START="-0.7299824810052561" LOG_EFFECT_SIZE="-0.3971146150465178" MODIFIED="2009-02-17 03:46:44 +1100" MODIFIED_BY="Margaret McCann" NO="7" P_CHI2="1.0" P_Z="0.01937396294948054" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="79" WEIGHT="100.0" Z="2.3382561755665034">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.8624883764709519" CI_START="0.1862162252866492" EFFECT_SIZE="0.40076093849080535" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.06424674908777951" LOG_CI_START="-0.7299824810052561" LOG_EFFECT_SIZE="-0.3971146150465178" ORDER="2013" O_E="0.0" SE="0.39105646437334696" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.1529251583281828" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8607236464198816E-31" CI_END="0.7163555095474747" CI_START="0.012661722655431583" DF="0" EFFECT_SIZE="0.09523809523809525" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" I2="100.0" ID="CMP-001.05.08" LOG_CI_END="-0.14487139456788029" LOG_CI_START="-1.897507203571996" LOG_EFFECT_SIZE="-1.021189299069938" MODIFIED="2009-11-04 14:41:51 +1100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.022372593699065288" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="2.283981917169742">
<NAME>Povidone-iodine ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.7163555095474747" CI_START="0.012661722655431583" EFFECT_SIZE="0.09523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.14487139456788029" LOG_CI_START="-1.897507203571996" LOG_EFFECT_SIZE="-1.021189299069938" ORDER="2017" O_E="0.0" SE="1.0295069498961917" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="1.0598845598845599" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.392652598904444" CI_END="0.20173990175928502" CI_START="0.15340204963048854" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17591848800546156" ESTIMABLE="YES" EVENTS_1="446" EVENTS_2="2596" I2="84.53022357462599" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.6952081949948887" LOG_CI_START="-0.8141688376669308" LOG_EFFECT_SIZE="-0.7546885163309098" METHOD="MH" MODIFIED="2009-11-03 13:53:20 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="2.267648155394042E-4" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06223317137009064" TOTALS="SUB" TOTAL_1="400000" TOTAL_2="400000" WEIGHT="300.0" Z="24.868095503357278">
<NAME>Catheter-related bacteraemia/100,000 catheter-days</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.696326299452222" CI_END="0.3208635859773932" CI_START="0.11769455126404166" DF="1" EFFECT_SIZE="0.194329348706212" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="1298" I2="89.68681571641733" ID="CMP-001.06.01" LOG_CI_END="-0.4936795671251796" LOG_CI_START="-0.929243642600364" LOG_EFFECT_SIZE="-0.7114616048627718" MODIFIED="2009-11-03 13:52:25 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0018463906637748995" P_Z="1.5244152841069884E-10" STUDIES="2" TAU2="0.11769457954182327" TOTAL_1="200000" TOTAL_2="200000" WEIGHT="100.00000000000001" Z="6.402911536690982">
<NAME>Topical antimicrobial ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.33490465663869917" CI_START="0.19268883504052187" EFFECT_SIZE="0.2540322580645161" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="248" LOG_CI_END="-0.4750788138264173" LOG_CI_START="-0.7151434489188518" LOG_EFFECT_SIZE="-0.5951111313726345" ORDER="132" O_E="0.0" SE="0.141015154992405" STUDY_ID="STD-HIPPO-Study" TOTAL_1="100000" TOTAL_2="100000" VAR="0.019885273937532002" WEIGHT="47.580003202654375"/>
<DICH_DATA CI_END="0.17991571648265461" CI_START="0.12906017941331258" EFFECT_SIZE="0.1523809523809524" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="1050" LOG_CI_END="-0.7449308973350499" LOG_CI_START="-0.8892077354929766" LOG_EFFECT_SIZE="-0.8170693164140133" ORDER="131" O_E="0.0" SE="0.08474892891583323" STUDY_ID="STD-Johnson-2002" TOTAL_1="100000" TOTAL_2="100000" VAR="0.007182380952380954" WEIGHT="52.41999679734564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.17991571648265464" CI_START="0.12906017941331263" DF="0" EFFECT_SIZE="0.15238095238095245" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="1050" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-0.7449308973350498" LOG_CI_START="-0.8892077354929764" LOG_EFFECT_SIZE="-0.817069316414013" MODIFIED="2009-02-17 03:57:11 +1100" MODIFIED_BY="Margaret McCann" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="100.0" Z="22.199355814705218">
<NAME>Mupirocin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.17991571648265461" CI_START="0.12906017941331258" EFFECT_SIZE="0.1523809523809524" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="1050" LOG_CI_END="-0.7449308973350499" LOG_CI_START="-0.8892077354929766" LOG_EFFECT_SIZE="-0.8170693164140133" ORDER="2019" O_E="0.0" SE="0.08474892891583323" STUDY_ID="STD-Johnson-2002" TOTAL_1="100000" TOTAL_2="100000" VAR="0.007182380952380954" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.33490465663869917" CI_START="0.19268883504052187" DF="0" EFFECT_SIZE="0.2540322580645161" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="248" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="-0.4750788138264173" LOG_CI_START="-0.7151434489188518" LOG_EFFECT_SIZE="-0.5951111313726345" MODIFIED="2009-02-17 03:57:11 +1100" MODIFIED_BY="Margaret McCann" NO="3" P_CHI2="1.0" P_Z="2.5430666333297973E-22" STUDIES="1" TAU2="0.0" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="100.0" Z="9.717352860742187">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.33490465663869917" CI_START="0.19268883504052187" EFFECT_SIZE="0.2540322580645161" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="248" LOG_CI_END="-0.4750788138264173" LOG_CI_START="-0.7151434489188518" LOG_EFFECT_SIZE="-0.5951111313726345" ORDER="2018" O_E="0.0" SE="0.141015154992405" STUDY_ID="STD-HIPPO-Study" TOTAL_1="100000" TOTAL_2="100000" VAR="0.019885273937532002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="71" EVENTS_2="892" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-04 12:19:46 +1100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="0.0" Z="0.0">
<NAME>Catheter-related bacteraemia/100,000 patient-days</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="71" EVENTS_2="892" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-04 12:19:46 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.1013413975462778" CI_START="0.06251728360959652" EFFECT_SIZE="0.0795964125560538" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="892" LOG_CI_END="-0.994213110875705" LOG_CI_START="-1.2039999004383908" LOG_EFFECT_SIZE="-1.0991065056570477" ORDER="2020" O_E="0.0" SE="0.12322979865047812" STUDY_ID="STD-Sesso-1998" TOTAL_1="100000" TOTAL_2="100000" VAR="0.015185583275437379" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="158" EVENTS_2="2041" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-04 12:19:56 +1100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="0.0" Z="0.0">
<NAME>Catheter-related bacteraemia/100,000 dialysis sessions</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="158" EVENTS_2="2041" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-04 12:19:56 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.0909915700347802" CI_START="0.06586080061252468" EFFECT_SIZE="0.07741303282704556" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="2041" LOG_CI_END="-1.0409988412719187" LOG_CI_START="-1.1813729942513773" LOG_EFFECT_SIZE="-1.1111859177616479" ORDER="2021" O_E="0.0" SE="0.08245647232339785" STUDY_ID="STD-Sesso-1998" TOTAL_1="100000" TOTAL_2="100000" VAR="0.006799069828019276" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.897842543456662" CI_END="0.7187768633629676" CI_START="0.19001865920580435" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3695686889393969" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="42" I2="15.223236918265469" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.14340591080000045" LOG_CI_START="-0.7212037506670048" LOG_EFFECT_SIZE="-0.4323048307335027" METHOD="MH" MODIFIED="2009-11-05 13:36:16 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.31628679870684806" P_Q="0.0" P_Z="0.003358485150552854" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10484608872449629" TOTALS="SUB" TOTAL_1="326" TOTAL_2="318" WEIGHT="400.0" Z="2.9328662730043398">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.948921271728331" CI_END="1.0710779782501902" CI_START="0.12128429221597314" DF="2" EFFECT_SIZE="0.3604232713077637" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" I2="32.17858953461238" ID="CMP-001.09.01" LOG_CI_END="0.029821090151156717" LOG_CI_START="-0.9161954418841263" LOG_EFFECT_SIZE="-0.4431871758664847" MODIFIED="2009-11-03 13:56:36 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22890221221547336" P_Z="0.0662989809404583" STUDIES="3" TAU2="0.30406871357110554" TOTAL_1="163" TOTAL_2="159" WEIGHT="100.00000000000001" Z="1.8363968782649827">
<NAME>Topical antimicrobial ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.7417553412225018" CI_START="0.06504188517884084" EFFECT_SIZE="0.2196478220574606" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.12973931773763567" LOG_CI_START="-1.186806879607978" LOG_EFFECT_SIZE="-0.6582730986728068" ORDER="135" O_E="0.0" SE="0.6209267184114601" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.38554998963722464" WEIGHT="44.777889925532335"/>
<DICH_DATA CI_END="2.126851770051534" CI_START="0.006663527661151314" EFFECT_SIZE="0.11904761904761904" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3277372230047844" LOG_CI_START="-2.1762957951285475" LOG_EFFECT_SIZE="-0.9242792860618817" ORDER="133" O_E="0.0" SE="1.4708813900148656" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="2.1634920634920634" WEIGHT="12.514249160502215"/>
<DICH_DATA CI_END="2.980312363738389" CI_START="0.23568121136029038" EFFECT_SIZE="0.8380952380952381" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.474261784458334" LOG_CI_START="-0.6276750382978729" LOG_EFFECT_SIZE="-0.07670662691976944" ORDER="134" O_E="0.0" SE="0.6472831443622404" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="0.418975468975469" WEIGHT="42.70786091396546"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.126851770051534" CI_START="0.006663527661151314" DF="0" EFFECT_SIZE="0.11904761904761905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.3277372230047844" LOG_CI_START="-2.1762957951285475" LOG_EFFECT_SIZE="-0.9242792860618816" MODIFIED="2009-02-17 03:57:02 +1100" MODIFIED_BY="Margaret McCann" NO="2" P_CHI2="1.0" P_Z="0.1479223769478505" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="1.4469091255738566">
<NAME>Mupirocin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="2.126851770051534" CI_START="0.006663527661151314" EFFECT_SIZE="0.11904761904761904" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3277372230047844" LOG_CI_START="-2.1762957951285475" LOG_EFFECT_SIZE="-0.9242792860618817" ORDER="2023" O_E="0.0" SE="1.4708813900148656" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="2.1634920634920634" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2787915419918606E-31" CI_END="0.7417553412225018" CI_START="0.06504188517884084" DF="0" EFFECT_SIZE="0.2196478220574606" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="100.0" ID="CMP-001.09.03" LOG_CI_END="-0.12973931773763567" LOG_CI_START="-1.186806879607978" LOG_EFFECT_SIZE="-0.6582730986728068" MODIFIED="2009-02-17 03:57:02 +1100" MODIFIED_BY="Margaret McCann" NO="3" P_CHI2="0.0" P_Z="0.014643539103536668" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="79" WEIGHT="100.0" Z="2.4410768278755204">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.7417553412225018" CI_START="0.06504188517884084" EFFECT_SIZE="0.2196478220574606" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.12973931773763567" LOG_CI_START="-1.186806879607978" LOG_EFFECT_SIZE="-0.6582730986728068" ORDER="2022" O_E="0.0" SE="0.6209267184114601" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.38554998963722464" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.980312363738389" CI_START="0.23568121136029038" DF="0" EFFECT_SIZE="0.8380952380952381" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="0.474261784458334" LOG_CI_START="-0.6276750382978729" LOG_EFFECT_SIZE="-0.07670662691976944" MODIFIED="2009-11-05 13:36:16 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="1.0" P_Z="0.7849538800027994" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="0.27286904844917864">
<NAME>Povidone-iodine ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="2.980312363738389" CI_START="0.23568121136029038" EFFECT_SIZE="0.8380952380952381" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.474261784458334" LOG_CI_START="-0.6276750382978729" LOG_EFFECT_SIZE="-0.07670662691976944" ORDER="2024" O_E="0.0" SE="0.6472831443622404" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="0.418975468975469" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3248667098018347" CI_END="0.4916886994675354" CI_START="0.04294021418362978" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14530388180226414" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.3083097730303373" LOG_CI_START="-1.3671357936553235" LOG_EFFECT_SIZE="-0.8377227833428303" METHOD="MH" MODIFIED="2009-11-04 14:42:20 +1100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9323522417017913" P_Q="0.0" P_Z="0.0019262637992216933" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="326" TOTAL_2="318" WEIGHT="400.0" Z="3.101371617995261">
<NAME>Mortality related to infection</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6624333549009174" CI_END="0.8146672839812548" CI_START="0.02591636915088409" DF="2" EFFECT_SIZE="0.14530388180226406" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-0.08901972406213562" LOG_CI_START="-1.5864258426235256" LOG_EFFECT_SIZE="-0.8377227833428306" MODIFIED="2009-11-03 13:58:11 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7180496320146585" P_Z="0.02830731409938319" STUDIES="3" TAU2="0.0" TOTAL_1="163" TOTAL_2="159" WEIGHT="100.0" Z="2.1930009020639445">
<NAME>Topical antimicrobial ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="1.0935713891649472" CI_START="0.0036863090662590256" EFFECT_SIZE="0.06349206349206349" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.038847139370366046" LOG_CI_START="-2.433408255621605" LOG_EFFECT_SIZE="-1.1972805581256194" ORDER="138" O_E="0.0" SE="1.4522150568798586" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="2.1089285714285713" WEIGHT="36.68533929788386"/>
<DICH_DATA CI_END="3.210024769883334" CI_START="0.00865344655231036" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.506508383614263" LOG_CI_START="-2.06281088438155" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="136" O_E="0.0" SE="1.509230856356236" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="2.2777777777777777" WEIGHT="33.965894721011104"/>
<DICH_DATA CI_END="8.409975104357049" CI_START="0.01447946241121332" EFFECT_SIZE="0.3489583333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9247947101788444" LOG_CI_START="-1.839247562184291" LOG_EFFECT_SIZE="-0.4572264260027232" ORDER="137" O_E="0.0" SE="1.623612113016018" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="2.6361162935323383" WEIGHT="29.348765981105046"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.210024769883334" CI_START="0.00865344655231036" DF="0" EFFECT_SIZE="0.16666666666666669" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.506508383614263" LOG_CI_START="-2.06281088438155" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2009-02-17 03:57:47 +1100" MODIFIED_BY="Margaret McCann" NO="2" P_CHI2="1.0" P_Z="0.23514860623703593" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="1.187200395275467">
<NAME>Mupirocin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="3.210024769883334" CI_START="0.00865344655231036" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.506508383614263" LOG_CI_START="-2.06281088438155" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="2026" O_E="0.0" SE="1.509230856356236" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="2.2777777777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0935713891649472" CI_START="0.0036863090662590256" DF="0" EFFECT_SIZE="0.06349206349206349" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.038847139370366046" LOG_CI_START="-2.433408255621605" LOG_EFFECT_SIZE="-1.1972805581256194" MODIFIED="2009-02-17 03:57:47 +1100" MODIFIED_BY="Margaret McCann" NO="3" P_CHI2="1.0" P_Z="0.05764746130876444" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="79" WEIGHT="100.0" Z="1.8983692203238978">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="1.0935713891649472" CI_START="0.0036863090662590256" EFFECT_SIZE="0.06349206349206349" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.038847139370366046" LOG_CI_START="-2.433408255621605" LOG_EFFECT_SIZE="-1.1972805581256194" ORDER="2025" O_E="0.0" SE="1.4522150568798586" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="2.1089285714285713" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.409975104357049" CI_START="0.01447946241121332" DF="0" EFFECT_SIZE="0.3489583333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="0.9247947101788444" LOG_CI_START="-1.839247562184291" LOG_EFFECT_SIZE="-0.4572264260027232" MODIFIED="2009-11-04 14:42:20 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5167053028370874" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="0.6484324329664748">
<NAME>Povidone-iodine ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="8.409975104357049" CI_START="0.01447946241121332" EFFECT_SIZE="0.3489583333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9247947101788444" LOG_CI_START="-1.839247562184291" LOG_EFFECT_SIZE="-0.4572264260027232" ORDER="2027" O_E="0.0" SE="1.623612113016018" STUDY_ID="STD-Levin-1991" TOTAL_1="63" TOTAL_2="66" VAR="2.6361162935323383" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.7230238856513225" CI_END="0.42061763241423245" CI_START="0.29188534263470944" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3503885297144136" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="303" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.3761125255163267" LOG_CI_START="-0.5347877130719055" LOG_EFFECT_SIZE="-0.4554501192941161" METHOD="MH" MODIFIED="2009-11-05 13:37:20 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.9729970369858858" P_Q="0.0" P_Z="2.2772257262340866E-29" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="701" TOTAL_2="653" WEIGHT="700.0" Z="11.251486061842737">
<NAME>Catheter removal due to infection</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimircobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4286582496489248" CI_END="0.5007095682470987" CI_START="0.2461295123072586" DF="3" EFFECT_SIZE="0.3510546992140062" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="81" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="-0.30041410942551205" LOG_CI_START="-0.6088363088337966" LOG_EFFECT_SIZE="-0.45462520912965443" MODIFIED="2009-11-05 13:37:08 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.698831060420272" P_Z="7.554342783497627E-9" STUDIES="4" TAU2="0.0" TOTAL_1="196" TOTAL_2="183" WEIGHT="100.0" Z="5.778112198587598">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (all organisms)</NAME>
<DICH_DATA CI_END="0.7705250962719616" CI_START="0.17062890115287638" EFFECT_SIZE="0.36259323006310956" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.11321321159198314" LOG_CI_START="-0.7679474060632332" LOG_EFFECT_SIZE="-0.4405803088276082" ORDER="141" O_E="0.0" SE="0.3845941068189449" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.147912626999862" WEIGHT="22.190199836625734"/>
<DICH_DATA CI_END="0.7891941447450208" CI_START="0.04540662908011847" EFFECT_SIZE="0.18930041152263374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.10281614556171267" LOG_CI_START="-1.3428807382717636" LOG_EFFECT_SIZE="-0.7228484419167381" ORDER="139" O_E="0.0" SE="0.7284200801766169" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="0.530595813204509" WEIGHT="6.185896439069995"/>
<DICH_DATA CI_END="1.250532840404473" CI_START="0.02169317494523902" EFFECT_SIZE="0.16470588235294117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.09709510127977287" LOG_CI_START="-1.6636768813518823" LOG_EFFECT_SIZE="-0.7832908900360547" ORDER="140" O_E="0.0" SE="1.0342861785597175" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.0697478991596638" WEIGHT="3.0682095791593027"/>
<DICH_DATA CI_END="0.5834307973624258" CI_START="0.24745225761598386" EFFECT_SIZE="0.3799621928166352" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" LOG_CI_END="-0.23401064965456997" LOG_CI_START="-0.6065085795748237" LOG_EFFECT_SIZE="-0.42025961461469685" ORDER="142" O_E="0.0" SE="0.21880712792964813" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.0478765592328214" WEIGHT="68.55569414514497"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.983884956456" CI_END="0.5564902814775167" CI_START="0.1568348128610159" DF="2" EFFECT_SIZE="0.2954268930793207" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="35" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="-0.2545424157633099" LOG_CI_START="-0.8045575299467531" LOG_EFFECT_SIZE="-0.5295499728550315" MODIFIED="2009-11-05 13:37:13 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.6114375907981735" P_Z="1.6060307869461256E-4" STUDIES="3" TAU2="0.0" TOTAL_1="127" TOTAL_2="116" WEIGHT="100.0" Z="3.774074013769233">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (excluding Sesso 1998)</NAME>
<DICH_DATA CI_END="0.7705250962719616" CI_START="0.17062890115287638" EFFECT_SIZE="0.36259323006310956" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.11321321159198314" LOG_CI_START="-0.7679474060632332" LOG_EFFECT_SIZE="-0.4405803088276082" ORDER="108" O_E="0.0" SE="0.3845941068189449" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.147912626999862" WEIGHT="70.56985114905802"/>
<DICH_DATA CI_END="0.7891941447450208" CI_START="0.04540662908011847" EFFECT_SIZE="0.18930041152263374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.10281614556171267" LOG_CI_START="-1.3428807382717636" LOG_EFFECT_SIZE="-0.7228484419167381" ORDER="109" O_E="0.0" SE="0.7284200801766169" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="0.530595813204509" WEIGHT="19.672548879354217"/>
<DICH_DATA CI_END="1.250532840404473" CI_START="0.02169317494523902" EFFECT_SIZE="0.16470588235294117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.09709510127977287" LOG_CI_START="-1.6636768813518823" LOG_EFFECT_SIZE="-0.7832908900360547" ORDER="110" O_E="0.0" SE="1.0342861785597175" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.0697478991596638" WEIGHT="9.75759997158776"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5834307973624258" CI_START="0.24745225761598386" DF="0" EFFECT_SIZE="0.3799621928166352" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="-0.23401064965456997" LOG_CI_START="-0.6065085795748237" LOG_EFFECT_SIZE="-0.42025961461469685" MODIFIED="2009-11-05 13:37:20 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="9.75467699422044E-6" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="4.42254113453908">
<NAME>Topical antimicrobial ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.5834307973624258" CI_START="0.24745225761598386" EFFECT_SIZE="0.3799621928166352" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" LOG_CI_END="-0.23401064965456997" LOG_CI_START="-0.6065085795748237" LOG_EFFECT_SIZE="-0.42025961461469685" ORDER="115" O_E="0.0" SE="0.21880712792964813" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.0478765592328214" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4417997844676744" CI_END="0.520226366764804" CI_START="0.23256610947334455" DF="2" EFFECT_SIZE="0.3478318877905585" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="60" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="-0.28380764012501786" LOG_CI_START="-0.6334535722433495" LOG_EFFECT_SIZE="-0.4586306061841837" MODIFIED="2009-02-17 03:59:30 +1100" MODIFIED_BY="Margaret McCann" NO="4" P_CHI2="0.4863145043219511" P_Z="2.721622708598161E-7" STUDIES="3" TAU2="0.0" TOTAL_1="113" TOTAL_2="104" WEIGHT="100.0" Z="5.141769932129832">
<NAME>Mupirocin ointment versus no ointment/placebo (all organisms)</NAME>
<DICH_DATA CI_END="0.7891941447450208" CI_START="0.04540662908011847" EFFECT_SIZE="0.18930041152263374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.10281614556171267" LOG_CI_START="-1.3428807382717636" LOG_EFFECT_SIZE="-0.7228484419167381" ORDER="2031" O_E="0.0" SE="0.7284200801766169" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="0.530595813204509" WEIGHT="7.950022267223029"/>
<DICH_DATA CI_END="1.250532840404473" CI_START="0.02169317494523902" EFFECT_SIZE="0.16470588235294117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.09709510127977287" LOG_CI_START="-1.6636768813518823" LOG_EFFECT_SIZE="-0.7832908900360547" ORDER="2030" O_E="0.0" SE="1.0342861785597175" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.0697478991596638" WEIGHT="3.943217400272331"/>
<DICH_DATA CI_END="0.5834307973624258" CI_START="0.24745225761598386" EFFECT_SIZE="0.3799621928166352" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" LOG_CI_END="-0.23401064965456997" LOG_CI_START="-0.6065085795748237" LOG_EFFECT_SIZE="-0.42025961461469685" ORDER="2029" O_E="0.0" SE="0.21880712792964813" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.0478765592328214" WEIGHT="88.10676033250463"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.012112928417117792" CI_END="0.5808209430307215" CI_START="0.056257615574726305" DF="1" EFFECT_SIZE="0.1807639381369313" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" I2="0.0" ID="CMP-001.11.05" LOG_CI_END="-0.23595773239285484" LOG_CI_START="-1.2498186789373271" LOG_EFFECT_SIZE="-0.7428882056650911" MODIFIED="2009-11-04 16:48:24 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9123627836934093" P_Z="0.004075525817222351" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="100.0" Z="2.872256067473046">
<NAME>Mupirocin ointment versus no ointment/placebo (excluding Sesso 1998)</NAME>
<DICH_DATA CI_END="0.7891941447450208" CI_START="0.04540662908011847" EFFECT_SIZE="0.18930041152263374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.10281614556171267" LOG_CI_START="-1.3428807382717636" LOG_EFFECT_SIZE="-0.7228484419167381" ORDER="117" O_E="0.0" SE="0.7284200801766169" STUDY_ID="STD-Johnson-2002" TOTAL_1="27" TOTAL_2="23" VAR="0.530595813204509" WEIGHT="66.84488406426988"/>
<DICH_DATA CI_END="1.250532840404473" CI_START="0.02169317494523902" EFFECT_SIZE="0.16470588235294117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.09709510127977287" LOG_CI_START="-1.6636768813518823" LOG_EFFECT_SIZE="-0.7832908900360547" ORDER="116" O_E="0.0" SE="1.0342861785597175" STUDY_ID="STD-Kamaliah-2004" TOTAL_1="17" TOTAL_2="14" VAR="1.0697478991596638" WEIGHT="33.15511593573013"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5834307973624258" CI_START="0.24745225761598386" DF="0" EFFECT_SIZE="0.3799621928166352" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" I2="0.0" ID="CMP-001.11.06" LOG_CI_END="-0.23401064965456997" LOG_CI_START="-0.6065085795748237" LOG_EFFECT_SIZE="-0.42025961461469685" MODIFIED="2009-11-03 14:00:48 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="9.75467699422044E-6" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="4.42254113453908">
<NAME>Mupirocin ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.5834307973624258" CI_START="0.24745225761598386" EFFECT_SIZE="0.3799621928166352" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" LOG_CI_END="-0.23401064965456997" LOG_CI_START="-0.6065085795748237" LOG_EFFECT_SIZE="-0.42025961461469685" ORDER="121" O_E="0.0" SE="0.21880712792964813" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.0478765592328214" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7705250962719616" CI_START="0.17062890115287638" DF="0" EFFECT_SIZE="0.36259323006310956" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" I2="0.0" ID="CMP-001.11.07" LOG_CI_END="-0.11321321159198314" LOG_CI_START="-0.7679474060632332" LOG_EFFECT_SIZE="-0.4405803088276082" MODIFIED="2009-02-17 03:59:17 +1100" MODIFIED_BY="Margaret McCann" NO="7" P_CHI2="1.0" P_Z="0.008345133560494095" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="79" WEIGHT="100.0" Z="2.6377774214068928">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.7705250962719616" CI_START="0.17062890115287638" EFFECT_SIZE="0.36259323006310956" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.11321321159198314" LOG_CI_START="-0.7679474060632332" LOG_EFFECT_SIZE="-0.4405803088276082" ORDER="2028" O_E="0.0" SE="0.3845941068189449" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.147912626999862" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="51" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:03:27 +1100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="69" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Frequency of hospitalisation</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="51" EVENTS_2="58" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-03 14:02:56 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="1.0109849833043423" CI_START="0.721092675380218" EFFECT_SIZE="0.8538230884557722" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="58" LOG_CI_END="0.004744704832845548" LOG_CI_START="-0.14200891583570516" LOG_EFFECT_SIZE="-0.06863210550142979" ORDER="2032" O_E="0.0" SE="0.08620380322284489" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.007431095690082963" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:04:08 +1100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="83" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Episodes of hospitalisation</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="19" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-02-11 23:52:10 +1100" MODIFIED_BY="Margaret McCann" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Polysporin ointment versus no ointment/placebo</NAME>
<DICH_DATA CI_END="0.713564883035861" CI_START="0.12660761504882964" EFFECT_SIZE="0.30057070386810397" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.1465665312202462" LOG_CI_START="-0.8975401720893896" LOG_EFFECT_SIZE="-0.5220533516548178" ORDER="2033" O_E="0.0" SE="0.4411256340260102" STUDY_ID="STD-HIPPO-Study" TOTAL_1="83" TOTAL_2="79" VAR="0.19459182499484945" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:04:51 +1100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="69" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Episodes of hospitalisations due to infection</NAME>
<GROUP_LABEL_1>Antimicrobial ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>No ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs antimicrobial ointment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs no ointment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="14" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-03 14:04:25 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Mupirocin ointment versus no ointment/placebo (<I>S. aureus</I> only)</NAME>
<DICH_DATA CI_END="0.9095205365970755" CI_START="0.13222782414966877" EFFECT_SIZE="0.34679089026915116" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.04118749030023007" LOG_CI_START="-0.8786771484570659" LOG_EFFECT_SIZE="-0.4599323193786481" ORDER="2034" O_E="0.0" SE="0.49194557084199336" STUDY_ID="STD-Sesso-1998" TOTAL_1="69" TOTAL_2="67" VAR="0.2420104446710547" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-11-04 14:43:10 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Topical honey versus topical antimicrobial ointments subgroup analysis</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3442885249727754" CI_START="0.15209625302811522" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.45217391304347826" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.12849249145255737" LOG_CI_START="-0.8178814848901824" LOG_EFFECT_SIZE="-0.3446944967188125" METHOD="MH" MODIFIED="2009-11-04 14:42:40 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.1533662162309802" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="148" TOTAL_2="152" WEIGHT="200.0" Z="1.4277417091472526">
<NAME>Exit site infection</NAME>
<GROUP_LABEL_1>Honey ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Antimicrobial ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antimicrobial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1110229729573864" CI_START="0.09685410829547536" DF="0" EFFECT_SIZE="0.45217391304347826" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.324492959491616" LOG_CI_START="-1.013881952929241" LOG_EFFECT_SIZE="-0.3446944967188125" MODIFIED="2009-02-11 23:56:29 +1100" MODIFIED_BY="Margaret McCann" NO="1" P_CHI2="1.0" P_Z="0.3127033543364556" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="76" WEIGHT="100.0" Z="1.009565844320894">
<NAME>Topical honey versus topical antimicrobial ointments</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="143" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnson-2005" TOTAL_1="51" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1110229729573864" CI_START="0.09685410829547536" EFFECT_SIZE="0.45217391304347826" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.324492959491616" LOG_CI_START="-1.013881952929241" LOG_EFFECT_SIZE="-0.3446944967188125" ORDER="144" O_E="0.0" SE="0.7861680486186756" STUDY_ID="STD-Quadri-1999" TOTAL_1="23" TOTAL_2="26" VAR="0.6180602006688963" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-02-11 23:57:04 +1100" MODIFIED_BY="Margaret McCann" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Topical honey versus mupirocin ointment</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2052" O_E="0.0" SE="0.0" STUDY_ID="STD-Johnson-2005" TOTAL_1="51" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1110229729573864" CI_START="0.09685410829547536" DF="0" EFFECT_SIZE="0.45217391304347826" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.324492959491616" LOG_CI_START="-1.013881952929241" LOG_EFFECT_SIZE="-0.3446944967188125" MODIFIED="2009-11-04 14:42:40 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3127033543364556" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="1.009565844320894">
<NAME>Topical honey versus povidone-iodine ointment</NAME>
<DICH_DATA CI_END="2.1110229729573864" CI_START="0.09685410829547536" EFFECT_SIZE="0.45217391304347826" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.324492959491616" LOG_CI_START="-1.013881952929241" LOG_EFFECT_SIZE="-0.3446944967188125" ORDER="126" O_E="0.0" SE="0.7861680486186756" STUDY_ID="STD-Quadri-1999" TOTAL_1="23" TOTAL_2="26" VAR="0.6180602006688963" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7359094754020745" CI_END="1.3781666144149816" CI_START="0.46348978507078764" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7992284704056375" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.13930172508021824" LOG_CI_START="-0.3339598329030346" LOG_EFFECT_SIZE="-0.09732905391140816" METHOD="MH" MODIFIED="2009-11-04 14:42:53 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6289801327502367" P_Q="0.0" P_Z="0.4201526251756148" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="148" TOTAL_2="152" WEIGHT="300.0" Z="0.8061564988655502">
<NAME>Catheter-related bacteraemia</NAME>
<GROUP_LABEL_1>Honey ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Antimicrobial ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antimicrobial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8679547377010373" CI_END="1.7270996772380576" CI_START="0.36984903438140676" DF="1" EFFECT_SIZE="0.7992284704056375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.23731740301346024" LOG_CI_START="-0.4319755108362766" LOG_EFFECT_SIZE="-0.09732905391140816" MODIFIED="2009-11-03 14:08:15 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3515222395136415" P_Z="0.5686514345452958" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="76" WEIGHT="100.0" Z="0.5700387270454358">
<NAME>Topical honey versus topical antimicrobial ointments</NAME>
<DICH_DATA CI_END="3.6089030030575056" CI_START="0.38351904825651656" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5573752096286442" LOG_CI_START="-0.41621306105722966" LOG_EFFECT_SIZE="0.07058107428570727" ORDER="145" O_E="0.0" SE="0.5718905695405475" STUDY_ID="STD-Johnson-2005" TOTAL_1="51" TOTAL_2="50" VAR="0.3270588235294118" WEIGHT="47.25870183514617"/>
<DICH_DATA CI_END="1.633103723545428" CI_START="0.19562180578422117" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.21301376901888996" LOG_CI_START="-0.7085827364404024" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="146" O_E="0.0" SE="0.5413503492830649" STUDY_ID="STD-Quadri-1999" TOTAL_1="23" TOTAL_2="26" VAR="0.2930602006688964" WEIGHT="52.74129816485383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6089030030575056" CI_START="0.38351904825651656" DF="0" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.5573752096286442" LOG_CI_START="-0.41621306105722966" LOG_EFFECT_SIZE="0.07058107428570727" MODIFIED="2009-02-11 23:59:23 +1100" MODIFIED_BY="Margaret McCann" NO="2" P_CHI2="1.0" P_Z="0.7762736915227468" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="50" WEIGHT="100.0" Z="0.28417836934842516">
<NAME>Topical honey versus mupirocin ointment</NAME>
<DICH_DATA CI_END="3.6089030030575056" CI_START="0.38351904825651656" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5573752096286442" LOG_CI_START="-0.41621306105722966" LOG_EFFECT_SIZE="0.07058107428570727" ORDER="2054" O_E="0.0" SE="0.5718905695405475" STUDY_ID="STD-Johnson-2005" TOTAL_1="51" TOTAL_2="50" VAR="0.3270588235294118" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.633103723545428" CI_START="0.19562180578422117" DF="0" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.21301376901888996" LOG_CI_START="-0.7085827364404024" LOG_EFFECT_SIZE="-0.24778448371075615" MODIFIED="2009-11-04 14:42:53 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2919154178308624" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="1.053929048393913">
<NAME>Topical honey versus povidone-iodine ointment</NAME>
<DICH_DATA CI_END="1.633103723545428" CI_START="0.19562180578422117" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.21301376901888996" LOG_CI_START="-0.7085827364404024" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="2055" O_E="0.0" SE="0.5413503492830649" STUDY_ID="STD-Quadri-1999" TOTAL_1="23" TOTAL_2="26" VAR="0.2930602006688964" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.921072820053325" CI_END="0.7025694467635202" CI_START="0.611819210408646" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6556260246330191" ESTIMABLE="YES" EVENTS_1="2594" EVENTS_2="3970" I2="89.97362154077116" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.15331074066771322" LOG_CI_START="-0.21337689079774608" LOG_EFFECT_SIZE="-0.18334381573272962" METHOD="MH" MODIFIED="2009-11-04 14:43:10 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.433849764476136E-6" P_Q="0.0" P_Z="5.416428237727073E-33" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.030686253246036306" TOTALS="SUB" TOTAL_1="400000" TOTAL_2="400000" WEIGHT="300.0" Z="11.965051026122818">
<NAME>Catheter-related bacteraemia/100,000 catheter-days</NAME>
<GROUP_LABEL_1>Honey ointment</GROUP_LABEL_1>
<GROUP_LABEL_2>Antimicrobial ointment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antimicrobial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.960536410026663" CI_END="1.4880845455507377" CI_START="0.46767722783649024" DF="1" EFFECT_SIZE="0.8342321349897116" ESTIMABLE="YES" EVENTS_1="1297" EVENTS_2="1985" I2="93.31574769384744" ID="CMP-002.03.01" LOG_CI_END="0.17262760635977767" LOG_CI_START="-0.3300537762658113" LOG_EFFECT_SIZE="-0.0787130849530168" MODIFIED="2009-02-12 00:00:33 +1100" MODIFIED_BY="Margaret McCann" NO="1" P_CHI2="1.097842275563643E-4" P_Z="0.5393425170540239" STUDIES="2" TAU2="0.16329383511236037" TOTAL_1="200000" TOTAL_2="200000" WEIGHT="99.99999999999999" Z="0.6138075407294834">
<NAME>Topical honey versus topical antimicrobial ointments</NAME>
<DICH_DATA CI_END="1.5267263736196237" CI_START="0.8529909219664" EFFECT_SIZE="1.1411764705882352" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="85" LOG_CI_END="0.18376120793037687" LOG_CI_START="-0.06905559082647268" LOG_EFFECT_SIZE="0.05735280855195209" ORDER="147" O_E="0.0" SE="0.14850583905311066" STUDY_ID="STD-Johnson-2005" TOTAL_1="100000" TOTAL_2="100000" VAR="0.022053984232868404" WEIGHT="47.04065118648502"/>
<DICH_DATA CI_END="0.6785512547590791" CI_START="0.5878582700442135" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="1200" EVENTS_2="1900" LOG_CI_END="-0.16841734208188586" LOG_CI_START="-0.23072736772852256" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="148" O_E="0.0" SE="0.0366012175044358" STUDY_ID="STD-Quadri-1999" TOTAL_1="100000" TOTAL_2="100000" VAR="0.0013396491228070176" WEIGHT="52.959348813514964"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5267263736196237" CI_START="0.8529909219664" DF="0" EFFECT_SIZE="1.1411764705882352" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="85" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.18376120793037687" LOG_CI_START="-0.06905559082647268" LOG_EFFECT_SIZE="0.05735280855195209" MODIFIED="2009-02-12 00:00:55 +1100" MODIFIED_BY="Margaret McCann" NO="2" P_CHI2="1.0" P_Z="0.3738654732011095" STUDIES="1" TAU2="0.0" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="100.0" Z="0.8892560915792499">
<NAME>Topical honey versus mupirocin ointment</NAME>
<DICH_DATA CI_END="1.5267263736196237" CI_START="0.8529909219664" EFFECT_SIZE="1.1411764705882352" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="85" LOG_CI_END="0.18376120793037687" LOG_CI_START="-0.06905559082647268" LOG_EFFECT_SIZE="0.05735280855195209" ORDER="2056" O_E="0.0" SE="0.14850583905311066" STUDY_ID="STD-Johnson-2005" TOTAL_1="100000" TOTAL_2="100000" VAR="0.022053984232868404" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6785512547590791" CI_START="0.5878582700442135" DF="0" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="1200" EVENTS_2="1900" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="-0.16841734208188586" LOG_CI_START="-0.23072736772852256" LOG_EFFECT_SIZE="-0.19957235490520417" MODIFIED="2009-11-04 14:43:10 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="3.7266075447885575E-36" STUDIES="1" TAU2="0.0" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="99.99999999999999" Z="12.555110477479289">
<NAME>Topical honey versus povidone-iodine ointment</NAME>
<DICH_DATA CI_END="0.6785512547590791" CI_START="0.5878582700442135" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="1200" EVENTS_2="1900" LOG_CI_END="-0.16841734208188586" LOG_CI_START="-0.23072736772852256" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="2057" O_E="0.0" SE="0.0366012175044358" STUDY_ID="STD-Quadri-1999" TOTAL_1="100000" TOTAL_2="100000" VAR="0.0013396491228070176" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-11-03 14:15:33 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Polyurethane transparent dressing versus dry dressing</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:11:07 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Central venous catheter infection</NAME>
<GROUP_LABEL_1>Transparent dressing</GROUP_LABEL_1>
<GROUP_LABEL_2>Dry dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transparent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dry</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0199847904557613" CI_START="0.03679194394033447" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48000475572610146" LOG_CI_START="-1.4342472651654263" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="2077" O_E="0.0" SE="1.124441112772009" STUDY_ID="STD-le-Corre-2003" TOTAL_1="29" TOTAL_2="29" VAR="1.2643678160919538" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:11:48 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Exit site infection</NAME>
<GROUP_LABEL_1>Transparent dressing</GROUP_LABEL_1>
<GROUP_LABEL_2>Dry dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transparent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dry</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="2078" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-le-Corre-2003" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:15:33 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="0.0" Z="0.0">
<NAME>Exit site infection/100,000 catheter-days</NAME>
<GROUP_LABEL_1>Transparent dressing</GROUP_LABEL_1>
<GROUP_LABEL_2>Dry dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transparent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dry</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.35028031252802505" CI_START="0.0012923750216374285" EFFECT_SIZE="0.02127659574468085" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="23" LOG_CI_END="-0.45558427147681896" LOG_CI_START="-2.888611444394616" LOG_EFFECT_SIZE="-1.6720978579357175" ORDER="2079" O_E="0.0" SE="1.429172205050658" STUDY_ID="STD-le-Corre-2003" TOTAL_1="100000" TOTAL_2="100000" VAR="2.0425331916893597" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:14:45 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Catheter-related bacteraemia</NAME>
<GROUP_LABEL_1>Transparent dressing</GROUP_LABEL_1>
<GROUP_LABEL_2>Dry dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transparent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dry</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.214673425796684" CI_START="0.04794164074844354" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.717227115482503" LOG_CI_START="-1.3192871068104655" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="2080" O_E="0.0" SE="1.1962585350828727" STUDY_ID="STD-le-Corre-2003" TOTAL_1="29" TOTAL_2="29" VAR="1.4310344827586206" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:15:07 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="100000" TOTAL_2="100000" WEIGHT="0.0" Z="0.0">
<NAME>Catheter-related bacteraemia/100,000 catheter-days</NAME>
<GROUP_LABEL_1>Transparent dressing</GROUP_LABEL_1>
<GROUP_LABEL_2>Dry dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transparent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dry</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0090258154888112" CI_START="0.40377973247091026" EFFECT_SIZE="0.6382978723404256" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="47" LOG_CI_END="0.0039022776154200556" LOG_CI_START="-0.39385548404753" LOG_EFFECT_SIZE="-0.194976603216055" ORDER="2081" O_E="0.0" SE="0.23364487813349166" STUDY_ID="STD-le-Corre-2003" TOTAL_1="100000" TOTAL_2="100000" VAR="0.054589929078014174" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-11-05 11:59:00 +1100" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Insertion technique - tunnelled versus non-tunnelled central venous catheters (CVC)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:17:19 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Exit site infection</NAME>
<GROUP_LABEL_1>Tunnelled CVC</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-tunnelled CVC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tunnelled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-tunnelled</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.610110860712435" CI_START="0.1736671604853754" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8202087432665675" LOG_CI_START="-0.7602822965116811" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="2083" O_E="0.0" SE="0.9283882603225667" STUDY_ID="STD-Atapour-2006" TOTAL_1="14" TOTAL_2="15" VAR="0.861904761904762" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:17:44 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Catheter-related bacteraemia</NAME>
<GROUP_LABEL_1>Tunnelled CVC</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-tunnelled CVC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tunnelled</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-tunnelled</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4256358843095474" CI_START="0.6766135746533234" EFFECT_SIZE="0.9821428571428571" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.15400861834367413" LOG_CI_START="-0.1696592933675873" LOG_EFFECT_SIZE="-0.007825337511956592" ORDER="2084" O_E="0.0" SE="0.19012413352119759" STUDY_ID="STD-Atapour-2006" TOTAL_1="14" TOTAL_2="15" VAR="0.036147186147186164" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-11-04 17:10:47 +1100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Haemodialysis nurse using heparin 3 times/week versus Intravenous Team using heparin 3 times/day</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:31:40 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Central venous catheter infection</NAME>
<GROUP_LABEL_1>Haemodialysis nurse</GROUP_LABEL_1>
<GROUP_LABEL_2>IV team</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs haemodialysis nurse</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs IV team</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7270985884096945" CI_START="0.14475143554497316" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2373171292178565" LOG_CI_START="-0.8393771205458188" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="2086" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Huraib-1994" TOTAL_1="20" TOTAL_2="20" VAR="0.4" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:31:30 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Exit site infection</NAME>
<GROUP_LABEL_1>Haemodialysis nurse</GROUP_LABEL_1>
<GROUP_LABEL_2>IV team</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs haemodialysis nurse</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs IV team</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="2087" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Huraib-1994" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:32:25 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Catheter-related bacteraemia</NAME>
<GROUP_LABEL_1>Haemodialysis nurse</GROUP_LABEL_1>
<GROUP_LABEL_2>IV team</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs haemodialysis nurse</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs IV team</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.938902847851195" CI_START="0.03780700379134716" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46818522971347326" LOG_CI_START="-1.4224277391527982" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="2088" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Huraib-1994" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-11-03 14:33:12 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Mortality (all-cause)</NAME>
<GROUP_LABEL_1>Haemodialysis nurse</GROUP_LABEL_1>
<GROUP_LABEL_2>IV team</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favs haemodialysis nurse</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favs IV team</GRAPH_LABEL_2>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="2089" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Huraib-1994" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-11-06 10:38:48 +1100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="151 flow chart.PNG" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-11-06 10:38:48 +1100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart of study selection procedure</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxgAAAK+CAIAAACuLS90AABMuUlEQVR42u3dvXnjsNZo4dPg9OEi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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-11-03 14:39:52 +1100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-11-03 14:39:52 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-11-03 14:34:23 +1100" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-03 14:39:52 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Database</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Search terms</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>MeSH descriptor Renal Dialysis, this term only</LI>
<LI>MeSH descriptor Hemofiltration explode all trees</LI>
<LI>(hemodialysis or haemodialysis):ti,ab,kw</LI>
<LI>(hemofiltration or haemofiltration):ti,ab,kw</LI>
<LI>(hemodiafiltration or haemodiafiltration):ti,ab,kw</LI>
<LI>dialysis:ti,ab,kw</LI>
<LI>(#1 OR #2 OR #3 OR #4 OR #5 OR #6)</LI>
<LI>catheter*:ti,ab,kw</LI>
<LI>(central next line*):ti,ab,kw</LI>
<LI>(#8 OR #9)</LI>
<LI>MeSH descriptor Infection, this term only</LI>
<LI>MeSH descriptor Sepsis explode all trees</LI>
<LI>(infect*):ti,ab,kw</LI>
<LI>(sepsis or septic*):ti,ab,kw</LI>
<LI>(bacteremi* or bacteraemi*):ti,ab,kw</LI>
<LI>(#11 OR #12 OR #13 OR #14 OR #15)#17 (#7 AND #10 AND #16)</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>Renal Dialysis/</LI>
<LI>exp Hemofiltration/</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodialfiltration or haemodiafiltration).tw.</LI>
<LI>dialysis.tw.</LI>
<LI>or/1-6</LI>
<LI>Catheterization/</LI>
<LI>Catheterization, Central Venous/</LI>
<LI>Catheters, Indwelling/</LI>
<LI>catheter$.tw.</LI>
<LI>central line$.tw.</LI>
<LI>or/8-12</LI>
<LI>Bacterial Infections/</LI>
<LI>Infection/</LI>
<LI>exp Sepsis/</LI>
<LI>infect$.tw.</LI>
<LI>(sepsis or septic$).tw.</LI>
<LI>bacter?emi$.tw.</LI>
<LI>or/14-19</LI>
<LI>and/7,13,20</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>Hemodialysis/</LI>
<LI>Hemodiafiltration/</LI>
<LI>Hemofiltration/</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodialfiltration or haemodiafiltration).tw.</LI>
<LI>dialysis.tw.</LI>
<LI>or/1-7</LI>
<LI>Catheter/</LI>
<LI>Dialysis Catheter/</LI>
<LI>Indwelling Catheter/</LI>
<LI>exp Central Venous Catheter/</LI>
<LI>Subclavian Vein Catheter/</LI>
<LI>Blood Vessel Catheterization/</LI>
<LI>Vein Catheterization/</LI>
<LI>Catheterization/</LI>
<LI>catheter$.tw.</LI>
<LI>central line$.tw.</LI>
<LI>or/9-18</LI>
<LI>Infection/</LI>
<LI>Bacterial Infection/</LI>
<LI>Bacteremia/</LI>
<LI>Sepsis/</LI>
<LI>Septicemia/</LI>
<LI>Septic Shock/</LI>
<LI>infect$.tw.</LI>
<LI>(sepsis or septic$).tw.</LI>
<LI>bacter?emi$.tw.</LI>
<LI>or/20-28</LI>
<LI>and/8,19,29</LI>
</OL>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>